Form **990**

Department of the Treasury
Internal Revenue Service

Return of Organization Exempt From Income Tax

Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations)
Do not enter social security numbers on this form as it may be made public.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2025

Open to Public Inspection

A For the 2025 calendar year, or tax year beginning APR 1, 2025 and ending MAR 31, 2026

B Check if applicable:
- ☐ Address change
- ☐ Name change
- ☐ Initial return
- ☐ Final return/ terminated
- ☐ Amended return
- ☐ Application pending

C Name of organization
BRIGHTFOCUS FOUNDATION

Doing business as

Number and street (or P.O. box if mail is not delivered to street address) 22512 GATEWAY CENTER DRIVE

Room/suite

City or town, state or province, country, and ZIP or foreign postal code CLARKSBURG, MD 20871

F Name and address of principal officer: STACY PAGOS HALLER
SAME AS C ABOVE

D Employer identification number
23-7337229

E Telephone number (301) 948-3244

G Gross receipts $ 64,803,492.

H(a) Is this a group return for subordinates? ☐ Yes ☒ No

H(b) Are all subordinates included? ☐ Yes ☐ No
If "No," attach a list. See instructions

H(c) Group exemption number

I Tax-exempt status: ☒ 501(c)(3) ☐ 501(c) ( ) (insert no.) ☐ 4947(a)(1) or ☐ 527

J Website: WWW.BRIGHTFOCUS.ORG

K Form of organization: ☒ Corporation ☐ Trust ☐ Association ☐ Other

L Year of formation: 1973

M State of legal domicile: DC

Part I Summary

Activities & Governance

1 Briefly describe the organization's mission or most significant activities: BRIGHTFOCUS FOUNDATION (BRIGHTFOCUS) SEEKS A WORLD FREE FROM DISEASES OF MIND AND SIGHT.

2 Check this box ☐ if the organization discontinued its operations or disposed of more than 25% of its net assets.

3	Number of voting members of the governing body (Part VI, line 1a)	3	14
4	Number of independent voting members of the governing body (Part VI, line 1b)	4	14
5	Total number of individuals employed in calendar year 2025 (Part V, line 2a)	5	57
6	Total number of volunteers (estimate if necessary)	6	127
7a	Total unrelated business revenue from Part VIII, column (C), line 12	7a	0.
b	Net unrelated business taxable income from Form 990-T, Part I, line 11	7b	0.

		Prior Year	Current Year
Revenue 8	Contributions and grants (Part VIII, line 1h)	52,879,488.	53,446,400.
9	Program service revenue (Part VIII, line 2g)	0.	0.
10	Investment income (Part VIII, column (A), lines 3, 4, and 7d)	9,840,578.	2,383,121.
11	Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	703,858.	334,465.
12	Total revenue - add lines 8 through 11 (must equal Part VIII, column (A), line 12)	63,423,924.	56,163,986.
Expenses 13	Grants and similar amounts paid (Part IX, column (A), lines 1-3)	16,943,701.	16,673,827.
14	Benefits paid to or for members (Part IX, column (A), line 4)	0.	0.
15	Salaries, other compensation, employee benefits (Part IX, column (A), lines 5-10)	6,479,211.	6,800,662.
16a	Professional fundraising fees (Part IX, column (A), line 11e)	1,027,076.	588,268.
b	Total fundraising expenses (Part IX, column (D), line 25) 15,928,882.		
17	Other expenses (Part IX, column (A), lines 11a-11d, 11f-24e)	28,845,021.	32,628,383.
18	Total expenses. Add lines 13-17 (must equal Part IX, column (A), line 25)	53,295,009.	56,691,140.
19	Revenue less expenses. Subtract line 18 from line 12	10,128,915.	-527,154.

		Beginning of Current Year	End of Year
Net Assets or Fund Balances 20	Total assets (Part X, line 16)	65,129,292.	72,560,169.
21	Total liabilities (Part X, line 26)	28,168,825.	32,404,075.
22	Net assets or fund balances. Subtract line 21 from line 20	36,960,467.	40,156,094.

Part II Signature Block

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Sign Here

Signature of officer Stacy Pagos Haller — Date 10/22/26

STACY PAGOS HALLER, PRESIDENT/CEO
Type or print name and title

Paid Preparer Use Only

Preparer's name	Preparer's signature	Date	Check if self-employed	PTIN
FRANK SMITH	FRANK SMITH	10/22/26	☐	P00639053

Firm's name CBIZ ADVISORS, LLC — Firm's EIN 88-1478669

Firm's address 1899 L STREET, NW #850
WASHINGTON, DC 20036 — Phone no. (202) 227-4000

May the IRS discuss this return with the preparer shown above? See instructions ☒ Yes ☐ No

SEE SCHEDULE O FOR ORGANIZATION MISSION STATEMENT CONTINUATION

Part III Statement of Program Service Accomplishments

Check if Schedule O contains a response or note to any line in this Part III X

1 Briefly describe the organization's mission:
BRIGHTFOCUS FOUNDATION FUNDS EXCEPTIONAL RESEARCH WORLDWIDE TO DEFEAT ALZHEIMER'S DISEASE, MACULAR DEGENERATION, AND GLAUCOMA AND PROVIDES EXPERT INFORMATION ON THESE HEARTBREAKING DISEASES. PLEASE REFER TO SCHEDULE O FOR A COMPLETE OVERVIEW OF OUR MISSION.

2 Did the organization undertake any significant program services during the year which were not listed on the prior Form 990 or 990-EZ? ..... Yes X No
If "Yes," describe these new services on Schedule O.

3 Did the organization cease conducting, or make significant changes in how it conducts, any program services? ..... Yes X No
If "Yes," describe these changes on Schedule O.

4 Describe the organization's program service accomplishments for each of its three largest program services, as measured by expenses. Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total expenses, and revenue, if any, for each program service reported.

4a (Code:) (Expenses $ 21,724,289. including grants of $ 10,102,288.) (Revenue $)
ALZHEIMER'S DISEASE RESEARCH (ADR)

PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR ALZHEIMER'S DISEASE RESEARCH.

4b (Code:) (Expenses $ 11,194,993. including grants of $ 5,205,926.) (Revenue $)
MACULAR DEGENERATION RESEARCH (MDR)

PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR MACULAR DEGENERATION RESEARCH.

4c (Code:) (Expenses $ 2,936,658. including grants of $ 1,365,613.) (Revenue $)
NATIONAL GLAUCOMA RESEARCH (NGR)

PLEASE REFER TO SCHEDULE O FOR A COMPLETE DESCRIPTION OF THE ACCOMPLISHMENTS FOR NATIONAL GLAUCOMA RESEARCH.

4d Other program services (Describe on Schedule O.)
(Expenses $ including grants of $) (Revenue $)

4e Total program service expenses 35,855,940.

Part IV Checklist of Required Schedules

			Yes	No
1	Is the organization described in section 501(c)(3) or 4947(a)(1) (other than a private foundation)? *If "Yes," complete Schedule A*	1	X	
2	Is the organization required to complete *Schedule B, Schedule of Contributors*? See instructions	2		X
3	Did the organization engage in direct or indirect political campaign activities on behalf of or in opposition to candidates for public office? *If "Yes," complete Schedule C, Part I*	3		X
4	**Section 501(c)(3) organizations.** Did the organization engage in lobbying activities, or have a section 501(h) election in effect during the tax year? *If "Yes," complete Schedule C, Part II*	4	X	
5	Is the organization a section 501(c)(4), 501(c)(5), or 501(c)(6) organization that receives membership dues, assessments, or similar amounts as defined in Rev. Proc. 98-19? *If "Yes," complete Schedule C, Part III*	5		X
6	Did the organization maintain any donor advised funds or any similar funds or accounts for which donors have the right to provide advice on the distribution or investment of amounts in such funds or accounts? *If "Yes," complete Schedule D, Part I*	6		X
7	Did the organization receive or hold a conservation easement, including easements to preserve open space, the environment, historic land areas, or historic structures? *If "Yes," complete Schedule D, Part II*	7		X
8	Did the organization maintain collections of works of art, historical treasures, or other similar assets? *If "Yes," complete Schedule D, Part III*	8		X
9	Did the organization report an amount in Part X, line 21, for escrow or custodial account liability; serve as a custodian for amounts not listed in Part X; or provide credit counseling, debt management, credit repair, or debt negotiation services? *If "Yes," complete Schedule D, Part IV*	9		X
10	Did the organization, directly or through a related organization, hold assets in donor-restricted endowments or in quasi-endowments? *If "Yes," complete Schedule D, Part V*	10	X	
11	If the organization's answer to any of the following questions is "Yes," then complete Schedule D, Parts VI, VII, VIII, IX, or X, as applicable.			
a	Did the organization report an amount for land, buildings, and equipment in Part X, line 10? *If "Yes," complete Schedule D, Part VI*	11a	X	
b	Did the organization report an amount for investments - other securities in Part X, line 12, that is 5% or more of its total assets reported in Part X, line 16? *If "Yes," complete Schedule D, Part VII*	11b	X	
c	Did the organization report an amount for investments - program related in Part X, line 13, that is 5% or more of its total assets reported in Part X, line 16? *If "Yes," complete Schedule D, Part VIII*	11c		X
d	Did the organization report an amount for other assets in Part X, line 15, that is 5% or more of its total assets reported in Part X, line 16? *If "Yes," complete Schedule D, Part IX*	11d		X
e	Did the organization report an amount for other liabilities in Part X, line 25? *If "Yes," complete Schedule D, Part X*	11e	X	
f	Did the organization's separate or consolidated financial statements for the tax year include a footnote that addresses the organization's liability for uncertain tax positions under FIN 48 (ASC 740)? *If "Yes," complete Schedule D, Part X*	11f	X	
12a	Did the organization obtain separate, independent audited financial statements for the tax year? *If "Yes," complete Schedule D, Parts XI and XII*	12a		X
b	Was the organization included in consolidated, independent audited financial statements for the tax year? *If "Yes," and if the organization answered "No" to line 12a, then completing Schedule D, Parts XI and XII is optional*	12b	X	
13	Is the organization a school described in section 170(b)(1)(A)(ii)? *If "Yes," complete Schedule E*	13		X
14a	Did the organization maintain an office, employees, or agents outside of the United States?	14a		X
b	Did the organization have aggregate revenues or expenses of more than $10,000 from grantmaking, fundraising, business, investment, and program service activities outside the United States, or aggregate foreign investments valued at $100,000 or more? *If "Yes," complete Schedule F, Parts I and IV*	14b	X	
15	Did the organization report on Part IX, column (A), line 3, more than $5,000 of grants or other assistance to or for any foreign organization? *If "Yes," complete Schedule F, Parts II and IV*	15	X	
16	Did the organization report on Part IX, column (A), line 3, more than $5,000 of aggregate grants or other assistance to or for foreign individuals? *If "Yes," complete Schedule F, Parts III and IV*	16		X
17	Did the organization report a total of more than $15,000 of expenses for professional fundraising services on Part IX, column (A), lines 6 and 11e? *If "Yes," complete Schedule G, Part I.* See instructions	17	X	
18	Did the organization report more than $15,000 total of fundraising event gross income and contributions on Part VIII, lines 1c and 8a? *If "Yes," complete Schedule G, Part II*	18		X
19	Did the organization report more than $15,000 of gross income from gaming activities on Part VIII, line 9a? *If "Yes," complete Schedule G, Part III*	19		X
20a	Did the organization operate one or more hospital facilities? *If "Yes," complete Schedule H*	20a		X
b	If "Yes" to line 20a, did the organization attach a copy of its audited financial statements to this return?	20b		
21	Did the organization report more than $5,000 of grants or other assistance to any domestic organization or domestic government on Part IX, column (A), line 1? *If "Yes," complete Schedule I, Parts I and II*	21	X	

Part IV Checklist of Required Schedules *(continued)*

			Yes	No
22	Did the organization report more than $5,000 of grants or other assistance to or for domestic individuals on Part IX, column (A), line 2? *If "Yes," complete Schedule I, Parts I and III*	22		X
23	Did the organization answer "Yes" to Part VII, Section A, line 3, 4, or 5, about compensation of the organization's current and former officers, directors, trustees, key employees, and highest compensated employees? *If "Yes," complete Schedule J*	23	X	
24a	Did the organization have a tax-exempt bond issue with an outstanding principal amount of more than $100,000 as of the last day of the year, that was issued after December 31, 2002? *If "Yes," answer lines 24b through 24d and complete Schedule K. If "No," go to line 25a*	24a		X
b	Did the organization invest any proceeds of tax-exempt bonds beyond a temporary period exception?	24b		
c	Did the organization maintain an escrow account other than a refunding escrow at any time during the year to defease any tax-exempt bonds?	24c		
d	Did the organization act as an "on behalf of" issuer for bonds outstanding at any time during the year?	24d		
25a	**Section 501(c)(3), 501(c)(4), and 501(c)(29) organizations.** Did the organization engage in an excess benefit transaction with a disqualified person during the year? *If "Yes," complete Schedule L, Part I*	25a		X
b	Is the organization aware that it engaged in an excess benefit transaction with a disqualified person in a prior year, and that the transaction has not been reported on any of the organization's prior Forms 990 or 990-EZ? *If "Yes," complete Schedule L, Part I*	25b		X
26	Did the organization report any amount on Part X, line 5 or 22, for receivables from or payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons? *If "Yes," complete Schedule L, Part II*	26		X
27	Did the organization provide a grant or other assistance to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor or employee thereof, a grant selection committee member, or to a 35% controlled entity (including an employee thereof) or family member of any of these persons? *If "Yes," complete Schedule L, Part III*	27		X
28	Was the organization a party to a business transaction with one of the following parties? (See the Schedule L, Part IV, instructions for applicable filing thresholds, conditions, and exceptions):			
a	A current or former officer, director, trustee, key employee, creator or founder, or substantial contributor? *If "Yes," complete Schedule L, Part IV*	28a		X
b	A family member of any individual described in line 28a? *If "Yes," complete Schedule L, Part IV*	28b		X
c	A 35% controlled entity of one or more individuals and/or organizations described in line 28a or 28b? *If "Yes," complete Schedule L, Part IV*	28c		X
29	Did the organization receive more than $25,000 in noncash contributions? *If "Yes," complete Schedule M*	29	X	
30	Did the organization receive contributions of art, historical treasures, or other similar assets, or qualified conservation contributions? *If "Yes," complete Schedule M*	30		X
31	Did the organization liquidate, terminate, or dissolve and cease operations? *If "Yes," complete Schedule N, Part I*	31		X
32	Did the organization sell, exchange, dispose of, or transfer more than 25% of its net assets? *If "Yes," complete Schedule N, Part II*	32		X
33	Did the organization own 100% of an entity disregarded as separate from the organization under Regulations sections 301.7701-2 and 301.7701-3? *If "Yes," complete Schedule R, Part I*	33	X	
34	Was the organization related to any tax-exempt or taxable entity? *If "Yes," complete Schedule R, Part II, III, or IV, and Part V, line 1*	34		X
35a	Did the organization have a controlled entity within the meaning of section 512(b)(13)?	35a		X
b	If "Yes" to line 35a, did the organization receive any payment from or engage in any transaction with a controlled entity within the meaning of section 512(b)(13)? *If "Yes," complete Schedule R, Part V, line 2*	35b		
36	**Section 501(c)(3) organizations.** Did the organization make any transfers to an exempt non-charitable related organization? *If "Yes," complete Schedule R, Part V, line 2*	36		X
37	Did the organization conduct more than 5% of its activities through an entity that is not a related organization and that is treated as a partnership for federal income tax purposes? *If "Yes," complete Schedule R, Part VI*	37		X
38	Did the organization complete Schedule O and provide explanations on Schedule O for Part VI, lines 11b and 19? **Note:** All Form 990 filers are required to complete Schedule O	38	X	

Part V Statements Regarding Other IRS Filings and Tax Compliance

Check if Schedule O contains a response or note to any line in this Part V ☐

				Yes	No
1a	Enter the number reported in box 3 of Form 1096. Enter -0- if not applicable	1a	77		
b	Enter the number of Forms W-2G included on line 1a. Enter -0- if not applicable	1b	0		
c	Did the organization comply with backup withholding rules for reportable payments to vendors and reportable gaming (gambling) winnings to prize winners?			1c X	

Part V Statements Regarding Other IRS Filings and Tax Compliance *(continued)*

			Yes	No
2a	Enter the number of employees reported on Form W-3, Transmittal of Wage and Tax Statements, filed for the calendar year ending with or within the year covered by this return **2a** 57			
b	If at least one is reported on line 2a, did the organization file all required federal employment tax returns?	**2b**	X	
3a	Did the organization have unrelated business gross income of $1,000 or more during the year?	**3a**		X
b	If "Yes," has it filed a Form 990-T for this year? *If "No" to line 3b, provide an explanation on Schedule O*	**3b**		
4a	At any time during the calendar year, did the organization have an interest in, or a signature or other authority over, a financial account in a foreign country (such as a bank account, securities account, or other financial account)?	**4a**		X
b	If "Yes," enter the name of the foreign country _____ See instructions for filing requirements for FinCEN Form 114, Report of Foreign Bank and Financial Accounts (FBAR).			
5a	Was the organization a party to a prohibited tax shelter transaction at any time during the tax year?	**5a**		X
b	Did any taxable party notify the organization that it was or is a party to a prohibited tax shelter transaction?	**5b**		X
c	If "Yes" to line 5a or 5b, did the organization file Form 8886-T?	**5c**		
6a	Does the organization have annual gross receipts that are normally greater than $100,000, and did the organization solicit any contributions that were not tax deductible as charitable contributions?	**6a**		X
b	If "Yes," did the organization include with every solicitation an express statement that such contributions or gifts were not tax deductible?	**6b**		
7	**Organizations that may receive deductible contributions under section 170(c).**			
a	Did the organization receive a payment in excess of $75 made partly as a contribution and partly for goods and services provided to the payor?	**7a**		X
b	If "Yes," did the organization notify the donor of the value of the goods or services provided?	**7b**		
c	Did the organization sell, exchange, or otherwise dispose of tangible personal property for which it was required to file Form 8282?	**7c**		X
d	If "Yes," indicate the number of Forms 8282 filed during the year **7d**			
e	Did the organization receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?	**7e**		X
f	Did the organization, during the year, pay premiums, directly or indirectly, on a personal benefit contract?	**7f**		X
g	If the organization received a contribution of qualified intellectual property, did the organization file Form 8899 as required?	**7g**		
h	If the organization received a contribution of cars, boats, airplanes, or other vehicles, did the organization file a Form 1098-C?	**7h**		
8	**Sponsoring organizations maintaining donor advised funds.** Did a donor advised fund maintained by the sponsoring organization have excess business holdings at any time during the year?	**8**		
9	**Sponsoring organizations maintaining donor advised funds.**			
a	Did the sponsoring organization make any taxable distributions under section 4966?	**9a**		
b	Did the sponsoring organization make a distribution to a donor, donor advisor, or related person?	**9b**		
10	**Section 501(c)(7) organizations.** Enter:			
a	Initiation fees and capital contributions included on Part VIII, line 12 **10a**			
b	Gross receipts, included on Form 990, Part VIII, line 12, for public use of club facilities **10b**			
11	**Section 501(c)(12) organizations.** Enter:			
a	Gross income from members or shareholders **11a**			
b	Gross income from other sources. (Do not net amounts due or paid to other sources against amounts due or received from them.) **11b**			
12a	**Section 4947(a)(1) non-exempt charitable trusts.** Is the organization filing Form 990 in lieu of Form 1041?	**12a**		
b	If "Yes," enter the amount of tax-exempt interest received or accrued during the year **12b**			
13	**Section 501(c)(29) qualified nonprofit health insurance issuers.**			
a	Is the organization licensed to issue qualified health plans in more than one state? **Note:** See the instructions for additional information the organization must report on Schedule O.	**13a**		
b	Enter the amount of reserves the organization is required to maintain by the states in which the organization is licensed to issue qualified health plans **13b**			
c	Enter the amount of reserves on hand **13c**			
14a	Did the organization receive any payments for indoor tanning services during the tax year?	**14a**		X
b	If "Yes," has it filed a Form 720 to report these payments? *If "No," provide an explanation on Schedule O*	**14b**		
15	Is the organization subject to the section 4960 tax on payment(s) of more than $1,000,000 in remuneration or excess parachute payment(s) during the year? If "Yes," see the instructions and file Form 4720, Schedule N.	**15**		X
16	Is the organization an educational institution subject to the section 4968 excise tax on net investment income? If "Yes," complete Form 4720, Schedule O.	**16**		X
17	**Section 501(c)(21) organizations.** Did the trust, or any disqualified or other person engage in any activities that would result in the imposition of an excise tax under section 4951, 4952 or 4953? If "Yes," complete Form 6069.	**17**		

Part VI Governance, Management, and Disclosure. *For each "Yes" response to lines 2 through 7b below, and for a "No" response to line 8a, 8b, or 10b below, describe the circumstances, processes, or changes on Schedule O. See instructions.*

Check if Schedule O contains a response or note to any line in this Part VI X

Section A. Governing Body and Management

				Yes	No
1a	Enter the number of voting members of the governing body at the end of the tax year	1a	14		
	If there are material differences in voting rights among members of the governing body, or if the governing body delegated broad authority to an executive committee or similar committee, explain on Schedule O.				
b	Enter the number of voting members included on line 1a, above, who are independent	1b	14		
2	Did any officer, director, trustee, or key employee have a family relationship or a business relationship with any other officer, director, trustee, or key employee?	2			X
3	Did the organization delegate control over management duties customarily performed by or under the direct supervision of officers, directors, trustees, or key employees to a management company or other person?	3			X
4	Did the organization make any significant changes to its governing documents since the prior Form 990 was filed?	4			X
5	Did the organization become aware during the year of a significant diversion of the organization's assets?	5			X
6	Did the organization have members or stockholders?	6			X
7a	Did the organization have members, stockholders, or other persons who had the power to elect or appoint one or more members of the governing body?	7a			X
b	Are any governance decisions of the organization reserved to (or subject to approval by) members, stockholders, or persons other than the governing body?	7b			X
8	Did the organization contemporaneously document the meetings held or written actions undertaken during the year by the following:				
a	The governing body?	8a		X	
b	Each committee with authority to act on behalf of the governing body?	8b		X	
9	Is there any officer, director, trustee, or key employee listed in Part VII, Section A, who cannot be reached at the organization's mailing address? *If "Yes," provide the names and addresses on Schedule O*	9			X

Section B. Policies *(This Section B requests information about policies not required by the Internal Revenue Code.)*

			Yes	No
10a	Did the organization have local chapters, branches, or affiliates?	10a		X
b	If "Yes," did the organization have written policies and procedures governing the activities of such chapters, affiliates, and branches to ensure their operations are consistent with the organization's exempt purposes?	10b		
11a	Has the organization provided a complete copy of this Form 990 to all members of its governing body before filing the form?	11a	X	
b	Describe on Schedule O the process, if any, used by the organization to review this Form 990.			
12a	Did the organization have a written conflict of interest policy? *If "No," go to line 13*	12a	X	
b	Were officers, directors, or trustees, and key employees required to disclose annually interests that could give rise to conflicts?	12b	X	
c	Did the organization regularly and consistently monitor and enforce compliance with the policy? *If "Yes," describe on Schedule O how this was done*	12c	X	
13	Did the organization have a written whistleblower policy?	13	X	
14	Did the organization have a written document retention and destruction policy?	14	X	
15	Did the process for determining compensation of the following persons include a review and approval by independent persons, comparability data, and contemporaneous substantiation of the deliberation and decision?			
a	The organization's CEO, Executive Director, or top management official	15a	X	
b	Other officers or key employees of the organization	15b	X	
	If "Yes" to line 15a or 15b, describe the process on Schedule O. See instructions.			
16a	Did the organization invest in, contribute assets to, or participate in a joint venture or similar arrangement with a taxable entity during the year?	16a		X
b	If "Yes," did the organization follow a written policy or procedure requiring the organization to evaluate its participation in joint venture arrangements under applicable federal tax law, and take steps to safeguard the organization's exempt status with respect to such arrangements?	16b		

Section C. Disclosure

17 List the states with which a copy of this Form 990 is required to be filed AK,AL,AR,CA,CT,FL,GA,HI,IL,KS,KY,ME

18 Section 6104 requires an organization to make its Forms 1023 (1024 or 1024-A, if applicable), 990, and 990-T (section 501(c)(3)s only) available for public inspection. Indicate how you made these available. Check all that apply.

X Own website X Another's website X Upon request ☐ Other *(explain on Schedule O)*

19 Describe on Schedule O whether (and if so, how) the organization made its governing documents, conflict of interest policy, and financial statements available to the public during the tax year.

20 State the name, address, and telephone number of the person who possesses the organization's books and records

JONATHAN WALSH - 301-556-9385

22512 GATEWAY CENTER DRIVE, CLARKSBURG, MD 20871

SEE SCHEDULE O FOR FULL LIST OF STATES

Part VII Compensation of Officers, Directors, Trustees, Key Employees, Highest Compensated Employees, and Independent Contractors

Check if Schedule O contains a response or note to any line in this Part VII ☐

Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees

1a Complete this table for all persons required to be listed. Report compensation for the calendar year ending with or within the organization's tax year.

- List all of the organization's **current** officers, directors, trustees (whether individuals or organizations), regardless of amount of compensation. Enter -0- in columns (D), (E), and (F) if no compensation was paid.
- List all of the organization's **current** key employees, if any. See the instructions for definition of "key employee."
- List the organization's five **current** highest compensated employees (other than an officer, director, trustee, or key employee) who received reportable compensation (box 5 of Form W-2, box 6 of Form 1099-MISC, and/or box 1 of Form 1099-NEC) of more than $100,000 from the organization and any related organizations.
- List all of the organization's **former** officers, key employees, and highest compensated employees who received more than $100,000 of reportable compensation from the organization and any related organizations.
- List all of the organization's **former directors or trustees** that received, in the capacity as a former director or trustee of the organization, more than $10,000 of reportable compensation from the organization and any related organizations.

See the instructions for the order in which to list the persons above.

☐ Check this box if neither the organization nor any related organization compensated any current officer, director, or trustee.

(A) Name and title	(B) Average hours per week (list any hours for related organizations below line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W-2/1099-MISC/ 1099-NEC)	(E) Reportable compensation from related organizations (W-2/1099-MISC/ 1099-NEC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional trustee	Officer	Key employee	Highest compensated employee	Former			
(1) STACY PAGOS HALLER PRESIDENT/CEO	45.00			X				437,480.	0.	61,079.
(2) NANCY KEACH SR. VP, STRATEGIC PARTNERSHIPS	45.00				X			277,991.	0.	66,712.
(3) R. BRIAN ELDERTON SR. VP, DEVELOPMENT	45.00				X			270,609.	0.	49,290.
(4) JONATHAN WALSH SVP, FINANCE & ADMINISTRATION	45.00				X			256,177.	0.	12,385.
(5) DIANE BOVENKAMP, PHD VP, SCIENTIFIC AFFAIRS	45.00				X			202,612.	0.	26,734.
(6) SHARYN ROSSI - PHD, DIR. OF SCIENT. PROGRAMS, NEUROSCIENCE	45.00					X		145,082.	0.	56,015.
(7) DAVID LOWING - SR. DIRECTOR CORPORATE & FOUNDATION RELATIONS	40.00					X		151,606.	0.	40,111.
(8) GABRIEL WUREH CONTROLLER	40.00					X		150,909.	0.	30,929.
(9) LISA MORGAN SENIOR DIRECTOR, ANNUAL GIVING	40.00					X		139,023.	0.	32,594.
(10) ANDREW JAIME ACCOUNTING MANAGER	40.00					X		124,075.	0.	6,706.
(11) PATRICIA M. STEWART CHAIR	10.00	X		X				0.	0.	0.
(12) SCOTT KAISER, MD VICE CHAIR	6.00	X		X				0.	0.	0.
(13) THOMAS F. FREDDO, OD, PHD SECRETARY	6.00	X		X				0.	0.	0.
(14) SHAWNA GOTTLIEB TREASURER	6.00	X		X				0.	0.	0.
(15) CECILIA ARRADAZA DIRECTOR	6.00	X						0.	0.	0.
(16) PAUL CAMPBELL DIRECTOR	5.00	X						0.	0.	0.
(17) HERBERT L. DRAYTON III DIRECTOR	5.00	X						0.	0.	0.

Part VII **Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees** *(continued)*

(A) Name and title	(B) Average hours per week (list any hours for related organizations below line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W-2/1099-MISC/ 1099-NEC)	(E) Reportable compensation from related organizations (W-2/1099-MISC/ 1099-NEC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional trustee	Officer	Key employee	Highest compensated employee	Former			
(18) DANA GRIFFIN DIRECTOR	5.00	X						0.	0.	0.
(19) TONYA MATTHEWS, PHD DIRECTOR	5.00	X						0.	0.	0.
(20) ANN SECLOW DIRECTOR	5.00	X						0.	0.	0.
(21) JAN M. STOUFFER, PHD DIRECTOR	6.00	X						0.	0.	0.
(22) ADAM MYERS DIRECTOR	5.00	X						0.	0.	0.
(23) JOHN PENN DIRECTOR	5.00	X						0.	0.	0.
(24) DALE YOUNG DIRECTOR	5.00	X						0.	0.	0.
1b Subtotal								2,155,564.	0.	382,555.
c Total from continuation sheets to Part VII, Section A								0.	0.	0.
d Total (add lines 1b and 1c)								2,155,564.	0.	382,555.

2 Total number of individuals (including but not limited to those listed above) who received more than $100,000 of reportable compensation from the organization 14

		Yes	No
3 Did the organization list any **former** officer, director, trustee, key employee, or highest compensated employee on line 1a? *If "Yes," complete Schedule J for such individual*	3		X
4 For any individual listed on line 1a, is the sum of reportable compensation and other compensation from the organization and related organizations greater than $150,000? *If "Yes," complete Schedule J for such individual*	4	X	
5 Did any person listed on line 1a receive or accrue compensation from any unrelated organization or individual for services rendered to the organization? *If "Yes," complete Schedule J for such person*	5		X

Section B. Independent Contractors

1 Complete this table for your five highest compensated independent contractors that received more than $100,000 of compensation from the organization. Report compensation for the calendar year ending with or within the organization's tax year.

(A) Name and business address	(B) Description of services	(C) Compensation
RKD GROUP, 35 PARKWOOD DRIVE, SUITE 160, HOPKINTON, MA 01748	PUBLIC AWARENESS CONSULTING & MATERIA	15,032,504.
ADSTRA LLC, 750 COLLEGE ROAD EAST, STE 201, PRINCETON , NJ 08540	MAIL LIST RENTAL	2,067,261.
DATA MANAGEMENT, INC. 160 STONE STREET, STONEVILLE, NC 27048	DATABASE MANAGEMENT	312,360.
THE STELTER COMPANY, 505 MARKET STREET, SUITE 300, WEST DES MOINES, IA 50266	MARKETING CONSULTING	213,312.
BAHIA RESORT HOTEL, 998 W. MISSION BAY DRIVE, SAN DIEGO, CA 92107	HOTEL CONFERENCE	185,598.

2 Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization 11

Part VIII Statement of Revenue

Check if Schedule O contains a response or note to any line in this Part VIII ☐

				(A) Total revenue	(B) Related or exempt function revenue	(C) Unrelated business revenue	(D) Revenue excluded from tax under sections 512 - 514
Contributions, Gifts, Grants and Other Similar Amounts	1a Federated campaigns	1a	127,036.				
	b Membership dues	1b					
	c Fundraising events	1c					
	d Related organizations	1d					
	e Government grants (contributions)	1e					
	f All other contributions, gifts, grants, and similar amounts not included above	1f	53319364.				
	g Noncash contributions included in lines 1a-1f	1g	$1,383,066.				
	h **Total.** Add lines 1a-1f			53446400.			
Program Service Revenue			**Business Code**				
	2a						
	b						
	c						
	d						
	e						
	f All other program service revenue						
	g **Total.** Add lines 2a-2f						
Other Revenue	3 Investment income (including dividends, interest, and other similar amounts)			1,452,128.			1452128.
	4 Income from investment of tax-exempt bond proceeds						
	5 Royalties			332,465.			332,465.
			(i) Real / (ii) Personal				
	6a Gross rents	6a					
	b Less: rental expenses	6b					
	c Rental income or (loss)	6c					
	d Net rental income or (loss)						
			(i) Securities / (ii) Other				
	7a Gross amount from sales of assets other than inventory	7a	9570499.				
	b Less: cost or other basis and sales expenses	7b	8639506.				
	c Gain or (loss)	7c	930,993.				
	d Net gain or (loss)			930,993.			930,993.
	8a Gross income from fundraising events (not including $ ____ of contributions reported on line 1c). See Part IV, line 18	8a					
	b Less: direct expenses	8b					
	c Net income or (loss) from fundraising events						
	9a Gross income from gaming activities. See Part IV, line 19	9a					
	b Less: direct expenses	9b					
	c Net income or (loss) from gaming activities						
	10a Gross sales of inventory, less returns and allowances	10a					
	b Less: cost of goods sold	10b					
	c Net income or (loss) from sales of inventory						
Miscellaneous Revenue			**Business Code**				
	11a OTHER INCOME		900099	2,000.			2,000.
	b						
	c						
	d All other revenue						
	e **Total.** Add lines 11a-11d			2,000.			
	12 **Total revenue.** See instructions			56163986.	0.	0.	2717586.

Part IX Statement of Functional Expenses

Section 501(c)(3) and 501(c)(4) organizations must complete all columns. All other organizations must complete column (A).

Check if Schedule O contains a response or note to any line in this Part IX ☐

Do not include amounts reported on lines 6b, 7b, 8b, 9b, and 10b of Part VIII.	(A) Total expenses	(B) Program service expenses	(C) Management and general expenses	(D) Fundraising expenses
1 Grants and other assistance to domestic organizations and domestic governments. See Part IV, line 21	13,331,134.	13,331,134.		
2 Grants and other assistance to domestic individuals. See Part IV, line 22				
3 Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See Part IV, lines 15 and 16	3,342,693.	3,342,693.		
4 Benefits paid to or for members				
5 Compensation of current officers, directors, trustees, and key employees	1,674,040.	959,544.	387,994.	326,502.
6 Compensation not included above to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B)				
7 Other salaries and wages	3,606,068.	1,827,988.	1,278,884.	499,196.
8 Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions)	361,892.	191,054.	114,246.	56,592.
9 Other employee benefits	812,270.	428,822.	256,426.	127,022.
10 Payroll taxes	346,392.	182,871.	109,353.	54,168.
11 Fees for services (nonemployees):				
a Management				
b Legal	108,166.	56,015.	41,972.	10,179.
c Accounting	74,334.	38,495.	28,844.	6,995.
d Lobbying				
e Professional fundraising services. See Part IV, line 17	588,268.			588,268.
f Investment management fees	278,280.		278,280.	
g Other. (If line 11g amount exceeds 10% of line 25, column (A), amount, list line 11g expenses on Sch O.)	1,541,198.	1,232,464.	168,979.	139,755.
12 Advertising and promotion	3,932,352.	1,017,795.		2,914,557.
13 Office expenses	1,140,306.	305,708.	374,921.	459,677.
14 Information technology	1,010,027.	652,008.	237,396.	120,623.
15 Royalties				
16 Occupancy	424,988.	234,826.	144,266.	45,896.
17 Travel	276,363.	216,080.	36,807.	23,476.
18 Payments of travel or entertainment expenses for any federal, state, or local public officials				
19 Conferences, conventions, and meetings	731,956.	670,713.	37,393.	23,850.
20 Interest				
21 Payments to affiliates				
22 Depreciation, depletion, and amortization	660,188.	354,318.	214,749.	91,121.
23 Insurance	109,360.	56,344.	34,201.	18,815.
24 Other expenses. Itemize expenses not covered above. (List miscellaneous expenses on line 24e. If line 24e amount exceeds 10% of line 25, column (A), amount, list line 24e expenses on Schedule O.)				
a PUB. AWARENESS POSTAGE	9,796,900.	4,707,030.	537,311.	4,552,559.
b PUB. AWARENESS PRINTING	7,694,187.	3,706,944.	398,072.	3,589,171.
c PUB. AWARENESS COMP.	2,888,160.	1,390,219.	142,903.	1,355,038.
d LIST RENTAL	1,961,618.	952,875.	83,321.	925,422.
e All other expenses				
25 **Total functional expenses.** Add lines 1 through 24e	56,691,140.	35,855,940.	4,906,318.	15,928,882.
26 **Joint costs.** Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here ☒ if following SOP 98-2 (ASC 958-720)	20,944,393.	9,255,359.	10,747,823.	941,211.

Part X Balance Sheet

Check if Schedule O contains a response or note to any line in this Part X ☐

				(A) Beginning of year		(B) End of year
Assets	1	Cash - non-interest-bearing		3,278,680.	1	3,947,980.
	2	Savings and temporary cash investments		6,619,066.	2	7,558,956.
	3	Pledges and grants receivable, net		9,183,959.	3	7,600,978.
	4	Accounts receivable, net		25,908.	4	15,653.
	5	Loans and other receivables from any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons			5	
	6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), and persons described in section 4958(c)(3)(B)			6	
	7	Notes and loans receivable, net			7	
	8	Inventories for sale or use		36,763.	8	25,552.
	9	Prepaid expenses and deferred charges		1,557,144.	9	1,549,246.
	10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a 9,517,495.			
	b	Less: accumulated depreciation	10b 5,972,221.	3,971,651.	10c	3,545,274.
	11	Investments - publicly traded securities		32,437,847.	11	39,016,685.
	12	Investments - other securities. See Part IV, line 11		8,018,274.	12	9,299,845.
	13	Investments - program-related. See Part IV, line 11			13	
	14	Intangible assets			14	
	15	Other assets. See Part IV, line 11			15	
	16	**Total assets.** Add lines 1 through 15 (must equal line 33)		65,129,292.	16	72,560,169.
Liabilities	17	Accounts payable and accrued expenses		1,551,998.	17	2,807,366.
	18	Grants payable		25,940,333.	18	28,995,439.
	19	Deferred revenue			19	
	20	Tax-exempt bond liabilities			20	
	21	Escrow or custodial account liability. Complete Part IV of Schedule D			21	
	22	Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons			22	
	23	Secured mortgages and notes payable to unrelated third parties			23	
	24	Unsecured notes and loans payable to unrelated third parties			24	
	25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17-24). Complete Part X of Schedule D		676,494.	25	601,270.
	26	**Total liabilities.** Add lines 17 through 25		28,168,825.	26	32,404,075.
Net Assets or Fund Balances		**Organizations that follow FASB ASC 958, check here** ☒ **and complete lines 27, 28, 32, and 33.**				
	27	Net assets without donor restrictions		25,140,265.	27	28,428,288.
	28	Net assets with donor restrictions		11,820,202.	28	11,727,806.
		Organizations that do not follow FASB ASC 958, check here ☐ **and complete lines 29 through 33.**				
	29	Capital stock or trust principal, or current funds			29	
	30	Paid-in or capital surplus, or land, building, or equipment fund			30	
	31	Retained earnings, endowment, accumulated income, or other funds			31	
	32	Total net assets or fund balances		36,960,467.	32	40,156,094.
	33	Total liabilities and net assets/fund balances		65,129,292.	33	72,560,169.

Form **990** (2025)

532011 12-15-25

Part XI Reconciliation of Net Assets

Check if Schedule O contains a response or note to any line in this Part XI X

1	Total revenue (must equal Part VIII, column (A), line 12)	1	56,163,986.
2	Total expenses (must equal Part IX, column (A), line 25)	2	56,691,140.
3	Revenue less expenses. Subtract line 2 from line 1	3	-527,154.
4	Net assets or fund balances at beginning of year (must equal Part X, line 32, column (A))	4	36,960,467.
5	Net unrealized gains (losses) on investments	5	3,480,815.
6	Donated services and use of facilities	6	
7	Investment expenses	7	
8	Prior period adjustments	8	
9	Other changes in net assets or fund balances (explain on Schedule O)	9	241,966.
10	Net assets or fund balances at end of year. Combine lines 3 through 9 (must equal Part X, line 32, column (B))	10	40,156,094.

Part XII Financial Statements and Reporting

Check if Schedule O contains a response or note to any line in this Part XII X

			Yes	No
1	Accounting method used to prepare the Form 990: ☐ Cash ☒ Accrual ☐ Other _____ If the organization changed its method of accounting from a prior year or checked "Other," explain on Schedule O.			
2a	Were the organization's financial statements compiled or reviewed by an independent accountant?	2a		X
	If "Yes," check a box below to indicate whether the financial statements for the year were compiled or reviewed on a separate basis, consolidated basis, or both: ☐ Separate basis ☐ Consolidated basis ☐ Both consolidated and separate basis			
b	Were the organization's financial statements audited by an independent accountant?	2b	X	
	If "Yes," check a box below to indicate whether the financial statements for the year were audited on a separate basis, consolidated basis, or both: ☐ Separate basis ☒ Consolidated basis ☐ Both consolidated and separate basis			
c	If "Yes" to line 2a or 2b, does the organization have a committee that assumes responsibility for oversight of the audit, review, or compilation of its financial statements and selection of an independent accountant?	2c	X	
	If the organization changed either its oversight process or selection process during the tax year, explain on Schedule O.			
3a	As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the Uniform Guidance, 2 C.F.R. Part 200, Subpart F?	3a		X
b	If "Yes," did the organization undergo the required audit or audits? If the organization did not undergo the required audit or audits, explain why on Schedule O and describe any steps taken to undergo such audits	3b		

SCHEDULE A
(Form 990)

Department of the Treasury
Internal Revenue Service

Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.
Attach to Form 990 or Form 990-EZ.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2025

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I Reason for Public Charity Status. (All organizations must complete this part.) See instructions.

The organization is not a private foundation because it is: (For lines 1 through 12, check only one box.)

1 ☐ A church, convention of churches, or association of churches described in **section 170(b)(1)(A)(i).**
2 ☐ A school described in **section 170(b)(1)(A)(ii).** (Attach Schedule E (Form 990).)
3 ☐ A hospital or a cooperative hospital service organization described in **section 170(b)(1)(A)(iii).**
4 ☐ A medical research organization operated in conjunction with a hospital described in **section 170(b)(1)(A)(iii).** Enter the hospital's name, city, and state: _____
5 ☐ An organization operated for the benefit of a college or university owned or operated by a governmental unit described in **section 170(b)(1)(A)(iv).** (Complete Part II.)
6 ☐ A federal, state, or local government or governmental unit described in **section 170(b)(1)(A)(v).**
7 ☒ An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in **section 170(b)(1)(A)(vi).** (Complete Part II.)
8 ☐ A community trust described in **section 170(b)(1)(A)(vi).** (Complete Part II.)
9 ☐ An agricultural research organization described in **section 170(b)(1)(A)(ix)** operated in conjunction with a land-grant college or university or a non-land-grant college of agriculture (see instructions). Enter the name, city, and state of the college or university: _____
10 ☐ An organization that normally receives (1) more than 33 1/3% of its support from contributions, membership fees, and gross receipts from activities related to its exempt functions, subject to certain exceptions; and (2) no more than 33 1/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See **section 509(a)(2).** (Complete Part III.)
11 ☐ An organization organized and operated exclusively to test for public safety. See **section 509(a)(4).**
12 ☐ An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in **section 509(a)(1)** or **section 509(a)(2)**. See **section 509(a)(3).** Check the box on lines 12a through 12d that describes the type of supporting organization and complete lines 12e, 12f, and 12g.

a ☐ **Type I.** A supporting organization operated, supervised, or controlled by its supported organization(s), typically by giving the supported organization(s) the power to regularly appoint or elect a majority of the directors or trustees of the supporting organization. **You must complete Part IV, Sections A and B.**
b ☐ **Type II.** A supporting organization supervised or controlled in connection with its supported organization(s), by having control or management of the supporting organization vested in the same persons that control or manage the supported organization(s). **You must complete Part IV, Sections A and C.**
c ☐ **Type III functionally integrated.** A supporting organization operated in connection with, and functionally integrated with, its supported organization(s) (see instructions). **You must complete Part IV, Sections A, D, and E.**
d ☐ **Type III non-functionally integrated.** A supporting organization operated in connection with its supported organization(s) that is not functionally integrated. The organization generally must satisfy a distribution requirement and an attentiveness requirement (see instructions). **You must complete Part IV, Sections A and D, and Part V.**
e ☐ Check this box if the organization received a written determination from the IRS that it is a Type I, Type II, Type III functionally integrated, or Type III non-functionally integrated supporting organization.
f Enter the number of supported organizations .....
g Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iii) Type of organization (described on lines 1-10 above (see instructions))	(iv) Is the organization listed in your governing document? Yes	(iv) No	(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)
Total						

Part II Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)

(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization fails to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year (or fiscal year beginning in)	(a) 2021	(b) 2022	(c) 2023	(d) 2024	(e) 2025	(f) Total
1 Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.")	46522410.	43451535.	43373203.	52879488.	53446400.	239673036
2 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf						
3 The value of services or facilities furnished by a governmental unit to the organization without charge						
4 **Total.** Add lines 1 through 3	46522410.	43451535.	43373203.	52879488.	53446400.	239673036
5 The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f)						
6 **Public support.** Subtract line 5 from line 4.						239673036

Section B. Total Support

Calendar year (or fiscal year beginning in)	(a) 2021	(b) 2022	(c) 2023	(d) 2024	(e) 2025	(f) Total
7 Amounts from line 4	46522410.	43451535.	43373203.	52879488.	53446400.	239673036
8 Gross income from interest, dividends, payments received on securities loans, rents, royalties, and income from similar sources	2074361.	1972869.	1910285.	1987753.	1784593.	9729861.
9 Net income from unrelated business activities, whether or not the business is regularly carried on						
10 Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)	7,500.		70.	4,126.	2,000.	13,696.
11 **Total support.** Add lines 7 through 10						249416593

12 Gross receipts from related activities, etc. (see instructions) 12

13 **First 5 years.** If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and **stop here** ☐

Section C. Computation of Public Support Percentage

14 Public support percentage for 2025 (line 6, column (f), divided by line 11, column (f))	14	96.09 %
15 Public support percentage from 2024 Schedule A, Part II, line 14	15	95.94 %

16a **33 1/3% support test - 2025.** If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box and **stop here.** The organization qualifies as a publicly supported organization ☒

b **33 1/3% support test - 2024.** If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this box and **stop here.** The organization qualifies as a publicly supported organization ☐

17a **10% -facts-and-circumstances test - 2025.** If the organization did not check a box on line 13, 16a, or 16b, and line 14 is 10% or more, and if the organization meets the facts-and-circumstances test, check this box and **stop here.** Explain in Part VI how the organization meets the facts-and-circumstances test. The organization qualifies as a publicly supported organization ☐

b **10% -facts-and-circumstances test - 2024.** If the organization did not check a box on line 13, 16a, 16b, or 17a, and line 15 is 10% or more, and if the organization meets the facts-and-circumstances test, check this box and **stop here.** Explain in Part VI how the organization meets the facts-and-circumstances test. The organization qualifies as a publicly supported organization ☐

18 **Private foundation.** If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see instructions ☐

Part III Support Schedule for Organizations Described in Section 509(a)(2)

(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year (or fiscal year beginning in)	(a) 2021	(b) 2022	(c) 2023	(d) 2024	(e) 2025	(f) Total
1 Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.")						
2 Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose						
3 Gross receipts from activities that are not an unrelated trade or business under section 513						
4 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf						
5 The value of services or facilities furnished by a governmental unit to the organization without charge						
6 **Total.** Add lines 1 through 5						
7a Amounts included on lines 1, 2, and 3 received from disqualified persons						
b Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year						
c Add lines 7a and 7b						
8 **Public support.** (Subtract line 7c from line 6.)						

Section B. Total Support

Calendar year (or fiscal year beginning in)	(a) 2021	(b) 2022	(c) 2023	(d) 2024	(e) 2025	(f) Total
9 Amounts from line 6						
10a Gross income from interest, dividends, payments received on securities loans, rents, royalties, and income from similar sources						
b Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975						
c Add lines 10a and 10b						
11 Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on						
12 Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)						
13 **Total support.** (Add lines 9, 10c, 11, and 12.)						

14 **First 5 years.** If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and **stop here** ☐

Section C. Computation of Public Support Percentage

15 Public support percentage for 2025 (line 8, column (f), divided by line 13, column (f))	15	%
16 Public support percentage from 2024 Schedule A, Part III, line 15	16	%

Section D. Computation of Investment Income Percentage

17 Investment income percentage for **2025** (line 10c, column (f), divided by line 13, column (f))	17	%
18 Investment income percentage from **2024** Schedule A, Part III, line 17	18	%

19a **33 1/3% support tests - 2025.** If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and **stop here.** The organization qualifies as a publicly supported organization ☐

b **33 1/3% support tests - 2024.** If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3%, and line 18 is not more than 33 1/3%, check this box and **stop here.** The organization qualifies as a publicly supported organization ☐

20 **Private foundation.** If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions ☐

Part IV Supporting Organizations

(Complete only if you checked a box on line 12 of Part I. If you checked box 12a, Part I, complete Sections A and B. If you checked box 12b, Part I, complete Sections A and C. If you checked box 12c, Part I, complete Sections A, D, and E. If you checked box 12d, Part I, complete Sections A and D, and complete Part V.)

Section A. All Supporting Organizations

			Yes	No
1	Are all of the organization's supported organizations listed by name in the organization's governing documents? *If "No," describe in* **Part VI** *how the supported organizations are designated. If designated by class or purpose, describe the designation. If historic and continuing relationship, explain.*	1		
2	Did the organization have any supported organization that does not have an IRS determination of status under section 509(a)(1) or (2)? *If "Yes," explain in* **Part VI** *how the organization determined that the supported organization was described in section 509(a)(1) or (2).*	2		
3a	Did the organization have a supported organization described in section 501(c)(4), (5), or (6)? *If "Yes," answer lines 3b and 3c below.*	3a		
b	Did the organization confirm that each supported organization qualified under section 501(c)(4), (5), or (6) and satisfied the public support tests under section 509(a)(2)? *If "Yes," describe in* **Part VI** *when and how the organization made the determination.*	3b		
c	Did the organization ensure that all support to such organizations was used exclusively for section 170(c)(2)(B) purposes? *If "Yes," explain in* **Part VI** *what controls the organization put in place to ensure such use.*	3c		
4a	Was any supported organization not organized in the United States ("foreign supported organization")? *If "Yes," and if you checked box 12a or 12b in Part I, answer lines 4b and 4c below.*	4a		
b	Did the organization have ultimate control and discretion in deciding whether to make grants to the foreign supported organization? *If "Yes," describe in* **Part VI** *how the organization had such control and discretion despite being controlled or supervised by or in connection with its supported organizations.*	4b		
c	Did the organization support any foreign supported organization that does not have an IRS determination under sections 501(c)(3) and 509(a)(1) or (2)? *If "Yes," explain in* **Part VI** *what controls the organization used to ensure that all support to the foreign supported organization was used exclusively for section 170(c)(2)(B) purposes.*	4c		
5a	Did the organization add, substitute, or remove any supported organizations during the tax year? *If "Yes," answer lines 5b and 5c below (if applicable). Also, provide detail in* **Part VI,** *including (i) the names and EIN numbers of the supported organizations added, substituted, or removed; (ii) the reasons for each such action; (iii) the authority under the organization's organizing document authorizing such action; and (iv) how the action was accomplished (such as by amendment to the organizing document).*	5a		
b	**Type I or Type II only.** Was any added or substituted supported organization part of a class already designated in the organization's organizing document?	5b		
c	**Substitutions only.** Was the substitution the result of an event beyond the organization's control?	5c		
6	Did the organization provide support (whether in the form of grants or the provision of services or facilities) to anyone other than (i) its supported organizations, (ii) individuals that are part of the charitable class benefited by one or more of its supported organizations, or (iii) other supporting organizations that also support or benefit one or more of the filing organization's supported organizations? *If "Yes," provide detail in* **Part VI.**	6		
7	Did the organization provide a grant, loan, compensation, or other similar payment to a substantial contributor (as defined in section 4958(c)(3)(C)), a family member of a substantial contributor, or a 35% controlled entity with regard to a substantial contributor? *If "Yes," complete Part I of Schedule L (Form 990).*	7		
8	Did the organization make a loan to a disqualified person (as defined in section 4958) not described on line 7? *If "Yes," complete Part I of Schedule L (Form 990).*	8		
9a	Was the organization controlled directly or indirectly at any time during the tax year by one or more disqualified persons, as defined in section 4946 (other than foundation managers and organizations described in section 509(a)(1) or (2))? *If "Yes," provide detail in* **Part VI.**	9a		
b	Did one or more disqualified persons (as defined on line 9a) hold a controlling interest in any entity in which the supporting organization had an interest? *If "Yes," provide detail in* **Part VI.**	9b		
c	Did a disqualified person (as defined on line 9a) have an ownership interest in, or derive any personal benefit from, assets in which the supporting organization also had an interest? *If "Yes," provide detail in* **Part VI.**	9c		
10a	Was the organization subject to the excess business holdings rules of section 4943 because of section 4943(f) (regarding certain Type II supporting organizations, and all Type III non-functionally integrated supporting organizations)? *If "Yes," answer line 10b below.*	10a		
b	Did the organization have any excess business holdings in the tax year? *(Use Schedule C, Form 4720, to determine whether the organization had excess business holdings.)*	10b		

Part IV Supporting Organizations *(continued)*

			Yes	No
11	Has the organization accepted a gift or contribution from any of the following persons?			
a	A person who directly or indirectly controls, either alone or together with persons described on lines 11b and 11c below, the governing body of a supported organization?	**11a**		
b	A family member of a person described on line 11a above?	**11b**		
c	A 35% controlled entity of a person described on line 11a or 11b above? *If "Yes" to line 11a, 11b, or 11c, provide detail in* **Part VI.**	**11c**		

Section B. Type I Supporting Organizations

			Yes	No
1	Did the governing body, members of the governing body, officers acting in their official capacity, or membership of one or more supported organizations have the power to regularly appoint or elect at least a majority of the organization's officers, directors, or trustees at all times during the tax year? *If "No," describe in* **Part VI** *how the supported organization(s) effectively operated, supervised, or controlled the organization's activities. If the organization had more than one supported organization, describe how the powers to appoint and/or remove officers, directors, or trustees were allocated among the supported organizations and what conditions or restrictions, if any, applied to such powers during the tax year.*	**1**		
2	Did the organization operate for the benefit of any supported organization other than the supported organization(s) that operated, supervised, or controlled the supporting organization? *If "Yes," explain in* **Part VI** *how providing such benefit carried out the purposes of the supported organization(s) that operated, supervised, or controlled the supporting organization.*	**2**		

Section C. Type II Supporting Organizations

			Yes	No
1	Were a majority of the organization's directors or trustees during the tax year also a majority of the directors or trustees of each of the organization's supported organization(s)? *If "No," describe in* **Part VI** *how control or management of the supporting organization was vested in the same persons that controlled or managed the supported organization(s).*	**1**		

Section D. All Type III Supporting Organizations

			Yes	No
1	Did the organization provide to each of its supported organizations, by the last day of the fifth month of the organization's tax year, (i) a written notice describing the type and amount of support provided during the prior tax year, (ii) a copy of the Form 990 that was most recently filed as of the date of notification, and (iii) copies of the organization's governing documents in effect on the date of notification, to the extent not previously provided?	**1**		
2	Were any of the organization's officers, directors, or trustees either (i) appointed or elected by the supported organization(s) or (ii) serving on the governing body of a supported organization? *If "No," explain in* **Part VI** *how the organization maintained a close and continuous working relationship with the supported organization(s).*	**2**		
3	By reason of the relationship described on line 2, above, did the organization's supported organizations have a significant voice in the organization's investment policies and in directing the use of the organization's income or assets at all times during the tax year? *If "Yes," describe in* **Part VI** *the role the organization's supported organizations played in this regard.*	**3**		

Section E. Type III Functionally Integrated Supporting Organizations

1 *Check the box next to the method that the organization used to satisfy the Integral Part Test during the year* **(see instructions).**

- **a** ☐ The organization satisfied the Activities Test. *Complete* **line 2** *below.*
- **b** ☐ The organization is the parent of each of its supported organizations. *Complete* **line 3** *below.*
- **c** ☐ The organization supported a governmental supported organization. *Describe in* **Part VI** *how you supported a governmental supported organization (see instructions).*

			Yes	No
2	Activities Test. **Answer lines 2a and 2b below.**			
a	Did substantially all of the organization's activities during the tax year directly further the exempt purposes of its supported organization(s)? *If "Yes," then in* **Part VI identify those supported organizations and explain** *how these activities directly furthered their exempt purposes, how the organization was responsive to each of its supported organizations, and how the organization determined that these activities constituted substantially all of its activities.*	**2a**		
b	Did the activities described on line 2a, above, constitute activities that, but for the organization's involvement, one or more of the organization's supported organization(s) would have been engaged in? *If "Yes," explain in* **Part VI** *the reasons for the organization's position that its supported organization(s) would have engaged in these activities but for the organization's involvement.*	**2b**		
3	Parent of Supported Organizations. **Answer lines 3a, 3b, and 3c below.**			
a	Are the organization and its supported organization(s) part of an integrated system (for example, a hospital system)? *If "Yes," provide details in* **Part VI.**	**3a**		
b	Did the organization direct the policies, programs, and activities of each of its supported organizations? *If "Yes," describe in Part VI the role played by the organization in this regard.*	**3b**		
c	Did the organization have the power to regularly appoint or elect (and remove) a majority of the officers, directors, or trustees of each of the supported organizations? *If "Yes" or "No," provide details in* **Part VI.**	**3c**		

Part V Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations

1 ☐ Check here if the organization satisfied the Integral Part Test as a qualifying trust on Nov. 20, 1970 (*explain in* **Part VI**). **See instructions.** All other Type III non-functionally integrated supporting organizations must complete Sections A through E.

Section A - Adjusted Net Income		(A) Prior Year	(B) Current Year (optional)
1 Net short-term capital gain	**1**		
2 Recoveries of prior-year distributions	**2**		
3 Other gross income (see instructions)	**3**		
4 Add lines 1 through 3.	**4**		
5 Depreciation and depletion	**5**		
6 Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions)	**6**		
7 Other expenses (see instructions)	**7**		
8 **Adjusted Net Income** (subtract lines 5, 6, and 7 from line 4)	**8**		

Section B - Minimum Asset Amount		(A) Prior Year	(B) Current Year (optional)
1 Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year):			
a Average monthly value of securities	**1a**		
b Average monthly cash balances	**1b**		
c Fair market value of other non-exempt-use assets	**1c**		
d **Total** (add lines 1a, 1b, and 1c)	**1d**		
e **Discount** claimed for blockage or other factors (*explain in detail in* **Part VI**):			
2 Acquisition indebtedness applicable to non-exempt-use assets	**2**		
3 Subtract line 2 from line 1d.	**3**		
4 Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions).	**4**		
5 Net value of non-exempt-use assets (subtract line 4 from line 3)	**5**		
6 Multiply line 5 by 0.035.	**6**		
7 Recoveries of prior-year distributions	**7**		
8 **Minimum Asset Amount** (add line 7 to line 6)	**8**		

Section C - Distributable Amount			Current Year
1 Adjusted net income for prior year (from Section A, line 8, column A)	**1**		
2 Enter 0.85 of line 1.	**2**		
3 Minimum asset amount for prior year (from Section B, line 8, column A)	**3**		
4 Enter greater of line 2 or line 3.	**4**		
5 Income tax imposed in prior year	**5**		
6 **Distributable Amount.** Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions).	**6**		

7 ☐ Check here if the current year is the organization's first as a non-functionally integrated Type III supporting organization (see instructions).

Part V Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations *(continued)*

Section D - Distributions		Current Year
1 Amounts paid to supported organizations to accomplish exempt purposes	1	
2 Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity	2	
3 Administrative expenses paid to accomplish exempt purposes of supported organizations	3	
4 Amounts paid to acquire exempt-use assets	4	
5 Qualified set-aside amounts (prior IRS approval required - *provide details in* **Part VI**)	5	
6 **Total annual distributions.** Add lines 1 through 5.	6	
7 Distributions to attentive supported organizations to which the organization is responsive (*provide details in* **Part VI**). See instructions.	7	
8 Distributable amount for 2025 from Section C, line 6	8	
9 Line 7 amount divided by line 8 amount	9	

Section E - Distribution Allocations (see instructions)	(i) Excess Distributions	(ii) Underdistributions Pre-2025	(iii) Distributable Amount for 2025
1 Distributable amount for 2025 from Section C, line 6			
2 Underdistributions, if any, for years prior to 2025 (reasonable cause required - *explain in* **Part VI**). See instructions.			
3 Excess distributions carryover, if any, to 2025			
a From 2020			
b From 2021			
c From 2022			
d From 2023			
e From 2024			
f **Total** of lines 3a through 3e			
g Applied to under distributions of prior years			
h Applied to 2025 distributable amount			
i Carryover from 2020 not applied (see instructions)			
j Remainder. Subtract lines 3g, 3h, and 3i from line 3f.			
4 Distributions for 2025 from Section D, line 6: $			
a Applied to underdistributions of prior years			
b Applied to 2025 distributable amount			
c Remainder. Subtract lines 4a and 4b from line 4.			
5 Remaining underdistributions for years prior to 2025, if any. Subtract lines 3g and 4a from line 2. For result greater than zero, *explain in* **Part VI.** See instructions.			
6 Remaining underdistributions for 2025. Subtract lines 3h and 4b from line 1. For result greater than zero, *explain in* **Part VI**. See instructions.			
7 **Excess distributions carryover to 2026.** Add lines 3j and 4c.			
8 Breakdown of line 7:			
a Excess from 2021			
b Excess from 2022			
c Excess from 2023			
d Excess from 2024			
e Excess from 2025			

Part VI **Supplemental Information.** Provide the explanations required by Part II, line 10; Part II, line 17a or 17b; Part III, line 12; Part IV, Section A, lines 1, 2, 3b, 3c, 4b, 4c, 5a, 6, 9a, 9b, 9c, 11a, 11b, and 11c; Part IV, Section B, lines 1 and 2; Part IV, Section C, line 1; Part IV, Section D, lines 2 and 3; Part IV, Section E, lines 1c, 2a, 2b, 3a, 3b, and 3c; Part V, line 1; Part V, Section B, line 1e; Part V, Section D, lines 5 and 7; and Part V, Section E, lines 2, 5, and 6. Also complete this part for any additional information. (See instructions.)

SCHEDULE A, PART II, LINE 10, EXPLANATION FOR OTHER INCOME:
SAVINGS BOND PAYOUT
2021 AMOUNT: $ 7,500.

MISCELLANEOUS
2023 AMOUNT: $ 70.
2024 AMOUNT: $ 4,126.
2025 AMOUNT: $ 2,000.

SCHEDULE C
(Form 990)

Department of the Treasury
Internal Revenue Service

Political Campaign and Lobbying Activities

For Organizations Exempt From Income Tax Under Section 501(c) and Section 527

Complete if the organization is described below. Attach to Form 990 or Form 990-EZ.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2025

Open to Public Inspection

If the organization answered "Yes" on Form 990, Part IV, line 3, or Form 990-EZ, Part V, line 46 (Political Campaign Activities), then:

- Section 501(c)(3) organizations: Complete Parts I-A and I-B. Do not complete Part I-C.
- Section 501(c) (other than section 501(c)(3)) organizations: Complete Parts I-A and I-C below. Do not complete Part I-B.
- Section 527 organizations: Complete Part I-A only.

If the organization answered "Yes" on Form 990, Part IV, line 4, or Form 990-EZ, Part VI, line 47 (Lobbying Activities), then:

- Section 501(c)(3) organizations that have filed Form 5768 (election under section 501(h)): Complete Part II-A. Do not complete Part II-B.
- Section 501(c)(3) organizations that have NOT filed Form 5768 (election under section 501(h)): Complete Part II-B. Do not complete Part II-A.

If the organization answered "Yes" on Form 990, Part IV, line 5 (Proxy Tax) (see separate instructions), or Form 990-EZ, Part V, line 35c (Proxy Tax) (see separate instructions), then:

- Section 501(c)(4), (5), or (6) organizations: Complete Part III.

Name of organization	Employer identification number (EIN)
BRIGHTFOCUS FOUNDATION	23-7337229

Part I-A Complete if the organization is exempt under section 501(c) or is a section 527 organization.

1 Provide a description of the organization's direct and indirect political campaign activities in Part IV.
2 Political campaign activity expenditures ..... $
3 Volunteer hours for political campaign activities .....

Part I-B Complete if the organization is exempt under section 501(c)(3).

1 Enter the amount of any excise tax incurred by the organization under section 4955 ..... $
2 Enter the amount of any excise tax incurred by organization managers under section 4955 ..... $
3 If the organization incurred a section 4955 tax, did it file Form 4720 for this year? ..... ☐ Yes ☐ No
4a Was a correction made? ..... ☐ Yes ☐ No
b If "Yes," describe in Part IV.

Part I-C Complete if the organization is exempt under section 501(c), except section 501(c)(3).

1 Enter the amount directly expended by the filing organization for section 527 exempt function activities ..... $
2 Enter the amount of the filing organization's funds contributed to other organizations for section 527 exempt function activities ..... $
3 Total exempt function expenditures. Add lines 1 and 2. Enter here and on Form 1120-POL, line 17b ..... $
4 Did the filing organization file **Form 1120-POL** for this year? ..... ☐ Yes ☐ No
5 Enter the names, addresses, and EINs of all section 527 political organizations to which the filing organization made payments. For each organization listed, enter the amount paid from the filing organization's funds. Also enter the amount of political contributions received that were promptly and directly delivered to a separate political organization, such as a separate segregated fund or a political action committee (PAC). If additional space is needed, provide information in Part IV.

(a) Name	**(b)** Address	**(c)** EIN	**(d)** Amount paid from filing organization's funds. If none, enter -0-.	**(e)** Amount of political contributions received and promptly and directly delivered to a separate political organization. If none, enter -0-.

Part II-A **Complete if the organization is exempt under section 501(c)(3) and filed Form 5768 (election under section 501(h)).**

A Check ☐ if the filing organization belongs to an affiliated group (and list in Part IV each affiliated group member's name, address, EIN, expenses, and share of excess lobbying expenditures).

B Check ☐ if the filing organization checked box A and "limited control" provisions apply.

Limits on Lobbying Expenditures (The term "expenditures" means amounts paid or incurred.)	(a) Filing organization's totals	(b) Affiliated group totals
1a Total lobbying expenditures to influence public opinion (grassroots lobbying)	0.	
b Total lobbying expenditures to influence a legislative body (direct lobbying)	0.	
c Total lobbying expenditures (add lines 1a and 1b)	0.	
d Other exempt purpose expenditures	55,824,592.	
e Total exempt purpose expenditures (add lines 1c and 1d)	55,824,592.	
f Lobbying nontaxable amount. Enter the amount from the following table in both columns.	1,000,000.	
g Grassroots nontaxable amount (enter 25% of line 1f)	250,000.	
h Subtract line 1g from line 1a. If zero or less, enter -0-	0.	
i Subtract line 1f from line 1c. If zero or less, enter -0-	0.	

IF the amount on line 1e, column (a) or (b), is:	THEN the lobbying nontaxable amount is:
not over $500,000	20% of the amount on line 1e.
over $500,000 but not over $1,000,000	$100,000 plus 15% of the excess over $500,000.
over $1,000,000 but not over $1,500,000	$175,000 plus 10% of the excess over $1,000,000.
over $1,500,000 but not over $17,000,000	$225,000 plus 5% of the excess over $1,500,000.
over $17,000,000	$1,000,000.

j If there is an amount other than zero on either line 1h or line 1i, did the organization file Form 4720 reporting section 4911 tax for this year? ☐ Yes ☐ No

4-Year Averaging Period Under Section 501(h)

(Some organizations that made a section 501(h) election do not have to complete all of the five columns below. See the separate instructions for lines 2a through 2f.)

Lobbying Expenditures During 4-Year Averaging Period

Calendar year (or fiscal year beginning in)	(a) 2022	(b) 2023	(c) 2024	(d) 2025	(e) Total
2a Lobbying nontaxable amount	1,000,000.	1,000,000.	1,000,000.	1,000,000.	4,000,000.
b Lobbying ceiling amount (150% of line 2a, column(e))					6,000,000.
c Total lobbying expenditures					
d Grassroots nontaxable amount	250,000.	250,000.	250,000.	250,000.	1,000,000.
e Grassroots ceiling amount (150% of line 2d, column (e))					1,500,000.
f Grassroots lobbying expenditures					

Part II-B Complete if the organization is exempt under section 501(c)(3) and has NOT filed Form 5768 (election under section 501(h)).

For each "Yes" response on lines 1a through 1i below, provide in Part IV a detailed description of the lobbying activity.	(a) Yes	(a) No	(b) Amount
1 During the year, did the filing organization attempt to influence foreign, national, state, or local legislation, including any attempt to influence public opinion on a legislative matter or referendum, through the use of:			
a Volunteers?			
b Paid staff or management (include compensation in expenses reported on lines 1c through 1i)?			
c Media advertisements?			
d Mailings to members, legislators, or the public?			
e Publications, or published or broadcast statements?			
f Grants to other organizations for lobbying purposes?			
g Direct contact with legislators, their staffs, government officials, or a legislative body?			
h Rallies, demonstrations, seminars, conventions, speeches, lectures, or any similar means?			
i Other activities?			
j Total. Add lines 1c through 1i			
2a Did the activities in line 1 cause the organization to not be described in section 501(c)(3)?			
b If "Yes," enter the amount of any tax incurred under section 4912			
c If "Yes," enter the amount of any tax incurred by organization managers under section 4912			
d If the filing organization incurred a section 4912 tax, did it file Form 4720 for this year?			

Part III-A Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6).

			Yes	No
1	Were substantially all (90% or more) dues received nondeductible by members?	1		
2	Did the organization make only in-house lobbying expenditures of $2,000 or less?	2		
3	Did the organization agree to carry over lobbying and political campaign activity expenditures from the prior year?	3		

Part III-B Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6) and if either (a) BOTH Part III-A, lines 1 and 2, are answered "No;" OR (b) Part III-A, line 3, is answered "Yes."

1	Dues, assessments, and similar amounts from members	1	
2	Section 162(e) nondeductible lobbying and political expenditures **(do not include amounts of political expenses for which the section 527(f) tax was paid):**		
a	Current year	2a	
b	Carryover from last year	2b	
c	Total	2c	
3	Aggregate amount reported in section 6033(e)(1)(A) notices of nondeductible section 162(e) dues	3	
4	If notices were sent and the amount on line 2c exceeds the amount on line 3, what portion of the excess does the organization agree to carryover to the reasonable estimate of nondeductible lobbying and political expenditures next year?	4	
5	Taxable amount of lobbying and political expenditures. See instructions	5	

Part IV Supplemental Information

Provide the descriptions required for Part I-A, line 1; Part I-B, line 4; Part I-C, line 5; Part II-A (affiliated group list); Part II-A, lines 1 and 2 (see instructions); and Part II-B, line 1. Also, complete this part for any additional information.

SCHEDULE D (Form 990)
(Rev. December 2024)
Department of the Treasury
Internal Revenue Service

Supplemental Financial Statements

Complete if the organization answered "Yes" on Form 990, Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b.
Attach to Form 990.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

Open to Public Inspection

Name of the organization
BRIGHTFOCUS FOUNDATION

Employer identification number
23-7337229

Part I Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts.

Complete if the organization answered "Yes" on Form 990, Part IV, line 6.

		(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year		
2	Aggregate value of contributions to (during year)		
3	Aggregate value of grants from (during year)		
4	Aggregate value at end of year		

5 Did the organization inform all donors and donor advisors in writing that the assets held in donor advised funds are the organization's property, subject to the organization's exclusive legal control? ☐ Yes ☐ No

6 Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit? ☐ Yes ☐ No

Part II Conservation Easements.

Complete if the organization answered "Yes" on Form 990, Part IV, line 7.

1 Purpose(s) of conservation easements held by the organization (check all that apply).
- ☐ Preservation of land for public use (for example, recreation or education)
- ☐ Preservation of a historically important land area
- ☐ Protection of natural habitat
- ☐ Preservation of a certified historic structure
- ☐ Preservation of open space

2 Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.

		Held at the End of the Tax Year
a	Total number of conservation easements 2a	
b	Total acreage restricted by conservation easements 2b	
c	Number of conservation easements on a certified historic structure included on line 2a 2c	
d	Number of conservation easements included on line 2c acquired after July 25, 2006, and not on a historic structure listed in the National Register 2d	

3 Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during the tax year _____

4 Number of states where property subject to conservation easement is located _____

5 Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and enforcement of the conservation easements it holds? ☐ Yes ☐ No

6 Staff and volunteer hours devoted to monitoring, inspecting, handling of violations, and enforcing conservation easements during the year _____

7 Amount of expenses incurred in monitoring, inspecting, handling of violations, and enforcing conservation easements during the year _____

8 Does each conservation easement reported on line 2d above satisfy the requirements of section 170(h)(4)(B)(i) and section 170(h)(4)(B)(ii)? ☐ Yes ☐ No

9 In Part XIII, describe how the organization reports conservation easements in its revenue and expense statement and balance sheet, and include, if applicable, the text of the footnote to the organization's financial statements that describes the organization's accounting for conservation easements.

Part III Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.

Complete if the organization answered "Yes" on Form 990, Part IV, line 8.

1a If the organization elected, as permitted under FASB ASC 958, not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide in Part XIII the text of the footnote to its financial statements that describes these items.

b If the organization elected, as permitted under FASB ASC 958, to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items.

(i) Revenue included on Form 990, Part VIII, line 1 $ _____

(ii) Assets included in Form 990, Part X $ _____

2 If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the following amounts required to be reported under FASB ASC 958 relating to these items:

a Revenue included on Form 990, Part VIII, line 1 $ _____

b Assets included in Form 990, Part X $ _____

Part III Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets *(continued)*

3 Using the organization's acquisition, accession, and other records, check any of the following that make significant use of its collection items (check all that apply).

a ☐ Public exhibition
b ☐ Scholarly research
c ☐ Preservation for future generations
d ☐ Loan or exchange program
e ☐ Other _____

4 Provide a description of the organization's collections and explain how they further the organization's exempt purpose in Part XIII.

5 During the year, did the organization solicit or receive donations of art, historical treasures, or other similar assets to be sold to raise funds rather than to be maintained as part of the organization's collection? ☐ Yes ☐ No

Part IV Escrow and Custodial Arrangements Complete if the organization answered "Yes" on Form 990, Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

1a Is the organization an agent, trustee, custodian, or other intermediary for contributions or other assets not included on Form 990, Part X? ☐ Yes ☐ No

b If "Yes," explain the arrangement in Part XIII and complete the following table:

		Amount
c Beginning balance	1c	
d Additions during the year	1d	
e Distributions during the year	1e	
f Ending balance	1f	

2a Did the organization include an amount on Form 990, Part X, line 21, for escrow or custodial account liability? ☐ Yes ☐ No

b If "Yes," explain the arrangement in Part XIII. Check here if the explanation has been provided in Part XIII ☐

Part V Endowment Funds Complete if the organization answered "Yes" on Form 990, Part IV, line 10.

	(a) Current year	(b) Prior year	(c) Two years back	(d) Three years back	(e) Four years back
1a Beginning of year balance	278,744.	286,823.	310,022.	325,000.	302,000.
b Contributions	26,236.	8,079.	23,199.	14,978.	13,634.
c Net investment earnings, gains, and losses	26,236.	-8,079.	-23,199.	-14,978.	23,000.
d Grants or scholarships					
e Other expenditures for facilities and programs	26,236.	8,079.	23,199.	14,978.	13,634.
f Administrative expenses					
g End of year balance	304,980.	278,744.	286,823.	310,022.	325,000.

2 Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as:

a Board designated or quasi-endowment .0000 %
b Permanent endowment 100 %
c Term endowment .0000 %

The percentages on lines 2a, 2b, and 2c should equal 100%.

3a Are there endowment funds not in the possession of the organization that are held and administered for the organization by:

		Yes	No
(i) Unrelated organizations?	3a(i)	X	
(ii) Related organizations?	3a(ii)		X
b If "Yes" on line 3a(ii), are the related organizations listed as required on Schedule R?	3b		

4 Describe in Part XIII the intended uses of the organization's endowment funds.

Part VI Land, Buildings, and Equipment

Complete if the organization answered "Yes" on Form 990, Part IV, line 11a. See Form 990, Part X, line 10.

Description of property	(a) Cost or other basis (investment)	(b) Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value
1a Land		1,147,363.		1,147,363.
b Buildings		5,701,776.	3,805,505.	1,896,271.
c Leasehold improvements				
d Equipment		2,425,251.	1,931,880.	493,371.
e Other		243,105.	234,836.	8,269.
Total. Add lines 1a through 1e. *(Column (d) must equal Form 990, Part X, line 10c, column (B))*				3,545,274.

532052 04-01-25

Part VII Investments - Other Securities

Complete if the organization answered "Yes" on Form 990, Part IV, line 11b. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1) Financial derivatives		
(2) Closely held equity interests		
(3) Other		
(A) MAKENA PERPETUAL PRIVATE		
(B) EQUITY FUND	3,889,565.	END-OF-YEAR MARKET VALUE
(C) MAKENA PERPETUAL VENTURE		
(D) CAPITAL FUND	5,410,280.	END-OF-YEAR MARKET VALUE
(E)		
(F)		
(G)		
(H)		
Total. (Col. (b) must equal Form 990, Part X, line 12, col. (B))	9,299,845.	

Part VIII Investments - Program Related.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11c. See Form 990, Part X, line 13.

(a) Description of investment	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1)		
(2)		
(3)		
(4)		
(5)		
(6)		
(7)		
(8)		
(9)		
Total. (Col. (b) must equal Form 990, Part X, line 13, col. (B))		

Part IX Other Assets

Complete if the organization answered "Yes" on Form 990, Part IV, line 11d. See Form 990, Part X, line 15.

(a) Description	(b) Book value
(1)	
(2)	
(3)	
(4)	
(5)	
(6)	
(7)	
(8)	
(9)	
Total. *(Column (b) must equal Form 990, Part X, line 15, col. (B))*	

Part X Other Liabilities

Complete if the organization answered "Yes" on Form 990, Part IV, line 11e or 11f. See Form 990, Part X, line 25.

1. (a) Description of liability	(b) Book value
(1) Federal income taxes	
(2) CHARITABLE GIFT ANNUITIES	415,428.
(3) CAPITAL LEASE OBLIGATIONS	74,648.
(4) PNC SAHYUN CRUT RESERVE G++ ST	42,134.
(5) ITB VAUD RESERVE	69,060.
(6)	
(7)	
(8)	
(9)	
Total. *(Column (b) must equal Form 990, Part X, line 25, col. (B))*	601,270.

2. Liability for uncertain tax positions. In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FASB ASC 740. Check here if the text of the footnote has been provided in Part XIII ... X

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return

Complete if the organization answered "Yes" on Form 990, Part IV, line 12a.

1	Total revenue, gains, and other support per audited financial statements			1	77,936,079.
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:				
a	Net unrealized gains (losses) on investments	2a	3,480,815.		
b	Donated services and use of facilities	2b	18,340,051.		
c	Recoveries of prior year grants	2c	231,664.		
d	Other (Describe in Part XIII.)	2d			
e	Add lines 2a through 2d			2e	22,052,530.
3	Subtract line 2e from line 1			3	55,883,549.
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:				
a	Investment expenses not included on Form 990, Part VIII, line 7b	4a	278,280.		
b	Other (Describe in Part XIII.)	4b	2,157.		
c	Add lines 4a and 4b			4c	280,437.
5	Total revenue. Add lines **3** and **4c.** *(This must equal Form 990, Part I, line 12.)*			5	56,163,986.

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return

Complete if the organization answered "Yes" on Form 990, Part IV, line 12a.

1	Total expenses and losses per audited financial statements			1	74,740,452.
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:				
a	Donated services and use of facilities	2a	18,340,051.		
b	Prior year adjustments	2b			
c	Other losses	2c			
d	Other (Describe in Part XIII.)	2d			
e	Add lines 2a through 2d			2e	18,340,051.
3	Subtract line 2e from line 1			3	56,400,401.
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:				
a	Investment expenses not included on Form 990, Part VIII, line 7b	4a	278,280.		
b	Other (Describe in Part XIII.)	4b	12,459.		
c	Add lines 4a and 4b			4c	290,739.
5	Total expenses. Add lines **3** and **4c.** *(This must equal Form 990, Part I, line 18.)*			5	56,691,140.

Part XIII Supplemental Information

Provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part IV, lines 1b and 2b; Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

PART V, LINE 4:
THE EARNINGS ON THIS ENDOWMENT ARE AVAILABLE FOR THE ALZHEIMER'S DISEASE RESEARCH PROGRAM, ARE RECORDED AS TEMPORARILY RESTRICTED INVESTMENT INCOME, AND ARE RELEASED AS SPENT.

PART X, LINE 2:
BRIGHTFOCUS PERFORMED AN EVALUATION OF UNCERTAINTY IN INCOME TAXES FOR THE YEAR ENDED MARCH 31, 2026, AND DETERMINED THAT THERE WERE NO MATTERS THAT WOULD REQUIRE RECOGNITION IN THE CONSOLIDATED FINANCIAL STATEMENTS OR THAT MAY HAVE ANY EFFECT ON ITS TAX-EXEMPT STATUS.

PART XI, LINE 4B - OTHER ADJUSTMENTS:

RECLASSED RENTAL EXPENSES TO OCCUPANCY	2,157.

PART XII, LINE 4B - OTHER ADJUSTMENTS:

CHANGE IN PRESENT VALUE OF GRANTS	10,302.
RECLASSED RENTAL EXPENSES TO OCCUPANCY	2,157.
TOTAL TO SCHEDULE D, PART XII, LINE 4B	12,459.

Part XIII Supplemental Information *(continued)*

SCHEDULE F (Form 990)
(Rev. December 2024)
Department of the Treasury
Internal Revenue Service

Statement of Activities Outside the United States

Complete if the organization answered "Yes" on Form 990, Part IV, line 14b, 15, or 16.
Attach to Form 990.
Go to *www.irs.gov/Form990* for instructions and the latest information.

OMB No. 1545-0047

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I General Information on Activities Outside the United States.

Complete if the organization answered "Yes" on Form 990, Part IV, line 14b.

1 **For grantmakers.** Does the organization maintain records to substantiate the amount of its grants and other assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ..... [X] **Yes** [ ] **No**

2 **For grantmakers.** Describe in Part V the organization's procedures for monitoring the use of its grants and other assistance outside the United States.

3 Activities per Region. (The following Part I, line 3 table can be duplicated if additional space is needed.)

(a) Region	**(b)** Number of offices in the region	**(c)** Number of employees, agents, and independent contractors in the region	**(d)** Activities conducted in the region (by type) (such as, fundraising, program services, investments, grants to recipients located in the region)	**(e)** If activity listed in (d) is a program service, describe specific type of service(s) in the region	**(f)** Total expenditures for and investments in the region
EAST ASIA AND THE PACIFIC	0	0	GRANTMAKING		600,000.
EUROPE (INCLUDING ICELAND & GREENLAND)	0	0	GRANTMAKING		1,978,749.
NORTH AMERICA	0	0	GRANTMAKING		371,070.
SOUTH AMERICA	0	0	GRANTMAKING		392,874.
3 a Subtotal	0	0			3,342,693.
b Total from continuation sheets to Part I	0	0			0.
c Totals (add lines 3a and 3b)	0	0			3,342,693.

For Paperwork Reduction Act Notice, see the Instructions for Form 990. **Schedule F (Form 990) (Rev. 12-2024)**

LHA 532071 04-01-25

Part II **Grants and Other Assistance to Organizations or Entities Outside the United States.** Complete if the organization answered "Yes" on Form 990, Part IV, line 15, for any recipient who received more than $5,000. Part II can be duplicated if additional space is needed.

1 (a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of noncash assistance	(h) Description of noncash assistance	(i) Method of valuation (book, FMV, appraisal, other)
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY VLADISLAVA SEGEN, PHD ENTITLED: A2026010F	198,760.	WIRE TRANSFER	0.		
		EAST ASIA AND THE PACIFIC	ALZHEIMER'S DISEASE RESEARCH BY YIFEI CAI, PHD ENTITLED: A2026015S	300,000.	WIRE TRANSFER	0.		
		EAST ASIA AND THE PACIFIC	ALZHEIMER'S DISEASE RESEARCH BY ELEANOR DRUMMOND, PHD ENTITLED: A2026018S	300,000.	WIRE TRANSFER	0.		
		SOUTH AMERICA	ALZHEIMER'S DISEASE RESEARCH BY CLAUDIA DURAN-ANIOTZ, PHD ENTITLED: A2026019S	299,684.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY HUGO FERNANDES, PHD ENTITLED: A2026020S	200,000.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY KEIR YONG, PHD ENTITLED: A2026032S	291,740.	WIRE TRANSFER	0.		
		NORTH AMERICA	NATIONAL GLAUCOMA RESEARCH BY JEREMY SIVAK, PHD ENTITLED: G2026013S	150,000.	WIRE TRANSFER	0.		
		NORTH AMERICA	MACULAR DEGENERATION RESEARCH BY ANAS FRANON, PHD ENTITLED: M2026004F	200,000.	WIRE TRANSFER	0.		

2 Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as a tax exempt 501(c)(3) organization by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter 15

3 Enter total number of other organizations or entities 1

Part II **Continuation of Grants and Other Assistance to Organizations or Entities Outside the United States.** (Schedule F (Form 990), Part II, line 1)

1 (a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of non-cash assistance	(h) Description of non-cash assistance	(i) Method of valuation (book, FMV, appraisal, other)
		EUROPE (INCLUDING ICELAND & GREENLAND)	MACULAR DEGENERATION RESEARCH BY SARAH PALKO, PHD ENTITLED: M2026006F	199,999.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	MACULAR DEGENERATION RESEARCH BY PETRA LARSEN, MD, PHD ENTITLED: M2026010N	450,000.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY DANIEL BOS, PHD ENTITLED: A2025028S	299,000.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	BIRAX RESEARCH FUNDING, ENTITLED: CA2023002	120,314.	WIRE TRANSFER	0.		
		NORTH AMERICA	MIND AND SIGHT DISEASES RESEARCH FUNDING, ENTITLED: CA2023003	21,070.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY JAMES COLE, PHD ENTITLED: CA2026001	104,810.	WIRE TRANSFER	0.		
		EUROPE (INCLUDING ICELAND & GREENLAND)	ALZHEIMER'S DISEASE RESEARCH BY BEN GOULT, PHD ENTITLED: CA2026002	114,126.	WIRE TRANSFER	0.		
		SOUTH AMERICA	ALZHEIMER'S DISEASE RESEARCH BY MARIA CAROLINA DALMASSO, PHD ENTITLED:	93,190.	WIRE TRANSFER	0.		

Part III **Grants and Other Assistance to Individuals Outside the United States.** Complete if the organization answered "Yes" on Form 990, Part IV, line 16.
Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	**(b)** Region	**(c)** Number of recipients	**(d)** Amount of cash grant	**(e)** Manner of cash disbursement	**(f)** Amount of noncash assistance	**(g)** Description of noncash assistance	**(h)** Method of valuation (book, FMV, appraisal, other)

Part IV Foreign Forms

1	Was the organization a U.S. transferor of property to a foreign corporation during the tax year? *If "Yes," the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see the Instructions for Form 926)*	☐ Yes	☒ No
2	Did the organization have an interest in a foreign trust during the tax year? *If "Yes," the organization may be required to separately file Form 3520, Annual Return To Report Transactions With Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see the Instructions for Forms 3520 and 3520-A; don't file with Form 990)*	☐ Yes	☒ No
3	Did the organization have an ownership interest in a foreign corporation during the tax year? *If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons With Respect to Certain Foreign Corporations (see the Instructions for Form 5471)*	☐ Yes	☒ No
4	Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? *If "Yes," the organization may be required to file Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund (see the Instructions for Form 8621)*	☐ Yes	☒ No
5	Did the organization have an ownership interest in a foreign partnership during the tax year? *If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons With Respect to Certain Foreign Partnerships (see the Instructions for Form 8865)*	☐ Yes	☒ No
6	Did the organization have any operations in or related to any boycotting countries during the tax year? *If "Yes," the organization may be required to separately file Form 5713, International Boycott Report (see the Instructions for Form 5713; don't file with Form 990)*	☐ Yes	☒ No

Part V **Supplemental Information**

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

PART I, LINE 2:
BEFORE AN INTERNATIONAL GRANT IS AWARDED OR PAID, BRIGHTFOCUS CONFIRMS THAT THE RECIPIENT AND/OR INSTITUTION SUPPORTING THE RESEARCH IS NOT INCLUDED ON THE OFAC (OFFICE OF FOREIGN ASSETS CONTROL) SANCTIONS LIST OR THE INTERNATIONAL BOYCOTT LIST ON THE FEDERAL REGISTER.

AFTER AN INTERNATIONAL GRANT IS AWARDED, BRIGHTFOCUS INTERACTS WITH ALL GRANTEES AT LEAST QUARTERLY BY E-MAIL OR AT SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS TO BRIGHTFOCUS. THESE ARE RECEIVED BY THE BRIGHTFOCUS SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF WITH BROAD EXPERTISE, INCLUDING IMAGING, MOLECULAR BIOLOGY AND SIGNALING PATHWAYS, CELL BIOLOGY, ANGIOGENESIS, BIOCHEMISTRY, NEUROSCIENCE, AND GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATES THE PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE BRIGHTFOCUS SCIENTIFIC REVIEW COMMITTEES, WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH BRIGHTFOCUS-SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, AND NOT RESOLVED AFTER INTERACTION WITH THE AWARD GRANTEE, THE BRIGHTFOCUS STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE SCIENTIFIC AFFAIRS COMMITTEE OF THE BOARD OF DIRECTORS. IN ACCORDANCE WITH THE GRANT AGREEMENT TERMS AND CONDITIONS, BRIGHTFOCUS MAY WITHHOLD FUNDING, OR DISCONTINUE AN AWARD, FOR ANY GRANTEE THAT FAILS TO ACHIEVE SUFFICIENT PROGRESS OR SUBMIT REQUIRED REPORTS.

AT THE CONCLUSION OF THE GRANT AWARD PERIOD, EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE BRIGHTFOCUS SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO THE IMPACT OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF BRIGHTFOCUS-SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY BRIGHTFOCUS. THIS IMPACT IS FURTHER SUPPORTED BY ANNUAL CATEGORY NORMALIZED CITATION IMPACT ANALYSIS THAT COMPARES BRIGHTFOCUS-SUPPORTED WORKS TO AN UNBIASED COMPARISON OF IMPACT PERFORMANCE VERSUS THE WORLD AVERAGE. BRIGHTFOCUS-SUPPORTED PUBLICATIONS WERE RECENTLY CITED AT 2 TIMES THE FREQUENCY OF THE WORLD AVERAGE. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF BRIGHTFOCUS GRANTEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES ADDITIONAL GRANTS FOR FOLLOW-ON PROJECTS SPAWNED BY THE BRIGHTFOCUS GRANT, WITH VALUES UP TO 8 TIMES THE LEVEL OF THE INITIAL BRIGHTFOCUS INVESTMENT.

BRIGHTFOCUS SOLICITS FEEDBACK FROM ITS GRANTEES AND PROVIDES AN ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THROUGH THE BRIGHTFOCUS FOUNDATION WEBSITE AND WITHIN THE SCIENTIFIC PROGRESS REPORTS, THERE ARE DESIGNATED SECTIONS WHERE AWARDEES ARE ASKED TO PROVIDE FEEDBACK TO THE FOUNDATION. THROUGH THIS MECHANISM, THEY ARE GIVEN THE ABILITY TO ANONYMOUSLY PROVIDE FEEDBACK OR COMMUNICATE THEIR CONCERNS TO PROGRAM STAFF OR THE BRIGHTFOCUS' COMPLIANCE OFFICE. ANY SUGGESTIONS, CONCERNS, COMPLAINTS, OR

Part V **Supplemental Information**

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE ATTENTION OF BRIGHTFOCUS IN THIS MANNER, SO THAT BRIGHTFOCUS CAN ADDRESS ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR LEADERSHIP PRESENTS AND SUMMARIZES THE STATUS AND PROGRESS ON GRANTS TO THE BRIGHTFOCUS BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS.

PART I, LINE 3:
BRIGHTFOCUS REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD USED IN ITS AUDITED FINANCIAL STATEMENTS WHICH IS ON AN ACCRUAL BASIS.

PART II, LINE 1:
BRIGHTFOCUS REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD USED IN ITS AUDITED FINANCIAL STATEMENTS WHICH IS ON AN ACCRUAL BASIS.

PART II, LINE 1, COLUMN (D)
REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY VLADISLAVA SEGEN, PHD ENTITLED: A2026010F TRACKING EARLY ALZHEIMER'S DISEASE OVER TIME THROUGH SPATIAL NAVIGATION. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE OFTEN DAMAGES THE BRAIN LONG BEFORE MEMORY PROBLEMS APPEAR. CURRENT TESTS AND BLOOD MARKERS CANNOT FULLY CAPTURE THESE EARLIEST CHANGES. THIS PROJECT USES VIRTUAL REALITY NAVIGATION TASKS, ADVANCED BRAIN IMAGING, AND SPINAL FLUID TESTS TO STUDY "PATH INTEGRATION"THE ABILITY TO TRACK ONE'S POSITION WHILE MOVINGWHICH IS DISRUPTED VERY EARLY IN ALZHEIMER'S. BY LINKING THESE NAVIGATION CHANGES TO BRAIN AND MOLECULAR CHANGES, THIS WORK AIMS TO DEVELOP A SENSITIVE NEW TOOL FOR EARLY DETECTION AND MONITORING OF THE DISEASE. GRANT AWARDED: $198760, GERMAN CENTER FOR NEURODEGENERATIVE DISEASES, MAGDEBURG, GERMANY.

REGION: EAST ASIA & THE PACIFIC (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY YIFEI CAI, PHD ENTITLED: A2026015S UNCOVERING MECHANISMS OF MYELIN-AXON PATHOLOGY IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: MYELIN AND AXONS INTERACT RECIPROCALLY TO ENABLE FAST SIGNAL TRANSDUCTION, NEURONAL PLASTICITY, LEARNING AND MEMORY. MYELIN AND AXONAL PATHOLOGY ARE INVOLVED IN ALZHEIMER'S DISEASE (AD). HOWEVER, THE PRECISE MECHANISMS OF MYELIN-AXON DISRUPTION REMAIN POORLY UNDERSTOOD. THIS PROJECT AIMS TO DELINEATE THE COMPLEX INTERACTION BETWEEN MYELIN AND AXONS BY USING SUBCELLULAR PROTEOMICS AT THE MYELIN-AXON INTERFACE, IPSC MODELING, INTRAVITAL IMAGING AND GENETIC MANIPULATION, WITH THE ULTIMATE GOAL TO IDENTIFY MOLECULAR TARGETS WITH THERAPEUTIC POTENTIAL TO REVERSE THE MYELIN-AXONAL DEFICIT IN AD. GRANT AWARDED: $300000, SHANGHAI JIAO TONG UNIVERSITY, SHANGHAI, CHINA.

REGION: EAST ASIA & THE PACIFIC (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY ELEANOR DRUMMOND, PHD ENTITLED: A2026018S EARLY PROTEIN DRIVERS OF ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THIS STUDY WILL EXPLORE THE PATHOLOGICAL ROLE OF TEN PROTEINS THAT WE BELIEVE TO PROMOTE THE DEVELOPMENT OF NEUROPATHOLOGY IN ALZHEIMER'S DISEASE (AD). WE WILL STUDY THE LOCATION OF EACH OF THESE PROTEINS IN THE BRAINS OF PEOPLE WITH AD, WILL DETERMINE IF THEY INTERACT WITH OTHER MAJOR PROTEINS THAT MAKE UP THE PLAQUES AND THE TANGLES IN AD, AND WILL DETERMINE IF THESE PROTEINS CAUSE CELL DEATH. TOGETHER, THESE

Part V **Supplemental Information**

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

RESULTS WILL HELP DETERMINE IF OUR PROTEINS OF INTEREST ARE POTENTIAL NEW DRUG TARGETS OR BIOMARKERS FOR AD. GRANT AWARDED: $300000, THE UNIVERSITY OF SYDNEY, SYDNEY, AUSTRALIA.

REGION: SOUTH AMERICA (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CLAUDIA DURAN-ANIOTZ, PHD ENTITLED: A2026019S HOW SOCIAL CONDITIONS AND LIFESTYLE INFLUENCE DEMENTIA BIOMARKERS IN LATIN AMERICA. INVESTIGATOR'S SUMMARY: DEMENTIA IN THE LATIN AMERICA POPULATION IS STRONGLY SHAPED BY SOCIAL DISPARITIES AND LIFESTYLE CHOICES, YET MOST RESEARCH COMES FROM OTHER REGIONS, LEAVING KEY QUESTIONS UNANSWERED OF THEIR ROLE IN DEMENTIA BIOLOGY. OUR STUDY WILL USE BLOOD DEMENTIA BIOMARKERS, A NON-INVASIVE TOOL FOR DETECTING BRAIN CHANGES ASSOCIATED WITH DEMENTIA, TO INVESTIGATE HOW THESE SOCIAL AND LIFESTYLE FACTORS IMPACT ON THE PRESENTATION AND CHARACTERIZATION OF DEMENTIA IN LATIN AMERICA. THE RESULTS WILL HELP IDENTIFY RISKS WE CAN CHANGE AND GUIDE FAIR, CULTURALLY RELEVANT STRATEGIES FOR CARE AND PREVENTION. GRANT AWARDED: $299684, ADOLFO IBANEZ UNIVERSITY, SANTIAGO, CHILE.

REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY HUGO FERNANDES, PHD ENTITLED: A2026020S MAPPING HOW CELL COMPARTMENTS HANDLE FATS IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: FATS (LIPIDS) MAKE UP AROUND 60% OF THE HUMAN BRAIN AND PLAY AN ESSENTIAL ROLE IN SUSTAINING BRAIN HEALTH. WE NOW KNOW THAT ALZHEIMER'S DISEASE SEVERELY DISRUPTS THE CELLULAR PATHWAYS RESPONSIBLE FOR MAKING AND ORGANISING THESE LIPIDS. HOWEVER, THE PRECISE DETAILS ON HOW THESE PATHWAYS WORK, AND WHAT GOES WRONG WITH THEM DURING THE DISEASE, ARE POORLY UNDERSTOOD. TO OVERCOME THIS KNOWLEDGE GAP, OUR TEAM WILL DEVELOP NEW METHODS TO MEASURE AND UNDERSTAND CHANGES IN LIPIDS INSIDE BRAIN CELLS. THESE FINDINGS COULD RESULT IN NEW THERAPEUTIC TARGETS TO TREAT THE DISEASE. GRANT AWARDED: $200000, UNIVERSITY OF OXFORD, OXFORD, UNITED KINGDOM.

REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY KEIR YONG, PHD ENTITLED: A2026032S VISUAL SYSTEM VULNERABILITY IN DEMENTIA: FROM DETECTION TO DETERMINANTS. INVESTIGATOR'S SUMMARY: CORTICAL VISUAL ('BRAINSIGHT' NOT EYESIGHT LOSS) IS THE EARLIEST SIGN OF DEMENTIA FOR PEOPLE WITH POSTERIOR CORTICAL ATROPHY, IN WHOM VULNERABILITY OF THE BRAIN'S VISUAL RATHER THAN MEMORY SYSTEM CAUSES 'VISUAL-LED ALZHEIMER'S DISEASE'. WE WILL USE A NOVEL BRAINSIGHT TEST AND BRAIN SCANS FROM 35,000 VOLUNTEERS IN A NATIONAL AGEING STUDY (UK BIOBANK) TO IMPROVE DETECTION OF VISUAL SYSTEM VULNERABILITY. WE WILL COMPARE GENETIC RISK FACTORS ASSOCIATED WITH VISUAL SYSTEM VULNERABILITY AND VISUAL-LED ALZHEIMER'S DISEASE TO DETERMINE WHY ALZHEIMER'S DISEASE MAY AFFECT PEOPLE IN DIFFERENT WAYS. GRANT AWARDED: $291740, UNIVERSITY COLLEGE LONDON, LONDON, UNITED KINGDOM.

REGION: NORTH AMERICA (WHICH INCLUDES CANADA AND MEXICO, BUT NOT THE U.S.) (D) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY JEREMY SIVAK, PHD ENTITLED: G2026013S SPATIALLY RESOLVING THE MOLECULAR MECHANISMS LINKING PRESSURE AND OPTIC NEUROPATHY IN GLAUCOMA. INVESTIGATOR'S SUMMARY: GLAUCOMA IRREVERSIBLY DAMAGES RETINAL AND OPTIC NERVE TISSUE, OFTEN IN ASSOCIATION WITH HIGH EYE PRESSURE. YET, HOW PRESSURE AFFECTS

Part V **Supplemental Information**

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

THIS TISSUE IN HUMAN EYES IS UNCLEAR. USING A NEW HUMAN TISSUE MODEL WE PROFILED ACUTE NEUROINFLAMMATORY RESPONSES TO PRESSURE. WE WILL COMPARE THESE DATA TO LONG-TERM CHANGES PRESENT IN GLAUCOMA SAMPLES TO UNCOVER CRITICAL LINKS BETWEEN PRESSURE AND DISEASE. GRANT AWARDED: $150000, UNIVERSITY HEALTH NETWORK, TORONTO, CANADA.

REGION: NORTH AMERICA (WHICH INCLUDES CANADA AND MEXICO, BUT NOT THE U.S.) (D) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY ANAS FRANON, PHD ENTITLED: M2026004F ROLE OF LACK OF SLEEP IN THE DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD) IS A LEADING CAUSE OF BLINDNESS IN DEVELOPED COUNTRIES. LATE PHASES OF THE DISEASE ARE MARKED BY RETINAL DEGENERATION, CHRONIC INFLAMMATION AND ABNORMAL BLOOD VESSEL GROWTH. AMD IS DRIVEN BY GENETIC AND ENVIRONMENTAL FACTORS. AN UNDERSTUDIED FACTOR THAT MAY PREDISPOSE TO NEUROINFLAMMATORY CONDITIONS SUCH AS AMD IS SLEEP DEFICIENCY (SD), AFFECTING NEARLY 30% OF AMERICAN ADULTS. HERE, WE INVESTIGATE A POTENTIAL ROLE OF SD IN CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH AMD AND HOW SD REPROGRAMS THE INNATE IMMUNE SYSTEM TOWARDS DESTRUCTIVE NEUROINFLAMMATION. GRANT AWARDED: $200000, HPITAL MAISONNEUVE-ROSEMONT, MONTREAL, CANADA.

PART II, LINE 1, COLUMN (D) CONTINUED
REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY SARAH PALKO, PHD ENTITLED: M2026006F HOW RETINAL CELLS DRIVE INFLAMMATION IN AGE RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD) CAUSES THE LOSS OF CENTRAL VISION AS KEY RETINAL CELLS DETERIORATE. INFLAMMATION PLAYS A MAJOR ROLE, AND IMMUNE CELLS FROM THE BLOOD CAN ENTER THE RETINA AND WORSEN DAMAGE. THIS PROJECT WILL TEST WHETHER SUPPORT CELLS IN THE RETINA, CALLED MLLER GLIA, SEND SIGNALS THAT ATTRACT THESE IMMUNE CELLS. BY BLOCKING ONE OF THEIR MAJOR SIGNALING PATHWAYS, WE AIM TO REDUCE HARMFUL IMMUNE CELLS FROM ENTERING THE TISSUE AND REDUCE THE DISEASE PROGRESSION IN MODELS OF AMD. GRANT AWARDED: $199999, TRINITY COLLEGE DUBLIN, DUBLIN, IRELAND.

REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY PETRA LARSEN, MD, PHD ENTITLED: M2026010N LINKING RETINAL IMAGING AND MOLECULAR CHANGES IN AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD) IS A LEADING CAUSE OF VISION LOSS, YET IT MAY AFFECT EACH PERSON DIFFERENTLY. THIS PROJECT COMBINES DETAILED EYE SCANS WITH GENETIC AND BLOOD-BASED MOLECULAR ANALYSES TO UNCOVER THE BIOLOGICAL PROCESSES BEHIND THESE DIFFERENCES. BY LINKING GENETIC AND MOLECULAR SIGNALS TO CHANGES IN THE RETINA, WE AIM TO IDENTIFY PEOPLE AT HIGHEST RISK, UNDERSTAND DISEASE PROGRESSION, AND GUIDE THE DEVELOPMENT OF PERSONALIZED STRATEGIES TO PROTECT VISION. THE ULTIMATE GOAL IS TO PRESERVE SIGHT, IMPROVE QUALITY OF LIFE, AND INFORM TARGETED INTERVENTIONS FOR AMD. GRANT AWARDED: $450000, GERMAN CENTER FOR NEURODEGENERATIVE DISEASES, BONN, GERMANY.

REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DANIEL BOS, MD, PHD ENTITLED: A2025028S CHANGES IN CEREBRAL BLOOD FLOW AND DEMENTIA. INVESTIGATOR'S SUMMARY: WE WILL INVESTIGATE HOW BLOOD FLOW AFFECTS THE WALLS OF NECK ARTERIES IN

Part V **Supplemental Information**

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

PEOPLE WHO SHOW EARLY SIGNS OF ARTERY DISEASE BUT DON'T YET HAVE SYMPTOMS. WE ALSO WANT TO FIND OUT WHAT FACTORSLIKE AGE, BLOOD PRESSURE, OR ARTERY SHAPEMIGHT INFLUENCE HOW MUCH PRESSURE THE BLOOD PUTS ON THESE ARTERY WALLS. WE WILL INVESTIGATE WHETHER UNUSUAL BLOOD FLOW IN THESE ARTERIES IS LINKED TO HIDDEN BRAIN PROBLEMS, LIKE SHRINKING BRAIN TISSUE OR EARLY MEMORY AND THINKING ISSUES. GRANT AWARDED: $299000, ERASMUS UNIVERSITY MEDICAL CENTER, ROTTERDAM, NETHERLANDS.

REGION: EUROPE (INCLUDING ICELAND AND GREENLAND) (D) PURPOSE OF GRANT: BIRAX RESEARCH FUNDING, ENTITLED: CA2023002 HIGH GRANULARITY IMMUNE PHENOTYPING IN AGEING TOWARDS MOLECULAR MARKERS OF DECLINED IMMUNITY, CHRONIC INFLAMMATION AND NEURODEGENERATIVE DISEASE. GRANT AWARDED: $120313.77, THE BRITISH COUNCIL, LONDON, UNITED KINGDOM.

REGION: NORTH AMERICA (D) PURPOSE OF GRANT: MIND AND SIGHT DISEASES RESEARCH FUNDING, ENTITLED: CA2023003 SUPPORT THE CANADIAN INSTITUTES OF HEALTH RESEARCH'S EXCELLENCE, DIVERSITY, AND INDEPENDENCE EARLY CAREER TRANSITION AWARD IN THE CATEGORIES OF BRAIN HEALTH AND VISION DISEASES. THESE AWARDS WILL PROVIDE EARLY-CAREER SUPPORT TO RESEARCHERS FROM SPECIFIC UNDERREPRESENTED GROUPS STUDYING TREATMENTS AND CURES FOR ALZHEIMER'S, AGE-RELATED MACULAR DEGENERATION, AND GLAUCOMA. GRANT AWARDED: $21070, CANADIAN INSTITUTES OF HEALTH RESEARCH, OTTAWA, CANADA.

REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JAMES COLE, PHD ENTITLED: CA2026001 HOW AGING AND ALZHEIMER'S AFFECT THE BRAIN'S BLOOD FLOW . INVESTIGATOR'S SUMMARY: MAKE A STATISTICAL MODEL OF HOW THE BRAIN'S BLOOD FLOW (CEREBRAL BLOOD FLOW: CBF) CHANGES OVER THE LIFESPAN USING A BRAIN SCANNING METHOD CALLED ARTERIAL SPIN LABELLING (ASL). THE MODEL WILL ALLOW US TO ESTABLISH WHAT IT 'NORMAL' CBF FOR A PERSON'S AGE AND SEX. IDENTIFY THE CONTRIBUTIONS OF CARDIOVASCULAR RISK FACTORS, ETHNICITY, AND GENETICS TO PATTERNS OF CBF IN COGNITIVELY UNIMPAIRED PEOPLE, OVER TIME. INVESTIGATE PATTERNS OF CBF AGEING TRAJECTORIES IN PATIENTS WITH CEREBRAL AMYLOID ANGIOPATHY (CAA), CEREBRAL SMALL VESSEL DISEASE (CSVD) OR ALZHEIMER'S DISEASE. GRANT AWARDED: $104810, UNIVERSITY COLLEGE LONDON, LONDON, UNITED KINGDOM.

REGION: EUROPE (INCLUDING ICELAND & GREENLAND) (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY BEN GOULT, PHD ENTITLED: CA2026002 A NEW ROLE FOR AMYLOID PRECURSOR PROTEIN AS A MECHANICAL LINKER IN NEURONS. INVESTIGATOR'S SUMMARY: SYNAPSES UNDERGO ACTIVITY-DEPENDENT STRUCTURAL CHANGES INVOLVING FORCE-BEARING/GENERATING ELEMENTS, INCLUDING THE CYTOSKELETON AND CELL ADHESION MOLECULES (CAMS). AMYLOID PRECURSOR PROTEIN (APP) IS NOT ONLY A KEY PROTEIN IN ALZHEIMER'S DISEASE (AD) DUE TO ITS SYNAPTOTOXIC CLEAVAGE PRODUCT, A PEPTIDE, BUT ALSO A SYNAPTIC CAM THAT FORMS BOTH CIS- AND TRANS-HOMODIMERS. WE RECENTLY SHOWED THAT APP INTERACTS WITH TALIN, WHICH ACTS AS A MECHANICAL SIGNALING HUB INDICATING THAT APP MIGHT BE FORMING A MECHANICAL LINKAGE. WE AIM TO TEST (I) WHETHER APP MEDIATED ADHESION COMPLEXES ARE FORCE BEARING, (II) ARE IMPACTED BY AD-ASSOCIATED VARIANTS, AND (III) HOW DOES MECHANO-SIGNALING UPSTREAM/DOWNSTREAM OF APP IMPACT ON APP METABOLISM, TOWARDS A BETTER UNDERSTANDING OF APP

Part V **Supplemental Information**

Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

(DYS)FUNCTION IN THE CONTEXT OF AD. GRANT AWARDED: $114126, UNIVERSITY OF LIVERPOOL, LIVERPOOL, UNITED KINGDOM.

REGION: SOUTH AMERICA (D) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MARIA CAROLINA DALMASSO, PHD ENTITLED: CA2026003 HOW BIOLOGY AND BLOOD MARKERS SHAPE ALZHEIMER'S RISK IN DIVERSE COMMUNITIES . INVESTIGATOR'S SUMMARY: WE WILL COMPARE BLOOD BIOMARKERS OF ALZHEIMER'S DISEASE IN GROUPS FROM GERMANY, ARGENTINA, AND BRAZIL, ASSESSING HOW ANCESTRY, HEALTH HISTORY, AND ENVIRONMENTAL EXPOSURES AFFECT BIOMARKER LEVELS AND ACCURACY. USING ADVANCED HIGH-THROUGHPUT METHODS, WE WILL MEASURE THOUSANDS OF BLOOD PROTEINS, INCLUDING LOW-ABUNDANCE ONES OFTEN MISSED BY STANDARD APPROACHES, TO IDENTIFY DISEASE-RELATED PATHWAYS AND POTENTIAL NEW BIOMARKERS. WE WILL INTEGRATE GENETIC, ENVIRONMENTAL, AND PROTEIN DATA TO UNCOVER SHARED AND POPULATION-SPECIFIC MECHANISMS RELEVANT FOR INCLUSIVE DIAGNOSIS. GRANT AWARDED: $93190, NEUROSCIENCES AND COMPLEX SYSTEMS UNIT, BUENOS AIRES, ARGENTINA.

SCHEDULE G (Form 990)

(Rev. December 2024)

Department of the Treasury
Internal Revenue Service

Supplemental Information Regarding Fundraising or Gaming Activities

Complete if the organization answered "Yes" on Form 990, Part IV, line 17, 18, or 19, or if the organization entered more than $15,000 on Form 990-EZ, line 6a.

Attach to Form 990 or Form 990-EZ.

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I Fundraising Activities. Complete if the organization answered "Yes" on Form 990, Part IV, line 17. Form 990-EZ filers are not required to complete this part.

1 Indicate whether the organization raised funds through any of the following activities. Check all that apply.

- **a** [X] Mail solicitations
- **b** [X] Internet and email solicitations
- **c** [ ] Phone solicitations
- **d** [ ] In-person solicitations
- **e** [X] Solicitation of nongovernment grants
- **f** [ ] Solicitation of government grants
- **g** [ ] Special fundraising events

2 a Did the organization have a written or oral agreement with any individual (including officers, directors, trustees, or key employees listed in Form 990, Part VII) or entity in connection with professional fundraising services? [X] **Yes** [ ] **No**

b If "Yes," list the 10 highest paid individuals or entities (fundraisers) pursuant to agreements under which the fundraiser is to be compensated at least $5,000 by the organization.

(i) Name and address of individual or entity (fundraiser)	**(ii)** Activity	**(iii)** Did fundraiser have custody or control of contributions? Yes	**(iii)** No	**(iv)** Gross receipts from activity	**(v)** Amount paid to (or retained by) fundraiser listed in col. **(i)**	**(vi)** Amount paid to (or retained by) organization
RKD GROUP - 35 PARKWOOD DRIVE, STE. 160, HOPKINTON,	FUNDRAISING AND COMMUNICATIONS CONSULTANT		X	39,920,110.	588,268.	39,331,842.
Total				39,920,110.	588,268.	39,331,842.

3 List all states in which the organization is registered or licensed to solicit contributions or has been notified it is exempt from registration or licensing.

AK,AL,AR,AZ,CA,CO,CT,DC,FL,GA,HI,IL,KS,KY,LA,MA,MD,ME,MI,MN,MO,MS,NC,ND,NH
NJ,NM,NV,OH,OK,OR,PA,RI,SC,TN,UT,VA,WA,WI,WV

Part II **Fundraising Events.** Complete if the organization answered "Yes" on Form 990, Part IV, line 18, or reported more than $15,000 of fundraising event contributions and gross income on Form 990-EZ, lines 1 and 6b. List events with gross receipts greater than $5,000.

		(a) Event #1	(b) Event #2	(c) Other events	(d) Total events (add col. (a) through col. (c))
		(event type)	(event type)	(total number)	
Revenue	1 Gross receipts				
	2 Less: Contributions				
	3 Gross income (line 1 minus line 2)				
Direct Expenses	4 Cash prizes				
	5 Noncash prizes				
	6 Rent/facility costs				
	7 Food and beverages				
	8 Entertainment				
	9 Other direct expenses				
	10 Direct expense summary. Add lines 4 through 9 in column (d)				
	11 Net income summary. Subtract line 10 from line 3, column (d)				

Part III **Gaming.** Complete if the organization answered "Yes" on Form 990, Part IV, line 19, or reported more than $15,000 on Form 990-EZ, line 6a.

		(a) Bingo	(b) Pull tabs/instant bingo/progressive bingo	(c) Other gaming	(d) Total gaming (add col. (a) through col. (c))
Revenue	1 Gross revenue				
Direct Expenses	2 Cash prizes				
	3 Noncash prizes				
	4 Rent/facility costs				
	5 Other direct expenses				
	6 Volunteer labor	☐ Yes_____ % ☐ No	☐ Yes_____ % ☐ No	☐ Yes_____ % ☐ No	
	7 Direct expense summary. Add lines 2 through 5 in column (d)				
	8 Net gaming income summary. Subtract line 7 from line 1, column (d)				

9 Enter the state(s) in which the organization conducts gaming activities: _____

a Is the organization licensed to conduct gaming activities in each of these states? ☐ Yes ☐ No

b If "No," explain: _____

10a Were any of the organization's gaming licenses revoked, suspended, or terminated during the tax year? ☐ Yes ☐ No

b If "Yes," explain: _____

11 Does the organization conduct gaming activities with nonmembers? ☐ Yes ☐ No

12 Is the organization a grantor, beneficiary or trustee of a trust, or a member of a partnership or other entity formed to administer charitable gaming? ☐ Yes ☐ No

13 Indicate the percentage of gaming activity conducted in:

a The organization's facility	**13a**	%
b An outside facility	**13b**	%

14 Enter the name and address of the person who prepares the organization's gaming/special events books and records:

Name _____

Address _____

15a Does the organization have a contract with a third party from whom the organization receives gaming revenue? ☐ Yes ☐ No

b If "Yes," enter the amount of gaming revenue received by the organization $ _____ and the amount of gaming revenue retained by the third party $ _____

c If "Yes," enter the name and address of the third party:

Name _____

Address _____

16 Gaming manager information:

Name _____

Gaming manager compensation $ _____

Description of services provided _____

☐ Director/officer ☐ Employee ☐ Independent contractor

17 Mandatory distributions:

a Is the organization required under state law to make charitable distributions from the gaming proceeds to retain the state gaming license? ☐ Yes ☐ No

b Enter the amount of distributions required under state law to be distributed to other exempt organizations or spent in the organization's own exempt activities during the tax year $

Part IV Supplemental Information. Provide the explanations required by Part I, line 2b, columns (iii) and (v); and Part III, lines 9, 9b, 10b, 15b, 15c, 16, and 17b, as applicable. Also provide any additional information. See instructions.

SCHEDULE G, PART I, LINE 2B, LIST OF TEN HIGHEST PAID FUNDRAISERS:

(I) NAME OF FUNDRAISER: RKD GROUP
(I) ADDRESS OF FUNDRAISER:
35 PARKWOOD DRIVE, STE. 160, HOPKINTON, MA 01748

PART I, LINE 2B, COLUMN (V):
IN THE CONTRACT WITH RKD GROUP, THE MANAGEMENT FEES ARE FIXED AMOUNTS PER MONTH FOR IN-SCOPE SERVICES THAT TOTALS $1,280,590 PER YEAR OF WHICH $655,028 HAS BEEN ALLOCATED UNDER PART IX, LINE 11(G) TO PROGRAM AND MANAGEMENT AND ARE NOT CONSIDERED TO BE THE PROFESSIONAL FUNDRAISING CONSULTANT FEE.

Part IV **Supplemental Information** *(continued)*

SCHEDULE I (Form 990)
(Rev. December 2024)
Department of the Treasury
Internal Revenue Service

Grants and Other Assistance to Organizations, Governments, and Individuals in the United States

Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.

Attach to Form 990.

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

Open to Public Inspection

Name of the organization
BRIGHTFOCUS FOUNDATION

Employer identification number
23-7337229

Part I General Information on Grants and Assistance

1 Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? ..... [X] Yes [ ] No

2 Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than $5,000. Part II can be duplicated if additional space is needed.

1 (a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of noncash assistance	(h) Purpose of grant or assistance
MASSACHUSETTS EYE AND EAR INFIRMARY - 243 CHARLES ST - BOSTON, MA 02114	42-2103591	501(C)(3)	450,000.	0.			MACULAR DEGENERATION RESEARCH BY RYOJI AMAMOTO, PHD ENTITLED: M2026008N
NORTHEASTERN UNIVERSITY 360 HUNTINGTON AVENUE BOSTON, MA 02115	04-1679980	501(C)(3)	450,000.	0.			MACULAR DEGENERATION RESEARCH BY AMIR VAHABIKASHI, PHD ENTITLED: M2026013N
PURDUE UNIVERSITY 206 S MARTIN JISCHKE DR WEST LAFAYETTE, IN 47907	35-6002041	501(C)(3)	450,000.	0.			MACULAR DEGENERATION RESEARCH BY SUNGHEE PARK, PHD ENTITLED: M2026012N
UNIVERSITY OF MICHIGAN 1000 VICTORS WAY ANN ARBOR, MI 48108	38-6006309	501(C)(3)	450,000.	0.			MACULAR DEGENERATION RESEARCH BY MARK DRAELOS, MD, PHD ENTITLED: M2026009N
UNIVERSITY OF MICHIGAN 1000 VICTORS WAY ANN ARBOR, MI 48108	38-6006309	501(C)(3)	450,000.	0.			MACULAR DEGENERATION RESEARCH BY JASON MILLER, MD, PHD ENTITLED: M2026011N
MASSACHUSETTS GENERAL HOSPITAL 114 SIXTEENTH ST CHARLESTOWN, MA 02129	04-2697983	501(C)(3)	445,800.	0.			MACULAR DEGENERATION RESEARCH BY DAVID VEYSSET, PHD ENTITLED: M2026014N

2 Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ..... 63.

3 Enter total number of other organizations listed in the line 1 table ..... 0.

Part II **Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments** (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
BRIGHAM AND WOMEN'S HOSPITAL 60 FENWOOD ROAD 10002I BOSTON, MA 02115	04-2312909	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY LAURA COX, PHD ENTITLED: A2026016S
EMORY UNIVERSITY 1599 CLIFTON ROAD NE, 4TH FLOOR ATLANTA, GA 30322	58-0566256	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY SAIMA RATHORE, PHD ENTITLED: A2026026S
EMORY UNIVERSITY 1599 CLIFTON ROAD NE, 4TH FLOOR ATLANTA, GA 30322	58-0566256	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY QI ZHANG, PHD ENTITLED: A2026033S
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI - 1425 MADISON AVENUE, FLOOR 9 ROOM 9-02C - NEW YORK, NY 10029	13-6171197	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY SELENE LOMOIO, PHD ENTITLED: A2026023S
MASSACHUSETTS GENERAL HOSPITAL 114 SIXTEENTH ST CHARLESTOWN, MA 02129	04-2697983	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY HEIDI JACOBS, PHD ENTITLED: A2026022S
MEMORIAL SLOAN KETTERING CANCER CENTER - 1275 YORK AVENUE - NEW YORK, NY 10065	13-1924236	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY JUSTIN PERRY, PHD ENTITLED: A2026025S
OKLAHOMA MEDICAL RESEARCH FOUNDATION - 825 NE 13TH STREET - OKLAHOMA CITY, OK 73104	73-0580274	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY SARAH OCANAS, PHD ENTITLED: A2026024S
THE J. DAVID GLADSTONE INSTITUTES 1650 OWENS ST SAN FRANCISCO, CA 94158	23-7203666	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY CHRISTINA THEODORIS, MD, PHD ENTITLED: A2026030S
THE OHIO STATE UNIVERSITY 460 W. 12TH AVE COLUMBUS, OH 43210	31-6025986	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY PAULA DESPLATS, PHD ENTITLED: A2026017S

Part II **Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments** (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH - 3500 CAMP BOWIE BLVD. - FORT WORTH, TX 76107	47-1744274	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY AUSTIN REYNOLDS, PHD ENTITLED: A2026027S
WASHINGTON UNIVERSITY IN ST.LOUIS 4370 DUNCAN AVE ST LOUIS, MO 63110	43-0653611	501(C)(3)	300,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY GILBERT GALLARDO, PHD ENTITLED: A2026021S
UNIVERSITY OF WISCONSIN-MADISON DEPARTMENT OF OPHTHALMOLOGY MADISON, WI 53706	39-6006492	501(C)(3)	299,997.	0.			ALZHEIMER'S DISEASE RESEARCH BY LEONARDO RIVERA RIVERA, PHD ENTITLED: A2026028S
UNIVERSITY OF CALIFORNIA, IRVINE UNIVERSITY OF CALIFORNIA, IRVINE 30 IRVINE, CA 92697	95-2226406	501(C)(3)	299,772.	0.			ALZHEIMER'S DISEASE RESEARCH BY VIVEK SWARUP, PHD ENTITLED: A2026029S
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO - 1550 4TH ST. ROCK HALL 381 - SAN FRANCISCO, CA 94143	94-6036493	501(C)(3)	299,548.	0.			ALZHEIMER'S DISEASE RESEARCH BY JENNIFER YOKOYAMA, PHD ENTITLED: A2026031S
EMORY UNIVERSITY 1599 CLIFTON ROAD NE, 4TH FLOOR ATLANTA, GA 30322	58-0566256	501(C)(3)	298,793.	0.			ALZHEIMER'S DISEASE RESEARCH BY FIKRI BIREY, PHD ENTITLED: A2026014S
MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE, FL 32224	59-3337028	501(C)(3)	235,163.	0.			ALZHEIMER'S DISEASE RESEARCH ENTITLED: CA2021010
LELAND STANFORD JUNIOR UNIVERSITY 1201 WELCH RD PALO ALTO, CA 94305	94-1156365	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY DANIEL PANYARD, PHD ENTITLED: A2026008F
MASSACHUSETTS GENERAL HOSPITAL 114 SIXTEENTH ST CHARLESTOWN, MA 02129	04-2697983	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY MATTHIAS HEBISCH, PHD ENTITLED: A2026005F

Part II **Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments** (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
MASSACHUSETTS GENERAL HOSPITAL 114 SIXTEENTH ST CHARLESTOWN, MA 02129	04-2697983	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY DOMINIKA PILAT, PHD ENTITLED: A2026009F
MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE, FL 32224	59-3337028	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY GOWOON SON, PHD ENTITLED: A2026011F
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE - 9000 ROCKVILLE PIKE - BETHESDA, MD 20892	52-0858115	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY SHAMCHAL BAKAVAYEV, PHD ENTITLED: A2026003F
OKLAHOMA MEDICAL RESEARCH FOUNDATION - 825 NE 13TH ST - OKLAHOMA CITY, OK 73104	73-0580274	501(C)(3)	200,000.	0.			MACULAR DEGENERATION RESEARCH BY XIANG (ERIC) MA, PHD ENTITLED: M2026005F
THE J. DAVID GLADSTONE INSTITUTES 1650 OWENS ST SAN FRANCISCO, CA 94158	23-7203666	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY HAOYUE ZHOU, PHD ENTITLED: A2026013F
THE SCHEPENS EYE RESEARCH INSTITUTE, INC. - 20 STANIFORD STREET - BOSTON, MA 02114	04-2129889	501(C)(3)	200,000.	0.			MACULAR DEGENERATION RESEARCH BY SUMAN CHAUDHARY, PHD ENTITLED: M2026003F
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL - 115 MASON FARM RD. 6109C NEUROSCIENCE RESEARCH BUILDING, CB 7250 - CHAPEL HILL,	56-6001393	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY MARTIN HSU, PHD ENTITLED: A2026006F
UNIVERSITY OF CALIFORNIA, IRVINE UNIVERSITY OF CALIFORNIA, IRVINE 30 IRVINE, CA 92697	95-2226406	501(C)(3)	200,000.	0.			MACULAR DEGENERATION RESEARCH BY MARCO BASSETTO, PHD ENTITLED: M2026001F
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO - 1550 4TH ST. ROCK HALL 381 - SAN FRANCISCO, CA 94143	94-6036493	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY AMANDA MCQUADE, PHD ENTITLED: A2026007F

Part II **Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments** (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION - 789 S LIMESTONE, TODD 565 - LEXINGTON, KY 40536	61-6033693	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY CALEB BAILEY, PHD ENTITLED: A2026002F
UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION - 789 S LIMESTONE, TODD 565 - LEXINGTON, KY 40536	61-6033693	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY CELLAS HAYES, PHD ENTITLED: A2026004F
UNIVERSITY OF OKLAHOMA, HEALTH SCIENCES CENTER - 608 STANTON L YOUNG BLVD DMEI 423PP - OKLAHOMA CITY, OK 73104	73-1563627	501(C)(3)	200,000.	0.			MACULAR DEGENERATION RESEARCH BY LILY WENJING WU, PHD ENTITLED: M2026007F
UNIVERSITY OF WISCONSIN-MADISON DEPARTMENT OF OPHTHALMOLOGY MADISON, WI 53706	39-6006492	501(C)(3)	200,000.	0.			ALZHEIMER'S DISEASE RESEARCH BY TOMAS VIKNER, PHD ENTITLED: A2026012F
UNIVERSITY OF WISCONSIN-MADISON DEPARTMENT OF OPHTHALMOLOGY MADISON, WI 53706	39-6006492	501(C)(3)	200,000.	0.			MACULAR DEGENERATION RESEARCH BY CELIA BISBACH, PHD ENTITLED: M2026002F
RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. - 150 BROADWAY, SUITE 301 - MENANDS, NY 12204	14-1410842	501(C)(3)	196,662.	0.			ALZHEIMER'S DISEASE RESEARCH
CALIFORNIA STATE UNIVERSITY, LOS ANGELES - 5151 STATE UNIVERSITY DR. - LOS ANGELES, CA 90032	95-4016653	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY NAVID AMINI, PHD ENTITLED: G2026001S
CLEVELAND CLINIC - LERNER RESEARCH INSTITUTE - 9500 EUCLID AVENUE - CLEVELAND, OH 44195	34-0714585	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY EVAN CAMERON, PHD ENTITLED: G2026003S
COLUMBIA UNIVERSITY 3227 BROADWAY L-5-055 NEW YORK, NY 10027	13-5598093	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY REVATHI BALASUBRAMANIAN, PHD ENTITLED: G2026002S

Part II **Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments** (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
DUKE UNIVERSITY 2351 ERWIN RD DURHAM, NC 27710	56-0532129	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY MYOUNGSUP SIM, PHD ENTITLED: G2026012S
INDIANA UNIVERSITY 635 BARNHILL DRIVE INDIANAPOLIS, IN 46202	35-6001673	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY CATIA GOMES, PHD ENTITLED: G2026008S
MASSACHUSETTS EYE AND EAR INFIRMARY - 243 CHARLES ST - BOSTON, MA 02114	42-2103591	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY NAZLEE ZEBARDAST, MD, PHD ENTITLED: G2026015S
NATIONAL EYE INSTITUTE, NIH 10 CENTER DRIVE RM 10N116, FLOOR 10 BETHESDA, MD 20852	52-0858115	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY KIYOHARU MIYAGISHIMA, PHD ENTITLED: G2026010S
THE UNIVERSITY OF UTAH DEPARTMENT OF NEUROBIOLOGY, 20 SOUTH 2030 EAST - SALT LAKE CITY, UT 84112	87-6000525	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY MONICA VETTER, PHD ENTITLED: G2026014S
UNIVERSITY OF CALIFORNIA, SAN DIEGO - 9500 GILMAN DRIVE - LA JOLLA, CA 92093	95-6006144	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY MARK CHRISTOPHER, PHD ENTITLED: G2026004S
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO - 1550 4TH ST. ROCK HALL 381 - SAN FRANCISCO, CA 94143	94-6036493	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY TYSON KIM, MD, PHD ENTITLED: G2026009S
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO - 1550 4TH ST. ROCK HALL 381 - SAN FRANCISCO, CA 94143	94-6036493	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY YVONNE OU, MD ENTITLED: G2026011S
UNIVERSITY OF HOUSTON COLLEGE OF OPTOMETRY 4401 MARTIN LUTHER KING BOULEVARD - HOUSTON, TX 77004	74-6001399	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY LUCA DELLA SANTINA, PHD, PHARMD ENTITLED: G2026006S

Part II **Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments** (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
UNIVERSITY OF PENNSYLVANIA, PERELMAN SCHOOL OF MEDICINE - 422 CURIE BLVD. - PHILADELPHIA, PA 19104	23-1352685	501(C)(3)	150,000.	0.			NATIONAL GLAUCOMA RESEARCH BY QI CUI, MD, PHD ENTITLED: G2026005S
GOOD SAMARITAN FOUNDATION 1225 NE 2ND AVENUE, 3RD FLOOR PORTLAND, OR 97232	23-7017276	501(C)(3)	149,910.	0.			NATIONAL GLAUCOMA RESEARCH BY STUART GARDINER, PHD ENTITLED: G2026007S
INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION - 1001 MAYPORT ROAD, PO BOX 331076 - ATLANTIC BEACH, FL 32233	86-2907045	501(C)(3)	115,000.	0.			ALZHEIMER'S DISEASE RESEARCH ENTITLED: CA2021011
HELEN KELLER FOUNDATION FOR RESEARCH & EDUCATION - 1201 11TH AVE. SOUTH, SUITE 300 - BIRMINGHAM, AL 35205	63-0983733	501(C)(3)	75,000.	0.			HELEN KELLER PRIZE FOR VISION RESEARCH FUNDING
RD MEETING, INC. 5040 NW 50TH TERRACE GAINESVILLE, FL 32606	84-1992631	501(C)(3)	65,000.	0.			TRAVEL GRANTS FOR MACULAR DEGENERATION CONFERENCE ATTENDEES AND CONFERENCE SUPPORT.
ARVO FOUNDATION FOR EYE RESEARCH 1801 ROCKVILLE PIKE, SUITE 400 ROCKVILLE, MD 20852	52-2322462	501(C)(3)	40,000.	0.			EYEFIND RESEARCH GRANT FUNDING
THE GLAUCOMA FOUNDATION 80 MAIDEN LANE, SUITE 700 NEW YORK, NY 10038	13-3174839	501(C)(3)	37,500.	0.			NATIONAL GLAUCOMA RESEARCH BY ARUNKUMAR VENKATESAN, PHD ENTITLED: CG202301
INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION - 1001 MAYPORT ROAD, PO BOX 331076 - ATLANTIC BEACH, FL 32233	86-2907045	501(C)(3)	32,500.	0.			TRAVEL GRANTS FOR MIND RESEARCH CONFERENCE ATTENDEES AND CONFERENCE SUPPORT
ARVO FOUNDATION FOR EYE RESEARCH 1801 ROCKVILLE PIKE, SUITE 400 ROCKVILLE, MD 20852	52-2322462	501(C)(3)	20,000.	0.			TRAVEL GRANTS FOR EYE RESEARCH CONFERENCE ATTENDEES

Part II **Continuation of Grants and Other Assistance to Domestic Organizations and Domestic Governments** (Schedule I (Form 990), Part II.)

(a) Name and address of organization or government	(b) EIN	(c) IRC section if applicable	(d) Amount of cash grant	(e) Amount of noncash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
DUKE EYE CENTER 2351 ERWIN RD DURHAM, NC 27710	56-0532129	501(C)(3)	8,489.	0.			EYE RESEARCH CONFERENCE SUPPORT
INTERNATIONAL SOCIETY FOR EYE RESEARCH - 655 BEACH STREET - SAN FRANCISCO, CA 94109	51-0171667	501(C)(3)	6,000.	0.			TRAVEL GRANTS FOR EYE RESEARCH CONFERENCE ATTENDEES
WESTERN GLAUCOMA FOUNDATION 1910 4TH AVE E PMB 264 OLYMPIA, WA 98506	11-3827410	501(C)(3)	6,000.	0.			GLAUCOMA RESEARCH CONFERENCE SUPPORT

Part III **Grants and Other Assistance to Domestic Individuals.** Complete if the organization answered "Yes" on Form 990, Part IV, line 22. Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	(b) Number of recipients	(c) Amount of cash grant	(d) Amount of non-cash assistance	(e) Method of valuation (book, FMV, appraisal, other)	(f) Description of noncash assistance

Part IV **Supplemental Information.** Provide the information required in Part I, line 2; Part III, column (b); and any other additional information.

PART I, LINE 2:
AFTER AN INTERNATIONAL GRANT IS AWARDED, BRIGHTFOCUS INTERACTS WITH ALL GRANTEES AT LEAST QUARTERLY BY E-MAIL OR AT SCIENTIFIC MEETINGS. IN ADDITION TO THESE INTERACTIONS, EACH GRANT RECIPIENT IS REQUIRED TO SUBMIT SEPARATE DETAILED ANNUAL SCIENTIFIC PROGRESS AND FINANCIAL REPORTS TO BRIGHTFOCUS. THESE ARE RECEIVED BY THE BRIGHTFOCUS SCIENTIFIC AFFAIRS DEPARTMENT, AND REVIEWED BY SCIENTIFIC STAFF WITH BROAD EXPERTISE, INCLUDING IMAGING, MOLECULAR BIOLOGY AND SIGNALING PATHWAYS, CELL BIOLOGY, ANGIOGENESIS, BIOCHEMISTRY, NEUROSCIENCE, AND GENETICS. SENIOR STAFF REVIEWS EACH PROGRESS REPORT AND EVALUATES THE PROJECT FOR SUFFICIENT PROGRESS TOWARDS THE SPECIFIC AIMS PROPOSED IN THE ORIGINAL APPLICATION OR ANY BUDGETARY CONCERNS. THIS EFFORT IS SUPPORTED BY ADDITIONAL SCIENTIFIC COUNSEL FROM MEMBERS OF THE BRIGHTFOCUS SCIENTIFIC REVIEW COMMITTEES, WHEN REQUIRED. IN ADDITION TO STATEMENTS OF EXPERIMENTAL PROGRESS, ALL GRANTEES ARE ASKED TO REPORT ANY TECHNICAL PUBLICATIONS, MEDIA REPORTS, OR PATENT APPLICATIONS IN WHICH BRIGHTFOCUS-SPONSORED RESEARCH IS DESCRIBED. IF SIGNIFICANT CONCERNS RELATED TO PROGRESS ON THE AWARDS ARE DISCOVERED, AND NOT RESOLVED AFTER INTERACTION WITH THE AWARD GRANTEE, THE BRIGHTFOCUS

Part IV Supplemental Information

STAFF RECOMMENDS APPROPRIATE ACTIONS TO THE CHAIR OF THE SCIENTIFIC AFFAIRS COMMITTEE OF THE BOARD OF DIRECTORS. IN ACCORDANCE WITH THE GRANT AGREEMENT TERMS AND CONDITIONS, BRIGHTFOCUS MAY WITHHOLD FUNDING, OR DISCONTINUE AN AWARD, FOR ANY GRANTEE THAT FAILS TO ACHIEVE SUFFICIENT PROGRESS OR SUBMIT REQUIRED REPORTS.

AT THE CONCLUSION OF THE GRANT AWARD PERIOD, EACH GRANTEE MUST COMPLETE AND SUBMIT A FINAL REPORT THAT IS ALSO REVIEWED BY THE BRIGHTFOCUS SENIOR SCIENTIFIC STAFF. EVALUATION OF THE WORK OF EACH GRANTEE IS QUALITATIVELY AND QUANTITATIVELY ASSESSED THROUGH VARIOUS METRICS RELATED TO THE IMPACT OF THE GRANT ON ITS TARGETED DISEASE FIELD. SUCH IMPACT METRICS HAVE REVEALED THAT 95% OF BRIGHTFOCUS-SUPPORTED RESEARCH RESULTS IN RESEARCH PUBLICATIONS THAT ADVANCE THE FIELDS SERVED BY BRIGHTFOCUS. THIS IMPACT IS FURTHER SUPPORTED BY ANNUAL CATEGORY NORMALIZED CITATION IMPACT ANALYSIS THAT COMPARES BRIGHTFOCUS-SUPPORTED WORKS TO AN UNBIASED COMPARISON OF IMPACT PERFORMANCE VERSUS THE WORLD AVERAGE. BRIGHTFOCUS-SUPPORTED PUBLICATIONS WERE RECENTLY CITED AT 2 TIMES THE FREQUENCY OF THE WORLD AVERAGE. A FINAL EXAMPLE OF IMPACT ASSESSMENT REVEALED THAT THE SUCCESSES OF BRIGHTFOCUS GRANTEES CONTINUE LONG AFTER THE GRANT EXPIRES. ON AVERAGE, EACH GRANTEE RECEIVES ADDITIONAL GRANTS FOR FOLLOW-ON PROJECTS SPAWNED BY THE BRIGHTFOCUS GRANT, WITH VALUES UP TO 8 TIMES THE LEVEL OF THE INITIAL BRIGHTFOCUS INVESTMENT.

BRIGHTFOCUS SOLICITS FEEDBACK FROM ITS GRANTEES AND PROVIDES AN ANONYMOUS FORUM FOR COLLECTING SUCH INFORMATION. THROUGH THE BRIGHTFOCUS FOUNDATION WEBSITE AND WITHIN THE SCIENTIFIC PROGRESS REPORTS, THERE ARE DESIGNATED SECTIONS WHERE AWARDEES ARE ASKED TO PROVIDE FEEDBACK TO THE FOUNDATION. THROUGH THIS MECHANISM, THEY ARE GIVEN THE ABILITY TO ANONYMOUSLY PROVIDE FEEDBACK OR COMMUNICATE THEIR CONCERNS TO PROGRAM STAFF OR THE BRIGHTFOCUS' COMPLIANCE OFFICE. ANY SUGGESTIONS, CONCERNS, COMPLAINTS, OR POSITIVE EXPERIENCES CAN BE OUTLINED AND BROUGHT TO THE ATTENTION OF BRIGHTFOCUS IN THIS MANNER, SO THAT BRIGHTFOCUS CAN ADDRESS ANY AREAS NEEDING IMPROVEMENT, REAFFIRM PRAISE-WORTHY POLICIES, OR OTHERWISE ASSESS NEEDS FOR PROGRAMMATIC CHANGE. THE SENIOR LEADERSHIP PRESENTS AND SUMMARIZES THE STATUS AND PROGRESS ON GRANTS TO THE BRIGHTFOCUS BOARD OF DIRECTORS AT EACH OF THEIR QUARTERLY BOARD MEETINGS.

PART II, LINE 1(H)
NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CALEB BAILEY, PHD ENTITLED: A2026002F DEFINING IMMUNOMETABOLIC CONTRIBUTIONS TO COGNITIVE IMPAIRMENT IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: CERTAIN MOLECULES WITHIN DIFFERENT BRAIN CELLS CAN GOVERN METABOLIC PROCESSES THAT MODULATE THE PROGRESSION OF ALZHEIMER'S DISEASE AND DEMENTIA. IN THIS STUDY, I HAVE IDENTIFIED A MOLECULE, REFERRED TO AS P38MAPK, IN A SUPPORTIVE BRAIN CELL TYPE, KNOWN AS ASTROCYTES, THAT MAY REGULATE THE NEUROBIOLOGICAL NETWORK INVOLVED IN COGNITIVE DECLINE IN ALZHEIMER'S DISEASE. THEREFORE, I AM PROPOSING TO USE CUTTING-EDGE NEUROSCIENCE TECHNIQUES TO ELIMINATE PRODUCTION OF P38MAPK IN SUCH ASTROCYTES BRAIN CELLS IN ATTEMPT TO SLOW DISEASE AND DEMENTIA PROGRESSION IN A MOUSE MODEL OF ALZHEIMER'S DISEASE.

NAME OF ORGANIZATION OR GOVERNMENT: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SHAMCHAL BAKAVAYEV, PHD ENTITLED: A2026003F VISUALIZING HOW

Part IV Supplemental Information

ALZHEIMER'S MUTATIONS ALTER PROTEIN LOCALIZATION IN HUMAN BRAIN CELLS. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE IS CAUSED IN PART BY PROTEINS IN THE BRAIN MOVING TO THE WRONG LOCATIONS DUE TO MUTATIONS, WHICH DISRUPT NORMAL CELL FUNCTION. THIS PROJECT WILL USE A PRECISE GENOME EDITING METHOD CALLED PRIME EDITING TO TAG ALZHEIMER'S RELATED PROTEINS AND INTRODUCE DISEASE-CAUSING MUTATIONS IN HUMAN STEM CELLS. THESE CELLS WILL BE DIFFERENTIATED INTO NEURONAL AND GLIAL CELL TYPES, AND ADVANCED IMAGING COMBINED WITH MACHINE LEARNING ALGORITHMS WILL MAP WHERE EACH PROTEIN IS NORMALLY LOCATED AND HOW MUTATIONS ALTER THEIR PLACEMENT, PROVIDING A RESOURCE TO GUIDE FUTURE THERAPIES.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CELLAS HAYES, PHD ENTITLED: A2026004F LONG-TERM CHANGES IN BLOOD BIOMARKERS ASSOCIATED WITH BRAIN WHITE MATTER INJURY. INVESTIGATOR'S SUMMARY: WHITE MATTER HYPERINTENSITIES (WMH) ARE SPOTS SEEN ON BRAIN SCANS THAT RAISE THE RISK FOR MEMORY LOSS, STROKE, AND DEMENTIA, BUT WE DO NOT YET KNOW WHY THEY FORM. THIS STUDY WILL FOLLOW BLOOD MARKERS OF MYELIN, THE PROTECTIVE COATING OF BRAIN, ALONG WITH ALZHEIMER'S-RELATED PROTEINS OVER 15 YEARS IN AFRICAN AMERICAN OLDER ADULTS FROM THE PLACE WITH THE 5TH HIGHEST DEMENTIA PREVALENCE IN THE UNITED STATES, JACKSON, MISSISSIPPI. RESULTS WILL SHOW WHETHER THESE BLOOD MARKERS CAN PREDICT WMH AND POINT TO THEIR BIOLOGICAL ORIGINS.

NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MATTHIAS HEBISCH, PHD ENTITLED: A2026005F "COGNITION IN A DISH" TO DEVELOP NEW ALZHEIMER'S THERAPIES. INVESTIGATOR'S SUMMARY: NO CURRENT TREATMENT FOR ALZHEIMER'S DISEASE CAN STOP OR REVERSE THE PROGRESSION OF COGNITIVE DECLINE AND DEMENTIA. WE HAVE BUILT A MODEL OF ALZHEIMER'S DISEASE IN HUMAN BRAIN ORGANOIDS THAT SHOWS ALL CLASSICAL DISEASE HALLMARKS, INCLUDING AMYLOID PLAQUES, TAU TANGLES, AND NEURONAL DEATH. NOW, WE WILL USE THIS MODEL TO STUDY THE DECLINE OF NEURONAL NETWORK COORDINATION AS A STAND-IN FOR COGNITION DURING THE PROGRESSION OF ALZHEIMER'S, ATTEMPT TO BLOCK NEURONAL NETWORK DEGRADATION BY IMPROVING CELLULAR ENERGY METABOLISM, AND EXPLORE WHEN ANTI-AMYLOID THERAPIES MIGHT BE MOST BENEFICIAL.

NAME OF ORGANIZATION OR GOVERNMENT: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY MARTIN HSU, PHD ENTITLED: A2026006F ASTROCYTIC NLRX1 CONTRIBUTES TO MULTIPLE ASPECTS OF ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE IS THE LEADING CAUSE OF DEMENTIA, MARKED BY MEMORY LOSS AND BRAIN CELL DYSFUNCTION. ASTROCYTES, SUPPORTIVE BRAIN CELLS, INFLUENCE DISEASE PROGRESSION. WE'RE STUDYING THE ROLE OF NLRX1 IN ASTROCYTE MITOCHONDRIA THAT REGULATES METABOLISM AND SUPPORTS NEURONAL HEALTH. OUR DATA SUGGEST NLRX1 WORSENS ALZHEIMER'S BY PROMOTING HARMFUL PROTEIN BUILDUP AND COGNITIVE DECLINE. REMOVING NLRX1 IN ASTROCYTES MAY BOOST THEIR PROTECTIVE FUNCTIONS, REDUCE TOXIC SIGNALS, AND SUPPORT NEURONS. THIS WORK COULD REVEAL NEW THERAPEUTIC TARGETS TO SLOW OR PREVENT ALZHEIMER'S DISEASE.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY AMANDA MCQUADE, PHD ENTITLED: A2026007F UNDERSTANDING THE LINK BETWEEN ALZHEIMER'S DISEASE RISK GENES AND IMMUNE RESPONSES IN THE BRAIN. INVESTIGATOR'S SUMMARY: LARGE SCALE STUDIES OF GENETIC RISK FACTORS FOR

Part IV Supplemental Information

ALZHEIMER'S DISEASE (AD) HAVE REVEALED THAT AD-RISK GENES ARE HIGHLY EXPRESSED IN IMMUNE CELLS. THIS SUGGESTS THAT CHANGES IN IMMUNE FUNCTION HAVE POTENTIAL TO ALTER SOMEONE'S RISK OF DISEASE ONSET, REPRESENTING A NOVEL THERAPEUTIC TARGET. TO UNCOVER COMMON MECHANISMS THAT UNDERLIE AD RISK, I WILL PERFORM A HIGH THROUGHPUT SCREEN OF IMMUNE CELL FUNCTION AFTER PERTURBING AD-RISK GENES. I WILL ALSO TEST THE IMPACT OF THESE IMMUNE ACTIVATION STATES IN MOUSE MODELS TO DETERMINE HOW BLOCKING OR ENRICHING IMMUNE ACTIVATION STATES ALTERS AD PROGRESSION.

NAME OF ORGANIZATION OR GOVERNMENT: LELAND STANFORD JUNIOR UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DANIEL PANYARD, PHD ENTITLED: A2026008F IDENTIFYING THE MOLECULAR CONNECTIONS BETWEEN CARDIOMETABOLIC PROBLEMS AND ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE UNDERLYING CAUSE OF ALZHEIMER'S DISEASE IS UNKNOWN, BUT THERE IS AMPLE EVIDENCE THAT CERTAIN CARDIOVASCULAR PROBLEMS MAY INCREASE THE RISK. THE GOAL OF THIS PROJECT IS TO DISCOVER THE KEY PROTEINS AND OTHER MOLECULES THAT CONNECT THESE CARDIOVASCULAR RISK FACTORS TO ALZHEIMER'S DISEASE BY USING DATA FROM SOME OF THE LARGEST HUMAN STUDIES AVAILABLE. AT THE COMPLETION OF THIS PROJECT, WE PLAN TO FOLLOW UP ON OUR FINDINGS BY TESTING WHETHER THESE MOLECULES CAN BE USED TO IMPROVE HOW WE DIAGNOSE OR TREAT PEOPLE WITH ALZHEIMER'S DISEASE.

PART II, LINE 1(H) CONTINUED
NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY DOMINIKA PILAT, PHD ENTITLED: A2026009F DEVELOPING A NON-INVASIVE GENE THERAPY FOR ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) IS THE MOST COMMON NEURODEGENERATIVE DISORDER AND A LEADING CAUSE OF DEMENTIA, YET EFFECTIVE TREATMENTS REMAIN UNAVAILABLE. THIS PROJECT EXPLORES A NOVEL STRATEGY TARGETING CD33, AN IMMUNE RECEPTOR REGULATING MICROGLIAL ACTIVITY. USING A NOVEL HUMANIZED CD33 MOUSE MODEL, WE WILL DELIVER SIRNA MOLECULES VIA PROPRIETARY NANOPARTICLES DESIGNED FOR MICROGLIAL UPTAKE AND EVALUATE THEIR CD33 SILENCING POTENTIAL. IMPORTANTLY, WE WILL USE AN INTRANASAL DELIVERY ROUTE TO ENABLE DIRECT ACCESS OF THESE PARTICLES TO THE BRAIN. THIS WORK COULD ADVANCE RNA-BASED THERAPIES FOR AD.

NAME OF ORGANIZATION OR GOVERNMENT: MAYO CLINIC JACKSONVILLE (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY GOWOON SON, PHD ENTITLED: A2026011F WHY ALZHEIMER'S DISEASE TARGETS SOME CELLS FIRST: A CLUE IN THE ANTERIOR HYPOTHALAMUS. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE DAMAGES SOME BRAIN CELLS EARLY WHILE SPARING OTHERS, BUT THE REASONS REMAIN UNCLEAR. THIS PROJECT FOCUSES ON THE HYPOTHALAMUS, A TINY NEUROMODULATORY SUBCORTICAL REGION THAT REGULATES SLEEP, MOOD, AND HORMONES, FUNCTIONS THAT ARE OFTEN DISRUPTED IN THE EARLY STAGES OF ALZHEIMER'S. USING ADVANCED MAPPING OF HUMAN BRAIN TISSUE AT THE GENE EXPRESSION LEVEL, WE WILL STUDY HOW SUPPORT HUMAN BRAIN CELLS AND THE CELLULAR MICROENVIRONMENT SHAPE WHICH NEURONS SURVIVE OR DEGENERATE, PAVING THE WAY FOR PRECISION TREATMENTS THAT IMPROVE DAILY LIFE BEYOND MEMORY LOSS.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WISCONSIN-MADISON (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY TOMAS VIKNER, PHD

Part IV Supplemental Information

ENTITLED: A2026012F QUANTIFYING CEREBROSPINAL FLUID FLOW DYNAMICS IN ALZHEIMER'S DISEASE USING 4D-FLOW MRI. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) IS CHARACTERIZED BY THE ACCUMULATION OF MISFOLDED PROTEINS IN THE BRAIN AND DYSFUNCTIONAL CLEARANCE TO CEREBROSPINAL FLUID (CSF), SUGGESTING THAT ALTERED CSF FLOW DYNAMICS COULD PLAY A ROLE IN THE PATHOPHYSIOLOGY. HOWEVER, SUCH FINDINGS ARE PRIMARILY BASED ON STUDIES IN ANIMALS. HERE, WE WILL USE A VELOCITY-SENSITIVE BRAIN IMAGING TECHNIQUE TO STUDY CSF FLOW DYNAMICS IN PATIENTS WITH OR AT RISK FOR AD, AIMING TO ADVANCE OUR UNDERSTAND OF ALTERED NEUROFLUID DYNAMICS IN AD AND ESTABLISH NEW FLOW IMAGING BIOMARKERS OF INTEREST IN AGING AND AD.

NAME OF ORGANIZATION OR GOVERNMENT: THE J. DAVID GLADSTONE INSTITUTES (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY HAOYUE ZHOU, PHD ENTITLED: A2026013F EXPLORING HOW SIGNALS FROM THE BODY INFLUENCE ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE BRAIN IS PROTECTED BY THE BLOOD BRAIN BARRIER (BBB), WHICH CONTROLS WHAT ENTERS FROM THE BLOODSTREAM. WHILE OFTEN REGARDED AS A RIGID SHIELD, OUR PREVIOUS RESEARCH SHOWED THAT PLASMA CAN CROSS THE HEALTHY BBB AND INTERACT WITH BRAIN CELLS. IN THIS PROPOSAL, WE WILL IDENTIFY THESE PROTEINS UNDER NORMAL CONDITIONS AND EXAMINE HOW THEIR TRANSPORT CHANGES IN THE EARLY ALZHEIMER'S DISEASE (AD). THIS WORK WILL REVEAL HOW SIGNALS FROM THE BODY SUPPORT OR HARM BRAIN FUNCTION AND GUIDE NEW STRATEGIES TO SLOW AD PROGRESSION BY MODULATING BBB TRANSPORT OF SPECIFIC PLASMA PROTEINS.

NAME OF ORGANIZATION OR GOVERNMENT: EMORY UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY FIKRI BIREY, PHD ENTITLED: A2026014S PROBING THE NOVEL ROLES OF NEUROMODULATORS IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THIS PROJECT WILL EXPLORE HOW BRAIN CHEMICALS LIKE SEROTONIN REGULATE CHOLESTEROL BALANCE IN NERVE CELLS AND HOW THIS GOES WRONG IN ALZHEIMER'S DISEASE. USING ADVANCED STEM CELL MODELS THAT MIMIC THE HUMAN BRAIN, WE WILL STUDY HOW LOSS OF A KEY ALZHEIMER'S RISK GENE DISRUPTS THIS REGULATION AND WHETHER BOOSTING SEROTONIN SIGNALING CAN RESTORE HEALTHY FUNCTION. OUR GOAL IS TO UNCOVER NEW WAYS TO PROTECT BRAIN CELLS AND SLOW DISEASE PROGRESSION.

NAME OF ORGANIZATION OR GOVERNMENT: BRIGHAM AND WOMEN'S HOSPITAL (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LAURA COX, PHD ENTITLED: A2026016S NEXT-GENERATION PROBIOTICS FOR ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE GUT MICROBIOME CHANGES IN AGING AND MAY CONTRIBUTE TO ALZHEIMER'S DISEASE AND MODIFYING THE GUT MICROBIOME WITH BENEFICIAL BACTERIA MAY SLOW BRAIN AGING AND AD, HOWEVER, THE CURRENT PROBIOTICS ARE NOT SPECIFICALLY DESIGNED TO PREVENT AND TREAT ALZHEIMER'S DISEASE. WE HAVE DISCOVERED NOVEL PROBIOTICS THAT PREVENT AMYLOID PLAQUE ACCUMULATION, AND THIS PROJECT WILL STUDY HOW THEY SLOW DISEASE PROCESSES IN AD BY REGULATING INFLAMMATION PRODUCING BENEFICIAL METABOLITES. THESE STUDIES WILL PROVIDE CRITICAL INFORMATION WHICH COULD THEN BE BROADLY USED TO PREVENT AND TREAT AD.

NAME OF ORGANIZATION OR GOVERNMENT: THE OHIO STATE UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY PAULA DESPLATS, PHD ENTITLED: A2026017S HOW DISRUPTED BODY CLOCKS WORSEN BRAIN CELL DAMAGE IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: THE CIRCADIAN CLOCK, WHICH CONTROLS OUR 24-HOUR BIOLOGICAL CYCLE, IS OFTEN DISRUPTED IN ALZHEIMER'S PATIENTS, CAUSING SLEEP PROBLEMS AND AGITATION. NEW RESEARCH SHOWS THAT THE HEALTH OF BRAIN CELLS CALLED OLIGODENDROCYTES

Part IV Supplemental Information

AND THEIR PRECURSORS IS CONNECTED TO THE CIRCADIAN RHYTHM. THESE CELLS ARE IMPORTANT FOR NERVE FUNCTION AND MEMORY BUT BECOME DYSFUNCTIONAL IN AD PATIENTS AND ANIMAL MODELS. THIS STUDY WILL EXPLORE HOW CIRCADIAN DISRUPTIONS AFFECT OLIGODENDROCYTES AND WHETHER RESTORING NORMAL RHYTHMS CAN HELP RECOVER THEIR FUNCTIONS, POTENTIALLY REDUCING NEUROPATHOLOGY IN AD.

NAME OF ORGANIZATION OR GOVERNMENT: WASHINGTON UNIVERSITY IN ST.LOUIS (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY GILBERT GALLARDO, PHD ENTITLED: A2026021S TARGETING PROINFLAMMATORY MOLECULES USING A CHIMERIC RECEPTOR TO REDUCE INFLAMMATION AND TAUOPATHY. INVESTIGATOR'S SUMMARY: BRAIN INFLAMMATION HAS RECENTLY BEEN SHOWN TO PROGRESS ALZHEIMER'S DISEASE PATHOLOGIES. OUR STUDIES AIM TO DEVELOP THERAPEUTIC STRATEGIES THAT SUPPRESS INFLAMMATORY MOLECULES REGULATING BRAIN INFLAMMATION. WE FURTHER AIM TO COMBINE THESE STRATEGIES WITH GENE THERAPY THAT WILL PROVIDE BRAIN SPECIFICITY AND A LONG-TERM TREATMENT APPROACH.

PART II, LINE 1(H) CONTINUED
NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY HEIDI JACOBS, PHD ENTITLED: A2026022S DORSAL RAPHE NUCLEUS: SEAM FOR EARLIEST DETECTION OF TAU AND SYMPTOMS. INVESTIGATOR'S SUMMARY: THE DORSAL RAPHE NUCLEUS (DRN, LATIN:"SEAM"), A TINY BRAINSTEM REGION PROVIDING SEROTONIN, REGULATES BEHAVIOR AND COGNITION AND IS ONE OF THE FIRST REGIONS VULNERABLE TO TAU. DUE TO ITS SIZE, DRN TAU HAS ONLY BEEN INVESTIGATED AT AUTOPSY. TAKING ADVANTAGE OF NEW METHODS, WE WILL EXAMINE TAU PATTERNS IN THE DRN, CHANGES IN DRN TAU, SPREADING OF TAU TO OTHER BRAIN AREAS AND "SEAM" DRN TAU TO COGNITIVE AND BEHAVIORAL CHANGES. THE OUTCOMES OF THIS INNOVATIVE PROJECT WILL INFORM THE FIELD ON THE EARLIEST BRAIN CHANGES IN ALZHEIMER'S DISEASE, IMPROVE EARLY DETECTION AND DESIGN OF CLINICAL TRIALS.

NAME OF ORGANIZATION OR GOVERNMENT: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SELENE LOMOIO, PHD ENTITLED: A2026023S AXONS, SYNAPSES, AND MYELIN: WHERE DOES ALZHEIMER'S STRIKE FIRST? INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE BEGINS YEARS BEFORE SYMPTOMS APPEAR, WITH ONE OF THE FIRST SIGNS BEING A BREAKDOWN OF THE FIBERS THAT CARRY SIGNALS BETWEEN NEURONS, BUT WE STILL DO NOT KNOW IF THIS DAMAGE OCCURS FIRST IN AXONS, SYNAPSES, OR MYELIN, WHICH TOGETHER CONTROL THE BRAIN'S COMMUNICATION SYSTEM. TO DETERMINE THIS, WE WILL GROW HUMAN BRAIN CELLS IN A NEW PLATFORM THAT RECREATES HOW THESE STRUCTURES CONNECT AND COMMUNICATE, ALLOWING US TO WATCH EARLY PROBLEMS AS THEY EMERGE. BY STUDYING GENETIC VARIANTS, WE AIM TO REVEAL HOW ALZHEIMER'S DISEASE STARTS AND OPEN PATHS FOR PREVENTION AND TREATMENT.

NAME OF ORGANIZATION OR GOVERNMENT: OKLAHOMA MEDICAL RESEARCH FOUNDATION (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SARAH OCANAS, PHD ENTITLED: A2026024S HOW OVARIAN IMMUNE CELLS MAY SHAPE ALZHEIMER'S RISK. INVESTIGATOR'S SUMMARY: WOMEN ARE MORE LIKELY TO DEVELOP ALZHEIMER'S DISEASE, BUT THE REASONS WHY ARE NOT FULLY UNDERSTOOD. THIS PROJECT EXPLORES HOW IMMUNE CELLS IN THE AGING OVARY MAY SEND SIGNALS TO THE BRAIN THAT WORSEN MEMORY PROBLEMS AND DRIVE DISEASE. BY STUDYING OVARIAN IMMUNE AGING IN ALZHEIMER'S MOUSE MODELS,

Part IV Supplemental Information

WE AIM TO DISCOVER NEW WAYS THE BODY'S OWN IMMUNE SYSTEM MAY INFLUENCE BRAIN HEALTH AND REVEAL NOVEL TARGETS FOR PROTECTING WOMEN'S MEMORY AS THEY AGE.

NAME OF ORGANIZATION OR GOVERNMENT: MEMORIAL SLOAN KETTERING CANCER CENTER (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JUSTIN PERRY, PHD ENTITLED: A2026025S DOES FRUCTOSE CONTRIBUTE TO NEURODEGENERATION AND ALZHEIMER'S DISEASE DEVELOPMENT? INVESTIGATOR'S SUMMARY: FRUCTOSE MAY CONTRIBUTE TO THE ONSET AND PROGRESSION OF ALZHEIMER'S DISEASE (AD), WITH INCREASED FRUCTOSE CONSUMPTION AND PRESENCE IN THE BRAIN ASSOCIATED WITH A HIGHER LIKELIHOOD OF DEVELOPING AD AND WORSE PROGNOSIS, BUT THE HOW REMAINS UNKNOWN. EXCITINGLY, WE FOUND THAT THE BRAIN'S GARBAGE COLLECTOR, MICROGLIA, CONSUME FRUCTOSE BUT AT THE COST OF THEIR GARBAGE COLLECTING DUTIES. WE WILL EXPLORE WHETHER THIS TRADE-OFF IS A DRIVER OF AD, TEST WHETHER FRUCTOSE METABOLISM IS A TREATMENT TARGET, AND ESTABLISH NON-INVASIVE IMAGING OF FRUCTOSE METABOLISM AS A DIAGNOSTIC AND PROGNOSTIC TOOL.

NAME OF ORGANIZATION OR GOVERNMENT: EMORY UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY SAIMA RATHORE, PHD ENTITLED: A2026026S USING PROTEIN SIGNATURES TO UNCOVER ALZHEIMER'S DISEASE SUBTYPES AND PREDICT DISEASE PROGRESSION. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE IS THE LEADING CAUSE OF DEMENTIA, BUT PATIENTS DIFFER GREATLY IN THEIR BIOLOGY AND IN HOW QUICKLY THE DISEASE PROGRESSES, MAKING TREATMENT AND PREDICTION DIFFICULT. OUR TEAM HAS GENERATED LARGE-SCALE CSF PROTEIN DATA FROM 1,104 PARTICIPANTS AND BUILT MODELS THAT CAN PREDICT DISEASE ONSET AND PROGRESSION, SHOWING THE POWER OF PROTEOMICS TO CAPTURE THIS COMPLEXITY. IN THIS PROJECT, WE WILL DEFINE CSF-BASED BIOLOGICAL SUBTYPES OF ADRD AND TEST WHETHER BLOOD-BASED PROTEINS CAN IDENTIFY THE SAME SUBTYPES AND TRAJECTORIES, OFFERING A SCALABLE AND NON-INVASIVE PATH TO DIAGNOSIS.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY AUSTIN REYNOLDS, PHD ENTITLED: A2026027S INVESTIGATING THE ROLE OF GENETIC ANCESTRY AND MITOCHONDRIAL DYSFUNCTION IN ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: MITOCHONDRIAL FUNCTION PLAYS A MAJOR ROLE IN SEVERAL PATHWAYS CONTRIBUTING TO ALZHEIMER'S DISEASE (AD) RISK, INCLUDING BOTH AMYLOID AND TAU. GENETIC ANCESTRY HOWEVER PLAYS A COMPLEX ROLE IN AD RISK, WITH ANCESTRY ON NUCLEAR AND MITOCHONDRIAL GENES HAVING CONTRADICTORY EFFECTS. THIS PROJECT WILL RESOLVE THIS CONTRADICTION AND MECHANISTICALLY LINK GENETIC ANCESTRY AND MITOCHONDRIAL FUNCTION TO AD RISK BY INVESTIGATING HOW DISCORDANCE BETWEEN MITOCHONDRIAL AND NUCLEAR GENETIC ANCESTRY CONTRIBUTES TO MITOCHONDRIAL DYSFUNCTION AND ALTERS AD BIOMARKER PROFILES IN A LARGE, GENETICALLY DIVERSE COHORT.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WISCONSIN-MADISON (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY LEONARDO RIVERA RIVERA, PHD ENTITLED: A2026028S SMALL VESSEL DISEASE BIOMARKERS TO IMPROVE UNDERSTANDING OF VASCULAR AND ALZHEIMER'S DEMENTIA. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE (AD) AND CEREBRAL SMALL VESSEL DISEASE (CSVD) ARE THE MOST FREQUENT CAUSES OF DEMENTIA; HOWEVER, CURRENT THERAPIES PRIMARILY TARGET AD-RELATED COGNITIVE DECLINE, LIMITING THEIR EFFECTIVENESS WHEN BOTH CSVD AND AD ARE PRESENT. DUE TO A GAP IN AVAILABLE BIOMARKERS, THE SEPARATION AND

Part IV Supplemental Information

CHARACTERIZATION OF CSVD- AND AD-RELATED COGNITIVE DECLINE IS CHALLENGING AND INCOMPLETE. IN THIS PROJECT, WE WILL EVALUATE NOVEL IMAGING MARKERS TO STUDY CSVD IN INDIVIDUALS WITH CONFIRMED AD AND COMORBID CSVD, AIMING TO ADVANCE BIOMARKERS AND THERAPEUTIC TARGETS FOR MULTI-ETIOLOGY DEMENTIA.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY VIVEK SWARUP, PHD ENTITLED: A2026029S MAPPING BRAIN RESILIENCE IN THE OLDEST-OLD: A MULTI-OMIC ATLAS OF COGNITIVE PROTECTION. INVESTIGATOR'S SUMMARY: ALZHEIMER'S DISEASE IS THE LEADING CAUSE OF DEMENTIA, YET PEOPLE AGED 90 AND OLDER SHOW STRIKING DIFFERENCES IN HOW THEIR BRAINS ARE AFFECTED. SOME REMAIN SHARP DESPITE HEAVY ALZHEIMER'S CHANGES, WHILE OTHERS DEVELOP MEMORY LOSS WITH LITTLE EVIDENCE OF THE DISEASE. THIS PROJECT WILL USE ADVANCED STATE-OF-THE ART GENOMICS TOOLS TO UNCOVER WHY SOME OF THE OLDEST-OLD STAY RESILIENT, WITH THE GOAL OF IDENTIFYING NEW WAYS TO PROTECT BRAIN HEALTH AS WE AGE AND ALSO IN DISEASE.

PART II, LINE 1(H) CONTINUED
NAME OF ORGANIZATION OR GOVERNMENT: THE J. DAVID GLADSTONE INSTITUTES (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY CHRISTINA THEODORIS, MD, PHD ENTITLED: A2026030S PREDICTING THERAPEUTIC INTERVENTIONS FOR RESILIENCE TO BRAIN AGING. INVESTIGATOR'S SUMMARY: ALZHEIMER DISEASE (AD) IS A DISEASE OF THE AGING BRAIN, WHERE CELLS PROGRESS ALONG A DEGENERATIVE TRAJECTORY, LEADING TO DEVASTATING EFFECTS ON QUALITY OF LIFE AND LONGEVITY. MOST STUDIES TEST FOR INTERVENTIONS THAT SHIFT CELLS TOWARDS HEALTHY AT THAT POINT IN TIME BUT FALL SHORT OF TESTING THERAPIES FOR THEIR LONG-TERM EFFICACY ACROSS EXTENDED LIFESPANS. TO ADDRESS THIS, WE WILL APPLY OUR NOVEL ARTIFICIAL INTELLIGENCE MODELS TO MAP HOW CELLS CHANGE OVER HUMAN BRAIN AGING AND ENABLE IN SILICO LONGITUDINAL TRIALS TO PREDICT TREATMENTS THAT PROMOTE AN AD-RESILIENT LONG-TERM TRAJECTORY.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY JENNIFER YOKOYAMA, PHD ENTITLED: A2026031S INVESTIGATING AUTOIMMUNE CONTRIBUTIONS TO ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: GIVEN THAT GENETIC AND CLINICAL EVIDENCE SUGGESTS A LINK BETWEEN AUTOIMMUNE DISEASE AND ALZHEIMER'S DISEASE (AD) RISK, OUR STUDY WILL USE ADVANCED SEQUENCING TECHNOLOGIES TO DETERMINE WHETHER AD PATIENTS POSSESS SELF-TARGETED AUTOANTIBODIES IN THEIR BLOOD OR BRAIN THAT MAY DRIVE DISEASE. ADDITIONALLY, WE WILL EXPLORE WHETHER FEMALE SEX IS ASSOCIATED WITH AN INCREASE OF PRO-INFLAMMATORY PROTEINS OR TRANSCRIPTS. OUR STUDY HAS THE POTENTIAL TO IDENTIFY A SUBSET OF AD PATIENTS WHO POSSESS AN IMMUNE-MEDIATED FORM OF DISEASE AND THAT MAY BENEFIT FROM THE DEVELOPMENT OF TARGETED IMMUNOTHERAPIES.

NAME OF ORGANIZATION OR GOVERNMENT: EMORY UNIVERSITY (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH BY QI ZHANG, PHD ENTITLED: A2026033S CLUSTERIN GLYCOSYLATION FOR EARLY DETECTION OF ALZHEIMER'S DISEASE. INVESTIGATOR'S SUMMARY: CLUSTERIN (CLU) IS RECOGNIZED AS THE THIRD MAJOR RISK FACTOR FOR ALZHEIMER'S DISEASE (AD), AND OUR RESEARCH EXAMINES HOW ALTERATIONS IN THE SUGAR STRUCTURES ON THE CLUSTERIN PROTEIN COULD SIGNAL THE DISEASE'S ONSET AND DIFFER BETWEEN MALES AND FEMALES. BY EMPLOYING CUTTING-EDGE MAPPING TECHNIQUES, WE AIM TO

Part IV Supplemental Information

IMPROVE EARLY DETECTION AND UNDERSTAND THE PROGRESSION OF ALZHEIMER'S. OUR GOAL IS TO SPEARHEAD THE DEVELOPMENT OF PERSONALIZED DIAGNOSTIC TOOLS AND TREATMENTS THAT ACCOUNT FOR INDIVIDUAL BIOLOGICAL DIFFERENCES.

NAME OF ORGANIZATION OR GOVERNMENT: CALIFORNIA STATE UNIVERSITY, LOS ANGELES (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY NAVID AMINI, PHD ENTITLED: G2026001S FOOT-BASED MONITORING AND FEEDBACK TO IMPROVE MOBILITY AND REDUCE FALLS IN GLAUCOMA. INVESTIGATOR'S SUMMARY: NEARLY HALF OF GLAUCOMA PATIENTS FALL EACH YEAR. THIS STUDY USES SMART INSOLES (SHOE INSERTS WITH MOTION AND PRESSURE SENSORS) TO TRACK HOW GLAUCOMA PATIENTS LIFT THEIR FEET WHILE WALKING AND DELIVER REAL-TIME VIBRATIONS ON THE SOLES TO CORRECT UNSAFE PATTERNS. THROUGH CONTINUOUS MONITORING AND PERSONALIZED FEEDBACK, WE AIM TO REDUCE FALLS AND IMPROVE MOBILITY, CONFIDENCE, AND QUALITY OF LIFE.

NAME OF ORGANIZATION OR GOVERNMENT: COLUMBIA UNIVERSITY (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY REVATHI BALASUBRAMANIAN, PHD ENTITLED: G2026002S MAL-DEVELOPMENT OF SCHLEMM'S CANAL IN CHILDREN WITH GLAUCOMA. INVESTIGATOR'S SUMMARY: THE SCHLEMM'S CANAL AND THE TRABECULAR MESHWORK ARE AQUEOUS HUMOR OUTFLOW TISSUES IN THE EYE THAT ARE CRITICAL FOR THE REGULATION OF INTRAOCULAR PRESSURE - A KEY DETERMINANT OF GLAUCOMA. DEVELOPMENT OF THE SCHLEMM'S CANAL IS AFFECTED IN SEVERAL EARLY-ONSET GLAUCOMAS. THIS APPLICATION WILL ELUCIDATE THE ROLE OF APELIN RECEPTOR IN SCHLEMM'S CANAL DEVELOPMENT AND PEDIATRIC GLAUCOMAS TYPES.

NAME OF ORGANIZATION OR GOVERNMENT: CLEVELAND CLINIC - LERNER RESEARCH INSTITUTE (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY EVAN CAMERON, PHD ENTITLED: G2026003S UNDERSTANDING OPTIC NERVE HEAD ASTROCYTE CONTRIBUTIONS TO GLAUCOMA. INVESTIGATOR'S SUMMARY: THIS PROJECT AIMS TO DEFINE THE SIGNALING PATHWAYS IN OPTIC NERVE HEAD (ONH) ASTROCYTES THAT REGULATE IMMUNE CELL-MEDIATED NEURODEGENERATION IN GLAUCOMA TO GUIDE THE DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN DIEGO (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY MARK CHRISTOPHER, PHD ENTITLED: G2026004S IMPROVING GLAUCOMA CARE WITH AGENTIC AI. INVESTIGATOR'S SUMMARY: THIS PROJECT WILL DEVELOP ADVANCED AI TOOLS THAT COMBINES IMAGING, FUNCTIONAL TESTING, AND CLINICAL MEASUREMENTS OVER TIME TO UNDERSTAND GLAUCOMA PROGRESSION. BY PROVIDING CLEAR, AUTOMATED SUMMARIES FOR DOCTORS, THESE TOOLS AIM TO IMPROVE DIAGNOSIS AND STAGING, GUIDE TREATMENT DECISIONS, AND REDUCE THE DOCUMENTATION BURDEN IN GLAUCOMA CARE.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF PENNSYLVANIA, PERELMAN SCHOOL OF MEDICINE (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY QI CUI, MD, PHD ENTITLED: G2026005S EXPLORING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR THE TREATMENT OF GLAUCOMA. INVESTIGATOR'S SUMMARY: IN GLAUCOMA, PRO-INFLAMMATORY MYELOID CELLS INDUCE RETINAL GANGLION CELL DEATH. WE WILL EXAMINE MONOCYTE INFILTRATION AND MICROGLIA ACTIVATION IN EXPERIMENTAL GLAUCOMA AND THE MODULATORY INFLUENCE OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP1RA). RESULTS WILL ENHANCE OUR UNDERSTANDING OF NEUROINFLAMMATORY PROCESSES IN GLAUCOMA AND CLARIFY MECHANISMS BEHIND GLP1RA-INDUCED RGC RESCUE.

Part IV Supplemental Information

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF HOUSTON (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY LUCA DELLA SANTINA, PHD, PHARMD ENTITLED: G2026006S USING AI TO DETECT LOSS OF CONNECTIONS BETWEEN NEURAL CELLS IN GLAUCOMA. INVESTIGATOR'S SUMMARY: DEATH OF RETINAL GANGLION CELL IN GLAUCOMA IS NOT EQUAL ACROSS THE RETINA, WITH NEURONS IN SOME REGIONS ABLE TO SURVIVE LONGER THAN OTHERS. THE REASON BEHIND THIS IS STILL LARGELY UNKNOWN. WE PROPOSE TO CREATE NEW AI TOOLS TO INVESTIGATE LARGE PORTIONS OF THE RETINA AND USE THEM TO ASSESS STRUCTURE AND FUNCTION OF SYNAPSES EARLY AFTER OCULAR PRESSURE ELEVATION IN ANIMAL MODELS OF GLAUCOMA.

PART II, LINE 1(H) CONTINUED
NAME OF ORGANIZATION OR GOVERNMENT: GOOD SAMARITAN FOUNDATION (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY STUART GARDINER, PHD ENTITLED: G2026007S MEASURING THE EFFECTS OF VISUAL STIMULI ON RETINAL BLOOD VESSELS AND FLOW. INVESTIGATOR'S SUMMARY: THIS PROJECT WILL OPTIMIZE AND COMPARE TWO DIFFERENT METHODS TO QUANTIFY THE RESPONSE OF THE EYE TO A VISUAL STIMULUS. WE WILL QUANTIFY THE EFFECT OF STIMULATION ON RETINAL ARTERIAL DIAMETER AND BLOOD FLOW. THE ULTIMATE GOAL IS TO USE THE OPTIMIZED TECHNIQUE TO UNCOVER IMPORTANT NEW INFORMATION ABOUT DISEASE MECHANISMS, AND POTENTIALLY PROVIDE NEW DIAGNOSTIC BIOMARKERS FOR DISEASE PROGRESSION.

NAME OF ORGANIZATION OR GOVERNMENT: INDIANA UNIVERSITY (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY CATIA GOMES, PHD ENTITLED: G2026008S REDUCING INFLAMMATION TO PROTECT VISION IN GLAUCOMA. INVESTIGATOR'S SUMMARY: GLAUCOMA IS CHARACTERIZED BY RETINAL GANGLION CELLS (RGCS) DEGENERATION. INFLAMMATORY ASTROCYTES AND MICROGLIA CLOSELY ASSOCIATE WITH RGC AXONS AT THE OPTIC NERVE HEAD, THE PRIMARY SITE OF INJURY. TO INVESTIGATE HOW THIS INFLAMMATORY CROSSTALK CONTRIBUTES TO AXONAL DEGENERATION IN GLAUCOMA, HUMAN STEM CELL-DERIVED MODELS AND MICROFLUIDIC DEVICES WILL BE EMPLOYED TO SPECIFICALLY STUDY RGC AXONS.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY TYSON KIM, MD, PHD ENTITLED: G2026009S NOVEL VISUALIZATION OF AQUEOUS OUTFLOW: UNCOVERING GLAUCOMA MECHANISMS AND THERAPEUTIC TARGETS. INVESTIGATOR'S SUMMARY: GLAUCOMA IS THE LEADING CAUSE OF IRREVERSIBLE BLINDNESS AND IS STRONGLY INFLUENCED BY ELEVATED PRESSURE AND IMPAIRED FLUID DRAINAGE FROM THE EYE. WE DEVELOPED A NEW IMAGING METHOD THAT VISUALIZES AND QUANTIFIES THIS DRAINAGE WITH MICROSCOPIC PRECISION IN THE LIVING EYE, UNCOVERING NEW INSIGHTS INTO OUTFLOW DYNAMICS AND OPENING OPPORTUNITIES FOR DISCOVERY AND THERAPEUTIC INNOVATION IN GLAUCOMA.

NAME OF ORGANIZATION OR GOVERNMENT: NATIONAL EYE INSTITUTE, NIH (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY KIYOHARU MIYAGISHIMA, PHD ENTITLED: G2026010S USING NATURE'S HIBERNATION STRATEGIES TO PROTECT VISION IN GLAUCOMA. INVESTIGATOR'S SUMMARY: GLAUCOMA, A LEADING CAUSE OF BLINDNESS, RESULTS FROM THE LOSS OF NERVE CELLS THAT CARRY VISION SIGNALS. CURRENT TREATMENTS FOCUS ON LOWERING EYE PRESSURE BUT DON'T WORK FOR ALL PATIENTS. THE HIBERNATING GROUND SQUIRREL NATURALLY PROTECTS ITS EYES UNDER EXTREME STRESS. WE WILL INVESTIGATE THE

Part IV Supplemental Information

PROTECTIVE EXOSOMES THEY RELEASE, AIMING TO DEVELOP NEW THERAPIES THAT DIRECTLY PRESERVE VISION.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY YVONNE OU, MD ENTITLED: G2026011S HOW NEURAL ACTIVITY SHAPES VISION RECOVERY IN GLAUCOMA. INVESTIGATOR'S SUMMARY: THIS PROJECT EXPLORES HOW LIGHT AND NEURAL ACTIVITY HELP THE RETINA PROTECT ITSELF FROM DAMAGE IN GLAUCOMA. BY STUDYING HOW RETINAL CELLS MAINTAIN AND REBUILD THEIR CONNECTIONS AFTER INJURY, WE AIM TO UNCOVER WAYS TO PRESERVE VISION AND STIMULATE REPAIR PROCESSES THAT COULD BENEFIT PEOPLE WITH GLAUCOMA AND RELATED NEURODEGENERATIVE DISEASES.

NAME OF ORGANIZATION OR GOVERNMENT: DUKE UNIVERSITY (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY MYOUNGSUP SIM, PHD ENTITLED: G2026012S ACTIVATING THE EYE'S OWN NITRIC OXIDE TO FIGHT GLAUCOMA. INVESTIGATOR'S SUMMARY: WE AIM TO DEVELOP SAFER, LONGER-LASTING GLAUCOMA TREATMENTS BY RESTORING THE EYE'S OWN NITRIC OXIDE (NO) PRODUCTION. BY TARGETING TINY SENSORY ORGANELLES CALLED PRIMARY CILIA WITH A SELECTIVE ENZYME INHIBITOR, WE SEEK TO ENHANCE FLUID DRAINAGE AND LOWER EYE PRESSURE NATURALLY.

NAME OF ORGANIZATION OR GOVERNMENT: THE UNIVERSITY OF UTAH (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY MONICA VETTER, PHD ENTITLED: G2026014S THE IMMUNE LANDSCAPE OF THE HUMAN OPTIC NERVE HEAD. INVESTIGATOR'S SUMMARY: WE WILL STUDY THE PROPERTIES OF RESIDENT MYELOID CELLS IN THE HUMAN OPTIC NERVE HEAD AND OPTIC NERVE, WILL ASSESS HOW THEY CHANGE IN GLAUCOMA AND DEFINE THE RESPONSES OF OTHER IMMUNE CELL POPULATIONS. BY MAPPING THESE CELLS AND DEFINING THEIR MOLECULAR SIGNATURES, WE AIM TO UNCOVER HOW NEUROIMMUNE RESPONSES MAY HAVE PROTECTIVE OR DETRIMENTAL EFFECTS AND IDENTIFY NEW TARGETS TO PROTECT VISION.

NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS EYE AND EAR INFIRMARY (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY NAZLEE ZEBARDAST, MD, PHD ENTITLED: G2026015S USING ARTIFICIAL INTELLIGENCE TO DISCOVER GENETIC RISK FACTORS FOR GLAUCOMA WORSENING. INVESTIGATOR'S SUMMARY: GLAUCOMA IS A LEADING CAUSE OF BLINDNESS WORLDWIDE, YET PHYSICIANS CANNOT PREDICT WHO WILL LOSE VISION QUICKLY. THIS PROJECT STUDIES THE ROLE OF GENETICS IN GLAUCOMA PROGRESSION USING CLINICAL DATA AND MACHINE LEARNING METHODS. DISCOVERIES MAY ALLOW EARLIER DETECTION OF HIGH-RISK PATIENTS, MORE PERSONALIZED TREATMENTS, AND NEW TARGETS TO SLOW OR PREVENT VISION LOSS.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF CALIFORNIA, IRVINE (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY MARCO BASSETTO, PHD ENTITLED: M2026001F HIJACK THE VITAMIN A TRANSPORTATION SYSTEM WITH ANTI-INFLAMMATORY DRUGS TO FIGHT AMD. INVESTIGATOR'S SUMMARY: NUMEROUS OCULAR BARRIERS PREVENT THE ACCUMULATION OF DRUGS IN THE EYE AND LIMIT THE DEVELOPMENT OF TREATMENTS FOR AGE-RELATED MACULAR DEGENERATION (AMD). THIS PROPOSAL AIMS TO LEVERAGE THE NATURAL TRANSPORTATION SYSTEM OF VITAMIN A IN THE EYE TO DELIVER ANTI-INFLAMMATORY DRUGS (I.E., ASPIRIN, IBUPROFEN) SELECTIVELY IN THE RETINA TO SUPPRESS THE INFLAMMATION ASSOCIATED WITH AMD. MY METHOD USES ORAL DRUG ADMINISTRATION AND MOVES AWAY FROM THE RISKS AND BURDENS ASSOCIATED WITH INTRAOCULAR INJECTIONS OF DRUGS, WHICH ARE THE STANDARD METHOD OF

Part IV Supplemental Information

DRUG ADMINISTRATION FOR TREATING AMD.

PART II, LINE 1(H) CONTINUED
NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF WISCONSIN-MADISON (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY CELIA BISBACH, PHD ENTITLED: M2026002F TARGETED REMOVAL OF DISEASE CAUSING PROTEIN IN AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: WE ARE DEVELOPING A NEW TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD). NAMD IS CAUSED IN PART BY ACCUMULATION OF A PROTEIN CALLED VEGF IN A REGION OF THE EYE WHERE ITS LEVELS ARE NORMALLY LOW. CURRENTLY, NAMD IS TREATED BY FREQUENT EYE INJECTIONS OF INHIBITORS WHICH BLOCK VEGF FUNCTION. WE ARE USING A NEW STRATEGY, TARGETED PROTEIN DEGRADATION, TO PHYSICALLY DESTROY VEGF USING THE BODY'S NATURAL WASTE DISPOSAL SYSTEM. OUR ULTIMATE GOAL IS TO CREATE A MORE EFFECTIVE, LOCALIZED, AND LONGER-LASTING THERAPY FOR NAMD THAT COULD IMPROVE PATIENT OUTCOMES AND QUALITY OF LIFE.

NAME OF ORGANIZATION OR GOVERNMENT: THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY SUMAN CHAUDHARY, PHD ENTITLED: M2026003F A NOVEL ANTIOXIDANT TO PREVENT VISION LOSS IN MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: LATE-STAGE DRY AGE-RELATED MACULAR DEGENERATION (AMD) AFFECTS THE CENTER OF THE VISUAL FIELD IN THE ELDERLY POPULATION. LIPID ACCUMULATION DURING AMD PROMOTES OXIDATIVE STRESS THAT ACCELERATES CELLULAR DAMAGE IN RETINAL PIGMENT EPITHELIUM (RPE). OUR STUDY EXPLORES A NOVEL STERICALLY HINDERED PHENOL, 2,2,5,7,8-PENTAMETHYL-6- CHROMANOL (PMC), WITH POTENT ANTIOXIDANT PROPERTIES AND ABILITY TO REDUCE RPE DEGENERATION. OUR AIM IS TO IDENTIFY AND VALIDATE THE KEY MECHANISMS INVOLVED IN THE THERAPEUTIC EFFICACY OF PMC USING CELL AND ANIMAL-BASED MODELS.

NAME OF ORGANIZATION OR GOVERNMENT: OKLAHOMA MEDICAL RESEARCH FOUNDATION (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY XIANG (ERIC) MA, PHD ENTITLED: M2026005F PROTECTING EYE BLOOD VESSELS TO SLOW VISION LOSS IN MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: THE CHOROID IS A LAYER OF BLOOD VESSELS BENEATH THE EYE'S LIGHT-SENSING NEURONS. IT DELIVERS THE OXYGEN AND NUTRIENTS NEEDED FOR CLEAR VISION. IN MACULAR DEGENERATION, THESE VESSELS SLOWLY "WEAR OUT" UNDER DISEASE STRESS, MUCH LIKE TIRES THAT LOSE THEIR TREAD OVER TIME. THIS PROCESS, CALLED CHOROIDAL ATROPHY, DEPRIVES LIGHT-SENSING CELLS OF CRITICAL SUPPORT AND LEADS TO VISION LOSS. THIS PROJECT AIMS TO UNCOVER MOLECULAR PATHWAYS THAT PROTECT THESE VESSELS FROM DISEASE DAMAGE, SUPPORTING THE BRIGHTFOCUS MISSION TO DEFEAT MACULAR DEGENERATION.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF OKLAHOMA, HEALTH SCIENCES CENTER (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY LILY WENJING WU, PHD ENTITLED: M2026007F RESTORATION OF CRUCIAL RETINAL LIPIDS TO PREVENT VISION LOSS IN AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: THE PROPOSAL INVESTIGATES WHETHER VERY LONG-CHAIN POLYUNSATURATED FATTY ACIDS (VLC-PUFAS) ARE AN ESSENTIAL FUEL FOR THE EYE'S MAINTENANCE CELLS, RPE, WHICH FAIL IN AMD, LEADING TO VISION LOSS. CURRENT DRUGS TREAT ONLY THE LATE STAGES OF THE DISEASE. WE HYPOTHESIZE THAT VLC-PUFA LOSS IS THE CAUSE OF THIS CRITICAL FAILURE. WE WILL DEMONSTRATE THIS BY USING HUMAN RPE CELLS TO MAP THE METABOLIC PATHWAY AND, USING GENE THERAPY, RESCUE THE DISEASE IN MICE. SUCCESS VALIDATES VLC-PUFA RESTORATION AS A NEW PREVENTATIVE

Part IV Supplemental Information

TREATMENT FOR EARLY AMD.

NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS EYE AND EAR INFIRMARY (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY RYOJI AMAMOTO, PHD ENTITLED: M2026008N PRESERVING CONE PHOTORECEPTORS IN DRY AGE-RELATED MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: DRY AGE-RELATED MACULAR DEGENERATION (DAMD) IS THE LEADING CAUSE OF IRREVERSIBLE BLINDNESS IN ADULTS OVER 50; YET, THERE IS NO EFFECTIVE TREATMENT TO PRESERVE OR RESTORE VISION. THE ROOT CAUSE OF DAMD IS THE DEGENERATION OF CONE PHOTORECEPTORS, THE CELLS THAT ARE ESSENTIAL FOR DAYLIGHT COLOR VISION. WE HAVE RECENTLY DISCOVERED A NOVEL GENETIC TARGET, THE RETINOIC ACID SIGNALING PATHWAY, THAT, WHEN ACTIVATED, CAN PROMOTE CONE SURVIVAL. IN THIS PROPOSAL, WE AIM TO DETERMINE WHETHER ACTIVATION OF THIS SIGNALING PATHWAY COULD ALSO PROMOTE CONE SURVIVAL IN MODELS OF DAMD.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF MICHIGAN (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY MARK DRAELOS, MD, PHD ENTITLED: M2026009N STUDYING EYE BLOOD FLOW DURING EXERCISE TO UNDERSTAND THE ORIGINS OF AMD. INVESTIGATOR'S SUMMARY: THIS PROPOSAL USES BLOOD VESSEL MAPPING DURING EXERCISE TO UNDERSTAND HOW BLOOD FLOW IN THE EYE IS INVOLVED IN THE DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION (AMD). MUCH LIKE HOW AN EXERCISE STRESS TEST REVEALS DISEASE IN VESSELS IN THE HEART, WE PROPOSE AN OCULAR STRESS TEST TO ALLOW US TO DETECT DISEASE AFFECTING THE EYE BEFORE VISION LOSS DEVELOPS. IN THIS PROPOSAL, WE FIRST COMPARE PATIENTS WITH AND WITHOUT AMD TO EVALUATE HOW THEIR BLOOD VESSELS BEHAVE DIFFERENTLY DURING EXERCISE AND THEN FOLLOW PATIENTS OVER TIME TO UNDERSTAND HOW THEIR BLOOD VESSELS CHANGE AS DISEASE EVOLVES.

NAME OF ORGANIZATION OR GOVERNMENT: UNIVERSITY OF MICHIGAN (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY JASON MILLER, MD, PHD ENTITLED: M2026011N THE RPE'S DECISION TO BURN VERSUS SECRETE FATS AND IMPLICATIONS FOR DRY AMD. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD), THE LEADING CAUSE OF IRREVERSIBLE VISION LOSS IN THE DEVELOPED WORLD, INVOLVES THE BUILD-UP OF TOXIC FATTY DEPOSITS OUTSIDE A CELL LAYER CALLED THE RETINAL PIGMENT EPITHELIUM (RPE). WHILE THE RPE HANDLES SIGNIFICANT AMOUNTS OF FAT AS PART OF ITS NORMAL FUNCTION, WE HYPOTHESIZE THAT IF WE CAN FORCE THE RPE TO DEGRADE THE FAT IT CONSUMES, IT WILL SECRETE LESS OF THE FAT, WHICH WILL LEAD TO LESS TOXIC FATTY DEPOSITS ACCUMULATING OUTSIDE THE CELL. IN THIS PROPOSAL, WE EXAMINE WHAT HAPPENS TO DEPOSITS WHEN WE PROMOTE RPE LIPID DEGRADATION VERSUS SECRETION.

NAME OF ORGANIZATION OR GOVERNMENT: PURDUE UNIVERSITY (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY SUNGHEE PARK, PHD ENTITLED: M2026012N UNCOVERING THE HIDDEN LINK BETWEEN LIVER HEALTH AND MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION IS THE LEADING CAUSE OF BLINDNESS IN THE ELDERLY, YET CURRENT TREATMENTS ONLY SLOW PROGRESSION AND FAIL TO ADDRESS SYSTEMIC DRIVERS OF DISEASE. THIS PROJECT WILL DEVELOP A HUMAN LIVERRETINA CHIP TO UNCOVER HOW AGE-RELATED METABOLIC DYSFUNCTION IN THE LIVER TRIGGERS COMPLEMENT ACTIVATION THAT DAMAGES RETINAL PIGMENT EPITHELIAL CELLS. UNDERSTANDING THIS CROSS-ORGAN IMMUNEMETABOLIC AXIS WILL ENABLE NEW THERAPEUTIC STRATEGIES TO PREVENT VISION LOSS AND IMPROVE HEALTH OUTCOMES IN THE AGING POPULATION.

Part IV Supplemental Information

PART II, LINE 1(H) CONTINUED
NAME OF ORGANIZATION OR GOVERNMENT: NORTHEASTERN UNIVERSITY (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY AMIR VAHABIKASHI, PHD ENTITLED: M2026013N RECREATING THE HUMAN RETINA IN THE LAB TO UNLOCK NEW TREATMENTS FOR MACULAR DEGENERATION. INVESTIGATOR'S SUMMARY: WE ARE CREATING A "RETINA-ON-A-CHIP" THAT RECREATES HOW KEY CELL TYPES IN THE HUMAN EYEPHOTORECEPTORS, RETINAL PIGMENT EPITHELIUM, AND TINY BLOOD VESSELSWORK TOGETHER TO SUPPORT VISION. USING STEM-CELLDERIVED TISSUES AND A MICROFLUIDIC DEVICE, THIS PLATFORM WILL MODEL EARLY EVENTS THAT LEAD TO AGE-RELATED MACULAR DEGENERATION, INCLUDING THE BUILDUP OF HARMFUL DEPOSITS AND LOSS OF RETINAL FUNCTION. BY ALLOWING REAL-TIME OBSERVATION AND TESTING OF POTENTIAL TREATMENTS, THIS TECHNOLOGY AIMS TO ACCELERATE SAFER AND MORE EFFECTIVE THERAPIES FOR BLINDING DISEASES.

NAME OF ORGANIZATION OR GOVERNMENT: MASSACHUSETTS GENERAL HOSPITAL (H) PURPOSE OF GRANT: MACULAR DEGENERATION RESEARCH BY DAVID VEYSSET, PHD ENTITLED: M2026014N ADVANCING AMD DIAGNOSIS WITH NOVEL SPECTROSCOPIC TOOLS. INVESTIGATOR'S SUMMARY: AGE-RELATED MACULAR DEGENERATION (AMD) IS A LEADING CAUSE OF VISION LOSS, LINKED TO HARMFUL DEPOSITS BENEATH THE RETINA. THIS PROJECT AIMS TO COMBINE TWO CUTTING-EDGE IMAGING TECHNIQUES, OPTICAL COHERENCE TOMOGRAPHY (OCT) AND RAMAN SPECTROSCOPY, TO ANALYZE BOTH THE STRUCTURE AND CHEMISTRY OF THESE DEPOSITS. BY IDENTIFYING HIGH-RISK MOLECULAR PROFILES, THE RESEARCH SEEKS TO IMPROVE EARLY DETECTION, GUIDE TREATMENTS, AND PROVIDE NEW INSIGHTS INTO AMD PROGRESSION. THIS INNOVATIVE APPROACH COULD TRANSFORM HOW AMD AND OTHER RETINAL DISEASES ARE DIAGNOSED AND MANAGED.

NAME OF ORGANIZATION OR GOVERNMENT: THE GLAUCOMA FOUNDATION (H) PURPOSE OF GRANT: NATIONAL GLAUCOMA RESEARCH BY ARUNKUMAR VENKATESAN, PHD ENTITLED: CG202301 INVESTIGATING THE ROLE OF IMPAIRED MITOCHONDRIAL DYNAMICS IN EXFOLIATION GLAUCOMA. INVESTIGATOR'S SUMMARY: EXFOLIATION GLAUCOMA (XFG) IS A MORE SEVERE FORM OF OPEN ANGLE GLAUCOMA AND A BLINDING DISEASE. THIS PROPOSAL AIMS TO STUDY DEFECTS IN MITOCHONDRIAL FUNCTION IN XFG PATIENT-DERIVED PRIMARY CELLS AND THE RELATIONSHIP OF MITOCHONDRIAL DYSFUNCTION TO CELLULAR SENESCENCE (AGING CELLS). THIS STUDY WILL EVALUATE HOW MITOCHONDRIAL FUNCTION IS IMPAIRED IN XFG AND EXAMINE THERAPEUTIC STRATEGIES TO ENHANCE MITOCHONDRIAL FUNCTION FOR THE TREATMENT OF XFG.

NAME OF ORGANIZATION OR GOVERNMENT: INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION (H) PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH ENTITLED: (CA2021011) INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION. INVESTIGATOR'S SUMMARY: THIS AWARD IS FOR THE CREATION, AND GROWTH OF, THE "INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION (ISMND) AND SUPPORT OF ITS BI-ANNUAL MEETINGS AND EDUCATIONAL AND SCIENTIFIC PURPOSES. IN ACCORDANCE WITH SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND THE PROVISIONS OF THE FLORIDA NOT FOR PROFIT CORPORATION ACT. THE INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION (ISMND) SHALL BE ORGANIZED AND OPERATED PRIMARILY AND EXCLUSIVELY FOR EDUCATIONAL AND SCIENTIFIC PURPOSES. THE INTERNATIONAL SOCIETY FOR MOLECULAR NEURODEGENERATION'S MISSION IS TO SERVE AS AN ACCELERATOR FOR THE CONTINUOUS IMPROVEMENT OF BRAIN AND EYE HEALTH AND WELL-BEING BY CREATING A MULTIDISCIPLINARY GLOBAL PLATFORM FOR SCIENTISTS, PHYSICIANS, AND THE PUBLIC FROM DIFFERENT FACETS AND

Part IV Supplemental Information

SCIENTIFIC DISCIPLINES TO MORE READILY CONNECT, SHARE AND COMMUNICATE SCIENTIFIC DISCOVERIES, AND DEVELOP CURES FOR NEURODEGENERATIVE DISEASES, IN THE HOPES OF A WORLD FREE OF BRAIN AND EYE DISEASES.

NAME OF ORGANIZATION OR GOVERNMENT: MAYO CLINIC JACKSONVILLE (H)
PURPOSE OF GRANT: ALZHEIMER'S DISEASE RESEARCH ENTITLED: (CA2021010) MOLECULAR NEURODEGENERATION JOURNAL. INVESTIGATOR'S SUMMARY: THE AIM OF MOLECULAR NEURODEGENERATION (MN) JOURNAL (HTTPS://LINK.SPRINGER.COM/JOURNAL/13024) IS TO SERVE THE SCIENTIFIC COMMUNITY BY PUBLISHING HIGH-IMPACT, HIGH-QUALITY, AND FRONT-LINE RESEARCH DISCOVERIES IN DIVERSE AREAS OF NEURODEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE AND EYE-RELATED DEGENERATIVE CONDITIONS. MN IS THE OFFICIAL JOURNAL OF THE BRIGHTFOCUS FOUNDATION. THE OPEN ACCESS PUBLISHING MODEL PROVIDES FREE ARTICLES TO THE GENERAL PUBLIC, AS WELL AS SCIENTISTS, CLINICIANS, AND OTHER HEALTHCARE. THE JOURNAL HAS SEEN FURTHER GROWTH IN RECENT YEARS IN PARTICULAR IN THE AREA OF SCIENTIFIC IMPACT AND REPUTATION. SOME OF THESE ARE REFLECTED IN THE FOLLOWING METRICS: 1) 2.8 MILLION DOWNLOADS IN 2025; 2) JOURNAL IMPACT FACTOR: 19.6 IN 2025; 3) RANKED NO. 5 AMONG 330 NEUROSCIENCE JOURNALS (WITHIN THE TOP 1.5% GLOBALLY); AND 4) REMAINS THE HIGHEST-RANKED OPEN-ACCESS PUBLICATION IN THE NEUROSCIENCE CATEGORY.

SCHEDULE J (Form 990)

(Rev. December 2024)

Department of the Treasury
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees
Complete if the organization answered "Yes" on Form 990, Part IV, line 23.
Attach to Form 990.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I Questions Regarding Compensation

			Yes	No
1a	Check the appropriate box(es) if the organization provided any of the following to or for a person listed on Form 990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.			
	☐ First-class or charter travel	☐ Housing allowance or residence for personal use		
	☐ Travel for companions	☐ Payments for business use of personal residence		
	☐ Tax indemnification and gross-up payments	☐ Health or social club dues or initiation fees		
	☐ Discretionary spending account	☐ Personal services (such as maid, chauffeur, chef)		
b	If any of the boxes on line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all of the expenses described above? If "No," complete Part III to explain	**1b**		
2	Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all directors, trustees, and officers, including the CEO/Executive Director, regarding the items checked on line 1a?	**2**		
3	Indicate which, if any, of the following the organization used to establish the compensation of the organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.			
	☒ Compensation committee	☐ Written employment contract		
	☒ Independent compensation consultant	☒ Compensation survey or study		
	☒ Form 990 of other organizations	☒ Approval by the board or compensation committee		
4	During the year, did any person listed on Form 990, Part VII, Section A, line 1a, with respect to the filing organization or a related organization:			
a	Receive a severance payment or change-of-control payment?	**4a**		X
b	Participate in or receive payment from a supplemental nonqualified retirement plan?	**4b**		X
c	Participate in or receive payment from an equity-based compensation arrangement?	**4c**		X
	If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.			
	Only section 501(c)(3), 501(c)(4), and 501(c)(29) organizations must complete lines 5-9.			
5	For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any compensation contingent on the revenues of:			
a	The organization?	**5a**		X
b	Any related organization?	**5b**		X
	If "Yes" on line 5a or 5b, describe in Part III.			
6	For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any compensation contingent on the net earnings of:			
a	The organization?	**6a**		X
b	Any related organization?	**6b**		X
	If "Yes" on line 6a or 6b, describe in Part III.			
7	For persons listed on Form 990, Part VII, Section A, line 1a, did the organization provide any nonfixed payments not described on lines 5 and 6? If "Yes," describe in Part III	**7**		X
8	Were any amounts reported on Form 990, Part VII, paid or accrued pursuant to a contract that was subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe in Part III	**8**		X
9	If "Yes" on line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)?	**9**		

Part II **Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees.** Use duplicate copies if additional space is needed.

For each individual whose compensation must be reported on Schedule J, report compensation from the organization on row (i) and from related organizations, described in the instructions, on row (ii). Do not list any individuals that aren't listed on Form 990, Part VII.

Note: The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and (E) amounts for that individual.

(A) Name and Title		(B) Breakdown of W-2 and/or 1099-MISC and/or 1099-NEC compensation			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation in column (B) reported as deferred on prior Form 990
		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation				
(1) STACY PAGOS HALLER	(i)	437,480.	0.	0.	36,290.	24,789.	498,559.	0.
PRESIDENT/CEO	(ii)	0.	0.	0.	0.	0.	0.	0.
(2) NANCY KEACH	(i)	277,991.	0.	0.	26,076.	40,636.	344,703.	0.
SR. VP, STRATEGIC PARTNERSHIPS	(ii)	0.	0.	0.	0.	0.	0.	0.
(3) R. BRIAN ELDERTON	(i)	270,609.	0.	0.	24,900.	24,390.	319,899.	0.
SR. VP, DEVELOPMENT	(ii)	0.	0.	0.	0.	0.	0.	0.
(4) JONATHAN WALSH	(i)	256,177.	0.	0.	6,419.	5,966.	268,562.	0.
SVP, FINANCE & ADMINISTRATION	(ii)	0.	0.	0.	0.	0.	0.	0.
(5) DIANE BOVENKAMP, PHD	(i)	202,612.	0.	0.	18,199.	8,535.	229,346.	0.
VP, SCIENTIFIC AFFAIRS	(ii)	0.	0.	0.	0.	0.	0.	0.
(6) SHARYN ROSSI - PHD, DIR. OF	(i)	145,082.	0.	0.	14,098.	41,917.	201,097.	0.
SCIENT. PROGRAMS, NEUROSCIENCE	(ii)	0.	0.	0.	0.	0.	0.	0.
(7) DAVID LOWING - SR. DIRECTOR	(i)	151,606.	0.	0.	0.	40,111.	191,717.	0.
CORPORATE & FOUNDATION RELATIONS	(ii)	0.	0.	0.	0.	0.	0.	0.
(8) GABRIEL WUREH	(i)	150,909.	0.	0.	1,545.	29,384.	181,838.	0.
CONTROLLER	(ii)	0.	0.	0.	0.	0.	0.	0.
(9) LISA MORGAN	(i)	139,023.	0.	0.	12,938.	19,656.	171,617.	0.
SENIOR DIRECTOR, ANNUAL GIVING	(ii)	0.	0.	0.	0.	0.	0.	0.
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							

Part III **Supplemental Information**

Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II. Also complete this part for any additional information.

PART I, LINE 3:
THE LAST COMPENSATION SURVEY WAS COMPLETED ON 3/9/2022.
GIVEN ANNOUNCED CEO RETIREMENT A SURVEY WAS NOT COMPLETED AND ARE UTILIZING
RECRUITER AND MARKET RATE TO DETERMINE NEXT CEO COMP.

SCHEDULE M (Form 990)

Department of the Treasury
Internal Revenue Service

Noncash Contributions

Complete if the organizations answered "Yes" on Form 990, Part IV, line 29 or 30.
Attach to Form 990.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2025

Open to Public Inspection

Name of the organization

BRIGHTFOCUS FOUNDATION

Employer identification number

23-7337229

Part I Types of Property

		(a) Check if applicable	(b) Number of contributions or items contributed	(c) Noncash contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining noncash contribution amounts
1	Art - Works of art				
2	Art - Historical treasures				
3	Art - Fractional interests				
4	Books and publications				
5	Clothing and household goods				
6	Cars and other vehicles				
7	Boats and planes				
8	Intellectual property				
9	Securities - Publicly traded	X	56	1,383,066.	FMV
10	Securities - Closely held stock				
11	Securities - Partnership, LLC, or trust interests				
12	Securities - Miscellaneous				
13	Qualified conservation contribution - Historic structures				
14	Qualified conservation contribution - Other				
15	Real estate - Residential				
16	Real estate - Commercial				
17	Real estate - Other				
18	Collectibles				
19	Food inventory				
20	Drugs and medical supplies				
21	Taxidermy				
22	Historical artifacts				
23	Scientific specimens				
24	Archeological artifacts				
25	Other ( )				
26	Other ( )				
27	Other ( )				
28	Other ( )				

			Yes	No
29	Number of Forms 8283 received by the organization during the tax year for contributions for which the organization completed Form 8283, Part V, Donee Acknowledgment	29		
30a	During the year, did the organization receive by contribution any property reported in Part I, lines 1 through 28, that it must hold for at least 3 years from the date of the initial contribution, and which isn't required to be used for exempt purposes for the entire holding period?	30a		X
b	If "Yes," describe the arrangement in Part II.			
31	Does the organization have a gift acceptance policy that requires the review of any nonstandard contributions?	31	X	
32a	Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash contributions?	32a		X
b	If "Yes," describe in Part II.			
33	If the organization didn't report an amount in column (c) for a type of property for which column (a) is checked, describe in Part II.			

Part II **Supplemental Information.** Provide the information required by Part I, lines 30b, 32b, and 33, and whether the organization is reporting in Part I, column (b), the number of contributions, the number of items received, or a combination of both. Also, complete this part for any additional information.

SCHEDULE M, PART I, COLUMN (B):
BRIGHTFOCUS REPORTS THE NUMBER OF CONTRIBUTIONS IN PART I, COLUMN B.

SCHEDULE O (Form 990)
(Rev. December 2024)
Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on Form 990 or 990-EZ or to provide any additional information.
Attach to Form 990 or Form 990-EZ.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

Open to Public Inspection

Name of the organization
BRIGHTFOCUS FOUNDATION

Employer identification number
23-7337229

FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION:
OUR VISION IS: A WORLD FREE FROM DISEASES OF MIND AND SIGHT.
COLLECTIVELY, MORE THAN 300 MILLION PEOPLE WORLDWIDE SUFFER FROM THESE DISEASES.

BRIGHTFOCUS HAS A PROVEN TRACK RECORD OF SUPPORTING THE MOST INNOVATIVE, EARLY-STAGE RESEARCH SEEKING TO FOSTER A BETTER UNDERSTANDING OF, TREATMENTS FOR, AND ULTIMATELY, A CURE FOR, THESE AGE-RELATED DISEASES WITH NO CURE. SINCE 1973, BRIGHTFOCUS HAS AWARDED MORE THAN $330 MILLION IN RESEARCH GRANTS TO THOUSANDS OF SCIENTISTS IN 28 COUNTRIES THROUGH ITS THREE PROGRAMS: ALZHEIMER'S DISEASE RESEARCH, MACULAR DEGENERATION RESEARCH, AND NATIONAL GLAUCOMA RESEARCH. THE RESEARCH WE SUPPORT IS CAREFULLY CHOSEN BY OUR SCIENTIFIC REVIEW COMMITTEES, COMPRISING WORLD-RENOWNED RESEARCHERS AND LEADERS IN THEIR FIELDS. OUR RESEARCH FUNDING HAS LED TO MAJOR CONTRIBUTIONS TO UNDERSTANDING, DIAGNOSING, PREVENTING, AND TREATING THESE DISEASES AND PROVIDES SUPPORT FOR SCIENTISTS WHO HAVE RECEIVED PRESTIGIOUS AWARDS, INCLUDING TWO NOBEL PRIZES.

THE WORLD-CLASS RESEARCH IDENTIFIED AND SUPPORTED BY BRIGHTFOCUS IS ON THE CUTTING EDGE OF THE FIGHT TO SAVE MIND AND SIGHT. OUR FUNDING ACTS AS A CATALYST IN EARLY-STAGE RESEARCH, AND BRIGHTFOCUS RESEARCH PROGRAMS ARE DESIGNED TO PROVIDE INITIAL FUNDING FOR HIGHLY INNOVATIVE EXPERIMENTAL IDEAS. DUE TO THE STRUCTURED GRANT REVIEW AND APPROVAL PROCESS, THE RESEARCH IMPACT OF BRIGHTFOCUS IS VERY HIGH. BRIGHTFOCUS FUNDING RECIPIENTS RECEIVE FOLLOW-ON GRANTS FROM OTHER SOURCES THAT ARE, ON AVERAGE, EIGHT TIMES LARGER THAN THEIR ORIGINAL BRIGHTFOCUS AWARD. THIS HIGH RETURN ON BRIGHTFOCUS INVESTMENT SPEAKS TO OUR ABILITY TO IDENTIFY PROMISING RESEARCH IN ITS EARLIEST STAGES AND SPAWN FUTURE SCIENTIFIC DISCOVERIES. IT IS OUR FIRM BELIEF THAT HAVING THE COURAGE TO INVEST IN INNOVATIVE IDEAS WILL LEAD TO REVOLUTIONARY APPROACHES AND LIFE-SAVING BREAKTHROUGHS.

ALONG WITH FUNDING CUTTING-EDGE RESEARCH TO FIND CURES FOR SOME OF THE WORLD'S COSTLIEST DISEASES, BRIGHTFOCUS ALSO PROVIDES VALUABLE, FREE, EXPERT EDUCATIONAL MATERIALS TO HUNDREDS OF THOUSANDS OF PEOPLE IMPACTED BY THESE DISEASES NATIONWIDE. WE GROUND THESE EDUCATIONAL MATERIALS IN THE LATEST RESEARCH FINDINGS AND BREAKTHROUGHS.

BRIGHTFOCUS ALSO INCREASES PUBLIC AWARENESS OF ALZHEIMER'S, MACULAR DEGENERATION, AND GLAUCOMA, AND COMMUNICATES WITH THOUGHT LEADERS AND ELECTED OFFICIALS ABOUT THE IMPORTANCE OF SCIENTIFIC RESEARCH IN THESE AREAS.

BRIGHTFOCUS' AWARD-WINNING PUBLIC SERVICE ANNOUNCEMENTS (PSAS) HAVE APPEARED ON TELEVISION, RADIO, AND IN PRINT THROUGHOUT THE NATION. THESE PSAS, "STOP AMD," "STOP GLAUCOMA," AND "FINDING ANSWERS IN THE FIGHT AGAINST ALZHEIMER'S," SEEK TO RAISE AWARENESS ABOUT THESE DISEASES AND THE IMPORTANCE OF EARLY DETECTION. SIMILAR MESSAGES HAVE BEEN DELIVERED THROUGH DONATED PRINT PSA SPACE IN AIRPORTS AND TRAIN STATIONS, AS WELL AS AT PHARMACIES, SUPERMARKETS AND DIGITALLY. IN FISCAL YEAR 2026, THESE PSA MESSAGES GENERATED OVER $18 MILLION IN

Name of the organization: BRIGHTFOCUS FOUNDATION
Employer identification number: 23-7337229

DONATED MEDIA SERVICES AND GARNERED NEARLY 390 MILLION IMPRESSIONS.

WE CONTINUE TO INCREASE OUR PRINT PUBLICATIONS, MANY IN SPANISH, THAT PROVIDE HELPFUL INFORMATION TO PATIENTS AND CAREGIVERS, AND REGULARLY PRODUCE NEW VIDEO AND AUDIO RESOURCES IN CONJUNCTION WITH ALLIES IN THE MEDICAL AND SCIENTIFIC COMMUNITIES.

PARTNERING WITH SEVERAL HIGH-PROFILE PUBLIC AND PRIVATE ORGANIZATIONS, BRIGHTFOCUS IS HELPING TO BETTER EDUCATE THE PUBLIC ON THE LATEST RESEARCH DEVELOPMENTS PERTAINING TO ALZHEIMER'S, MACULAR DEGENERATION, AND GLAUCOMA, AS WELL AS THE IMPORTANCE OF EQUITABLE PARTICIPATION IN CLINICAL RESEARCH TO ACCELERATE THE PATH TO CURES FOR NEURODEGENERATIVE DISEASES.

SPECIFICALLY, BRIGHTFOCUS PRODUCES AND DISSEMINATES FREE INFORMATION PROGRAMS INCLUDING:

MACULAR CHATS AND GLAUCOMA CHATS. SINCE 2014, THESE AUDIO DISCUSSIONS HAVE BROUGHT TOGETHER PATIENTS AND CAREGIVERS FOR INTERACTIVE MONTHLY TELEPHONE FORUMS TO LEARN FROM AND ASK QUESTIONS OF LEADING VISION DISEASE EXPERTS. THE CHATS ARE ARCHIVED ON OUR WEBSITE, WITH AUDIO AND PRINT TRANSCRIPTS AVAILABLE IN SEVERAL ACCESSIBLE FORMATS ONLINE, INCLUDING AS PODCASTS ON SPOTIFY AND APPLE ITUNES.

ZOOM IN ON DEMENTIA AND ALZHEIMER'S, A MONTHLY VIRTUAL DISCUSSION OPEN TO THE PUBLIC FEATURING WORLD-RENOWNED RESEARCH SCIENTISTS WHO SHARE THE LATEST BREAKTHROUGHS AND FINDINGS IN THE FIELD. ALL EPISODES ARE RECORDED AND AVAILABLE TO WATCH ON DEMAND ON OUR WEBSITE AND YOUTUBE.

LET'S TALK ALZHEIMER'S IS A PODCAST ADAPTED FROM BRIGHTFOCUS' "ZOOM IN ON DEMENTIA & ALZHEIMER'S" SERIES THAT HELPS LISTENERS UNDERSTAND ALZHEIMER'S DISEASE AND OTHER DEMENTIAS THROUGH TRUSTED SCIENTIFIC INSIGHT. EPISODES FEATURE CONVERSATIONS WITH LEADING SCIENTISTS AND MEDICAL EXPERTS ABOUT DIAGNOSIS, RISK REDUCTION, CLINICAL TRIALS, AND THE LATEST TREATMENTS.

WE REGULARLY PUBLISH ARTICLES AND RESOURCES PROVIDING LAY-PERSON INFORMATION ABOUT COMMONLY ASKED DISEASE QUESTIONS. TWO MILLION VISITORS EACH YEAR TO OUR WEBSITE, WWW.BRIGHTFOCUS.ORG, FIND A WEALTH OF INFORMATION ON RESEARCH, SYMPTOMS, AND THE LATEST TREATMENTS.

BRIGHTFOCUS IS A PRESENTING PARTNER OF SEVERAL DOCUMENTARY FILMS, INCLUDING ANDRE ROYO'S "FRAGMENTS OF JOY," LAUREN AND SETH ROGEN'S "TAKING CARE," AND GLEN CAMPBELL: I'LL BE ME, AND EXECUTES ASSOCIATED EDUCATIONAL IMPACT CAMPAIGNS. THESE FILMS ARE SHOWN IN COMMUNITY SETTINGS ACROSS THE COUNTRY TO INCREASE AWARENESS OF, AND PARTICIPATION IN ALZHEIMER'S CLINICAL RESEARCH.

BRIGHTFOCUS HAS A LONG-RUNNING AND ROBUST DIRECT MAIL PROGRAM ACROSS THE THREE RESEARCH AREAS IT SUPPORTS. BRIGHTFOCUS MAILS AWARENESS-RAISING MATERIALS ACROSS ITS THREE PROGRAM AREAS TO OVER 560,000 NATIONAL HOUSEHOLDS, WITH MESSAGES FOCUSING ON:

RISK FACTORS AND SYMPTOM RECOGNITION THROUGH PUBLIC AWARENESS AND STEPS THE PUBLIC SHOULD TAKE THAT MAY HELP REDUCE THEIR RISK.

LIFESTYLE CHOICES THAT PROMOTE GOOD HEALTH, ENCOURAGING READERS TO TAKE ACTION TO REDUCE THE LIKELIHOOD OF THE ONSET OF THE DISEASE.

RESEARCH RESULTS AND TREATMENTS AVAILABLE TO ADDRESS THE DISEASE.

Name of the organization: BRIGHTFOCUS FOUNDATION
Employer identification number: 23-7337229

BRIGHTFOCUS REGULARLY INTERACTS WITH ADVOCACY ORGANIZATIONS, GOVERNMENTS AT ALL LEVELS, AND MEMBERS OF THE MEDIA, TO CALL GREATER ATTENTION TO DISEASES OF MIND AND SIGHT AND SHARE THE LATEST RESEARCH AND BEST PRACTICES WITH PUBLIC FIGURES AND KEY STAKEHOLDERS. THROUGH OUR OWN OUTREACH EFFORTS, AS WELL AS VIA ACTIVE ROLES IN ADVOCACY COALITIONS, WE HELP ADVANCE THE CAUSE OF PIONEERING SCIENCE AND BETTER POSITION BRIGHTFOCUS AS A RESOURCE FOR THOSE STRUGGLING WITH AND SEARCHING FOR CURES FOR THESE TERRIBLE DISEASES.

BRIGHTFOCUS IS THE PRESENTING SPONSOR OF THE HELEN KELLER PRIZE FOR VISION RESEARCH, ONE OF THE MOST PRESTIGIOUS RECOGNITIONS IN THE FIELD. SELECTED BY A PANEL OF THE WORLD'S FOREMOST VISION SCIENTISTS, EACH YEAR'S LAUREATE IS HONORED FOR A GROUNDBREAKING CONTRIBUTION OR DISCOVERY TO SAVE SIGHT. BRIGHTFOCUS BEGAN ITS SPONSORSHIP IN 2015 TO CALL GREATER ATTENTION TO VISION RESEARCH ACROSS THE PRIVATE AND PUBLIC SECTORS. BRIGHTFOCUS WAS HONORED IN 2023 FOR ITS CONTRIBUTIONS TO ADVANCING GLOBAL VISION RESEARCH BY THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY (ARVO) FOUNDATION.

FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:
ALZHEIMER'S DISEASE RESEARCH (ADR)

ALZHEIMER'S DISEASE IS THE ONLY CAUSE OF DEATH AMONG THE TOP 10 IN AMERICA WITHOUT A WAY TO PREVENT, CURE, OR EVEN SLOW ITS PROGRESSION. IT IS AN IRREVERSIBLE DEGENERATION OF THE BRAIN THAT CAUSES DISRUPTIONS IN MEMORY, COGNITION, PERSONALITY, AND OTHER FUNCTIONS AND INEVITABLY LEADS TO DEATH. AN ESTIMATED 55 MILLION PEOPLE WORLDWIDE HAVE ALZHEIMER'S DISEASE OR OTHER DEMENTIAS, WITH WOMEN AND BLACK AND HISPANIC ADULTS MOST AT RISK.

ALZHEIMER'S DISEASE RESEARCH (ADR), A BRIGHTFOCUS FOUNDATION PROGRAM, FUNDS RESEARCH FOCUSED ON UNDERSTANDING THE CAUSES OF ALZHEIMER'S DISEASE, EARLY DETECTION, TREATMENTS TO HELP SLOW OR STOP ITS PROGRESSION, AND ULTIMATELY TO PREVENT THE DISEASE ALTOGETHER. ADR ANNUALLY AWARDS PEER-REVIEWED GRANTS TO SCIENTISTS FROM INSTITUTIONS WORLDWIDE WHO ARE CONDUCTING BIOMEDICAL AND CLINICAL RESEARCH ON ALZHEIMER'S DISEASE.

SINCE INCEPTION, ADR HAS INVESTED OVER $200 MILLION IN RESEARCH GRANTS TO DEFEAT ALZHEIMER'S DISEASE. DURING THE FISCAL YEAR ENDING MARCH 31, 2026, ADR AWARDED $9.2 MILLION IN PEER-REVIEWED GRANT AWARDS TO 37 NEW RESEARCH PROJECTS.

NOTABLE PROJECTS INCLUDE A FOCUS ON SUBCORTICAL SYSTEMS DRIVING HOMEOSTATIC FAILURES, ARTIFICIAL INTELLIGENCE- SUPPORTED ALGORITHMS TO PREDICT CHANGES IN CELL STATES IN THE FACE OF DISEASE, EARLY PROTEIN DRIVERS OF NEURODEGENERATION, AND A VISUAL VULNERABILITY INDEX THAT CAN BE EMPLOYED POINT OF CARE TO DETECT EARLY NEURODEGENERATIVE BRAIN CHANGES. ADDITIONAL INFORMATION ABOUT SPECIFIC PROJECTS IS INCLUDED IN SCHEDULES F & I.

BRIGHTFOCUS IS HONORED TO HAVE SUPPORTED THE EARLY RESEARCH OF TWO NOBEL PRIZE WINNERS. DR. STANLEY PRUSINER AND DR. PAUL GREENGARD, WHOSE WORK HAS BEEN INSTRUMENTAL IN OUR CURRENT UNDERSTANDING OF ALZHEIMER'S DISEASE.

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

BRIGHTFOCUS CONTINUES ITS PARTNERSHIP WITH THE ACADEMIC JOURNAL MOLECULAR NEURODEGENERATION AS THE OFFICIAL JOURNAL OF BRIGHTFOCUS FOUNDATION. THE JOURNAL PUBLISHES TECHNICAL PAPERS RELATED TO NEURODEGENERATION IN THE THREE DISEASE AREAS AND IS CURRENTLY RANKED IN THE TOP 5 NEUROSCIENCE JOURNALS FOR IMPACT. TO ACCELERATE SCIENTIFIC PROGRESS, IT IS THE TOP RANKED OPEN-ACCESS NEUROSCIENCE JOURNAL, AND ALL CONTENT IS FREE OF CHARGE. THIS OPEN ACCESS ENSURES MAXIMAL REACH OF JOURNAL CONTENTS TO SCIENTISTS AND CARE PROVIDERS WORLDWIDE. MOLECULAR NEURODEGENERATION IS CURRENTLY THE HIGHEST-RANKED OPEN-ACCESS PUBLICATION IN THE NEUROSCIENCE CATEGORY.

IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, ALZHEIMER'S DISEASE RESEARCH TRAINS AND EDUCATES THE NEXT GENERATION OF SCIENTISTS THROUGH ITS ALZHEIMER'S FAST TRACK PROGRAM AND PROVIDES EXPERT RESOURCES ON DETECTING, TREATING, AND LIVING WITH THE DISEASE. THESE ARE AVAILABLE ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG/ADR.

FORM 990, PART III, LINE 4B, DESCRIPTION OF PROGRAM SERVICE:
MACULAR DEGENERATION RESEARCH (MDR)

AGE-RELATED MACULAR DEGENERATION IS A LEADING CAUSE OF VISION LOSS IN THE UNITED STATES. IT DESTROYS THE MACULA, THE PART OF THE EYE THAT PROVIDES SHARP, CENTRAL VISION NEEDED FOR SEEING OBJECTS CLEARLY. THE MOST COMMON EYE CONDITION IN PEOPLE AGE 60 AND OLDER, IT CAN LEAD TO VISION LOSS IN ONE OR BOTH EYES, MAKING IT DIFFICULT TO RECOGNIZE FACES, DRIVE A CAR, OR READ. AT LEAST 20 MILLION AMERICANS HAVE SOME TYPE OF MACULAR DEGENERATION, INCLUDING BOTH THE EARLY AND LATER STAGES OF THE WET AND DRY TYPES.

MACULAR DEGENERATION RESEARCH (MDR), A BRIGHTFOCUS FOUNDATION PROGRAM, HAS AWARDED OVER $60 MILLION IN RESEARCH GRANTS TO STUDY THE DISEASE. MDR GRANTS ARE AVAILABLE TO MACULAR DEGENERATION RESEARCHERS WORLDWIDE. MDR PLACES SPECIAL EMPHASIS ON ENCOURAGING APPLICATIONS FROM EMERGING SCIENTISTS AND THOSE WITH CUTTING-EDGE IDEAS.

DURING THE FISCAL YEAR ENDING MARCH 31, 2026, MDR AWARDED $4.7 MILLION IN PEER-REVIEWED GRANT AWARDS TO 16 NEW RESEARCH PROJECTS

IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, MACULAR DEGENERATION RESEARCH PROVIDES EXPERT RESOURCES ON DETECTING, TREATING, AND LIVING WITH THIS DISEASE. THESE ARE AVAILABLE ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG/MDR.

FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:
NATIONAL GLAUCOMA RESEARCH (NGR)

GLAUCOMA IS THE SECOND LEADING CAUSE OF BLINDNESS WORLDWIDE, AFFECTING APPROXIMATELY 80 MILLION PEOPLE GLOBALLY, ACCORDING TO THE WORLD HEALTH ORGANIZATION. MORE THAN FOUR MILLION AMERICANS ARE LIVING WITH GLAUCOMA. IN THE UNITED STATES, GLAUCOMA IS A LEADING CAUSE OF BLINDNESS AMONG BLACK AND HISPANIC AMERICANS. WITH EARLY DETECTION AND TREATMENT, GLAUCOMA OFTEN CAN BE MANAGED TO PROTECT EYES FROM MORE SERIOUS VISION LOSS. BECAUSE IT OFTEN PRESENTS NO EARLY SYMPTOMS, IT IS

Name of the organization: BRIGHTFOCUS FOUNDATION
Employer identification number: 23-7337229

ESTIMATED THAT HALF OF THE PEOPLE LIVING WITH GLAUCOMA ARE NOT AWARE THAT THEY HAVE THE DISEASE.

NATIONAL GLAUCOMA RESEARCH (NGR), A BRIGHTFOCUS FOUNDATION PROGRAM, HAS AWARDED OVER $55 MILLION WORLDWIDE IN RESEARCH GRANTS TOWARD THE STUDY OF GLAUCOMA. NGR-SUPPORTED RESEARCH HAS FOCUSED ON THE EYE-BRAIN CONNECTION, HOW PRESSURE BUILDUP IN THE EYE CAN AFFECT SYNAPTIC NERVE COMMUNICATIONS, NEUROPROTECTION AND OPTIC NERVE REGENERATION, DISCOVERING GLAUCOMA RISK GENES, AI/DEEP LEARNING AND NEW IMAGING MODALITIES, SLEEP DISTURBANCE AND GLAUCOMA RISK, DEVELOPING EARLY GLAUCOMA SCREENING, AND PURSUING NOVEL GENETIC COUNSELING AND COMMUNICATION STRATEGIES, AMONGST OTHER INNOVATIVE PURSUITS.

NGR GRANTS ARE AVAILABLE TO GLAUCOMA RESEARCHERS WORLDWIDE. NGR PLACES SPECIAL EMPHASIS ON ENCOURAGING APPLICATIONS FROM EARLY-CAREER SCIENTISTS AND THOSE WITH CUTTING-EDGE IDEAS. ANNUAL GRANT APPLICATIONS ARE PEER-REVIEWED, AND RECIPIENT SELECTIONS ARE BASED ON SCIENTIFIC MERIT.

DURING THE FISCAL YEAR ENDING MARCH 31, 2026, NGR AWARDED $2.3 MILLION IN PEER-REVIEWED GRANT AWARDS FOR 16 NEW PROJECTS. DETAILS ABOUT SPECIFIC PROJECTS ARE INCLUDED IN SCHEDULES F & I.

IN ADDITION TO SUPPORTING CUTTING-EDGE RESEARCH, NATIONAL GLAUCOMA RESEARCH PROVIDES EXPERT RESOURCES ON DETECTING, TREATING, AND LIVING WITH THE DISEASE. THESE ARE AVAILABLE ON OUR WEBSITE, WWW.BRIGHTFOCUS.ORG/NGR.

FORM 990, PART VI, SECTION B, LINE 11B:
A DRAFT OF THE FEDERAL FORM 990 IS DISTRIBUTED TO THE AUDIT COMMITTEE FOR REVIEW PRIOR TO BEING SUBMITTED TO THE INTERNAL REVENUE SERVICE. THE DRAFT FEDERAL FORM 990 IS DISTRIBUTED EARLY ENOUGH TO PROVIDE EACH COMMITTEE MEMBER WITH A REASONABLE AMOUNT OF TIME FOR REVIEW AND SUBMISSION OF QUESTIONS OR COMMENTS PRIOR TO THE FILING DEADLINE. THE FINAL FEDERAL FORM 990 IS DISTRIBUTED TO EACH MEMBER OF THE FULL BOARD OF DIRECTORS PRIOR TO BEING FILED WITH THE INTERNAL REVENUE SERVICE. THE DRAFT OR FINAL FEDERAL FORM 990 MAY BE DISTRIBUTED IN PERSON, BY REGULAR MAIL, E-MAIL, OR FAX.

FORM 990, PART VI, SECTION B, LINE 12C:
BRIGHTFOCUS HAS ALL EMPLOYEES, OFFICERS, AND DIRECTORS AGREE TO THE CODE OF CONDUCT THAT INCLUDES ADHERENCE TO THE CONFLICT OF INTEREST AND IMPLEMENTATION POLICY. EACH BOARD DIRECTOR, OFFICER, AND EMPLOYEE IS REQUIRED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE STATEMENT ANNUALLY.

EMPLOYEES MEET ANNUALLY WITH THE BRIGHTFOCUS' CHIEF COMPLIANCE OFFICER TO REVIEW THEIR CONFLICT OF INTEREST STATEMENTS, AND GIVE AN ANNUAL CONFLICT OF INTEREST COMPLIANCE REPORT TO THE BOARD CHAIR AND VICE CHAIR. IF A CONFLICT IS REPORTED, IT IS THEN REFERRED TO THE PRESIDENT/CEO AND/OR BRIGHTFOCUS' LEGAL COUNSEL AND, IF APPROPRIATE AND NECESSARY, THEN TO THE BOARD OF DIRECTORS OR ITS APPOINTED COMMITTEE FOR FURTHER ACTION.

THE DIRECTOR'S AND OFFICER'S STATEMENTS ARE REVIEWED BY THE BRIGHTFOCUS LEGAL COUNSEL. IF A CONFLICT IS REPORTED, IT IS THEN REFERRED TO THE BOARD OF DIRECTORS OR ITS APPOINTED COMMITTEE FOR FURTHER ACTION.

Name of the organization: BRIGHTFOCUS FOUNDATION
Employer identification number: 23-7337229

AT THE TIME OF THE BRIGHTFOCUS DISCUSSION AND DECISION CONCERNING A CONFLICT OF INTEREST, THE CONFLICTED PARTY IS NOT PRESENT IN THE MEETING.

FORM 990, PART VI, SECTION B, LINE 15:
BRIGHTFOCUS' BOARD OF DIRECTORS HAS OVERALL AUTHORITY AND RESPONSIBILITY FOR APPROVING THE ANNUAL BUDGET WHICH INCLUDES SALARY AND BENEFITS FOR ALL EMPLOYEES AT EVERY LEVEL INCLUDING NON-DIRECTOR OFFICERS AND KEY EMPLOYEES. ALL PAY ADJUSTMENTS ARE MADE ON A YEARLY BASIS EFFECTIVE APRIL 1ST, THE BEGINNING OF THE BRIGHTFOCUS FISCAL YEAR.

BEFORE APPROVING THE COMPENSATION OF THE PRESIDENT/CEO, THE BOARD DETERMINES THE TOTAL COMPENSATION TO BE PROVIDED BY BRIGHTFOCUS TO THE PRESIDENT/CEO IS REASONABLE CONSIDERING THE POSITION, RESPONSIBILITY AND QUALIFICATION OF THE POSITION HELD, INCLUDING THE RESULT OF AN EVALUATION OF PRIOR PERFORMANCE FOR BRIGHTFOCUS, IF APPLICABLE. THE PRESIDENT/CEO IS EVALUATED YEARLY BY THE BOARD OF DIRECTORS USING AN IN-DEPTH GOAL ATTAINMENT STRUCTURE, THAT INCLUDES A SELF-ASSESSMENT AND A BOARD OF DIRECTOR'S ASSESSMENT AND EVALUATION AGAINST SET GOALS, OUTCOMES, AND DELIVERABLES. IN ADDITION, THE BOARD OF DIRECTORS PERIODICALLY ENGAGES AN OUTSIDE CONSULTANT TO OBTAIN AND CONSIDER APPROPRIATE DATA, INCLUDING A SALARY SURVEY, WHICH INCLUDES INFORMATION COMPILED FROM THE FEDERAL FORM 990 OF OTHER ORGANIZATIONS, CONCERNING COMPENSATION PAID TO CEOS IN SIMILAR CIRCUMSTANCES. IN MAKING THE DETERMINATION, THE BOARD OF DIRECTORS CONSIDERS TOTAL COMPENSATION TO INCLUDE THE SALARY AND VALUE OF ALL BENEFITS PROVIDED BY BRIGHTFOCUS TO THE INDIVIDUAL IN PAYMENT FOR SERVICES. AT THE TIME OF THE BRIGHTFOCUS BOARD DISCUSSION AND DECISION CONCERNING THE PRESIDENT/CEO'S COMPENSATION, THE PRESIDENT/CEO IS NOT PRESENT IN THE MEETING.

THE BOARD OF DIRECTORS SHALL SET FORTH THE BASIS FOR ITS DECISIONS WITH RESPECT TO COMPENSATION IN THE MINUTES OF THE MEETING AT WHICH THE DECISIONS ARE MADE, INCLUDING THE CONCLUSIONS OF THE EVALUATION AND THE BASIS FOR DETERMINING THAT THE INDIVIDUAL'S COMPENSATION WAS REASONABLE CONSIDERING THE EVALUATION AND COMPARABILITY DATA.

THE PRESIDENT/CEO IS CHARGED WITH SETTING THE SALARIES OF ALL OTHER EMPLOYEES IN ACCORDANCE WITH A COMPENSATION STRUCTURE AND BUDGET APPROVED BY THE BOARD OF DIRECTORS. THE PRESIDENT/CEO AND HUMAN RESOURCES REVIEW EMPLOYEE COMPENSATION AND BENEFITS THAT INCLUDE KEY EMPLOYEES, BY PERIODICALLY ENGAGING AN OUTSIDE CONSULTANT TO CONDUCT COMPENSATION AND BENEFIT BENCHMARKING STUDIES THAT INCLUDE VARIOUS REGIONAL AND NATIONAL NON-PROFIT COMPENSATION REPORTS AND SURVEYS. COMPENSATION DELIBERATIONS AND DECISIONS INCLUDE THE REVIEW OF SELF AND SUPERVISORY EVALUATIONS OF EMPLOYEE PERFORMANCE COMPARED TO SET INDIVIDUAL AND ORGANIZATIONAL GOALS.

FORM 990, PART VI, LINE 17, LIST OF STATES RECEIVING COPY OF FORM 990:
AK,AL,AR,CA,CT,FL,GA,HI,IL,KS,KY,ME,MD,MA,MI,MN,MO,MS,NC,ND,NH,NJ,NM,NY,OH
OK,OR,PA,RI,SC,TN,UT,VA,WA,WI,WV

FORM 990, PART VI, SECTION C, LINE 19:
BRIGHTFOCUS MAKES ITS GOVERNING DOCUMENTS INCLUDING ITS ARTICLES OF INCORPORATION AND BYLAWS, THE FEDERAL FORM 1023, THE 501(C)(3) LETTER OF DETERMINATION FROM THE INTERNAL REVENUE SERVICE, CONFLICT OF INTEREST POLICY, AUDITED FINANCIAL STATEMENTS AND FEDERAL FORM 990 AVAILABLE TO THE PUBLIC UPON REQUEST. IN ADDITION, THE PUBLIC ALSO HAS ACCESS TO THE ANNUAL REPORT, AUDITED FINANCIAL STATEMENTS, THE 501(C)(3) LETTER OF DETERMINATION

Name of the organization: BRIGHTFOCUS FOUNDATION

Employer identification number: 23-7337229

FROM THE INTERNAL REVENUE SERVICE, AND FEDERAL FORM 990 ON ITS WEBSITE AT WWW.BRIGHTFOCUS.ORG.

FORM 990, PART XI, LINE 9, CHANGES IN NET ASSETS:

RECOVERIES OF PRIOR YEAR GRANTS	231,664.
CHANGE IN PRESENT VALUE OF GRANTS	10,302.
TOTAL TO FORM 990, PART XI, LINE 9	241,966.

FORM 990, PART XII, LINE 2C:

THE PROCESS HAS NOT CHANGED FROM PRIOR YEAR.

SCHEDULE R (Form 990)
(Rev. January 2025)
Department of the Treasury
Internal Revenue Service

Related Organizations and Unrelated Partnerships

Complete if the organization answered "Yes" on Form 990, Part IV, line 33, 34, 35b, 36, or 37.
Attach to Form 990.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

Open to Public Inspection

Name of the organization
BRIGHTFOCUS FOUNDATION

Employer identification number
23-7337229

Part I **Identification of Disregarded Entities.** Complete if the organization answered "Yes" on Form 990, Part IV, line 33.

(a) Name, address, and EIN (if applicable) of disregarded entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Total income	(e) End-of-year assets	(f) Direct controlling entity
AMERICAN HEALTH ASSISTANCE, LLC - 23-7337229 22512 GATEWAY CENTER DRIVE CLARKSBURG, MD 20871	OWNER OF BRIGHTFOCUS HEADQUARTERS	MARYLAND	0.	3,035,634.	BRIGHTFOCUS FOUNDATION
NATIONAL DEVELOPMENT, LLC - 23-7337229 22512 GATEWAY CENTER DRIVE CLARKSBURG, MD 20871	PROPERTY RENTAL AND MANAGEMENT	MARYLAND	0.	0.	BRIGHTFOCUS FOUNDATION

Part II **Identification of Related Tax-Exempt Organizations.** Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related tax-exempt organizations during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	(g) Section 512(b)(13) controlled entity? Yes	(g) Section 512(b)(13) controlled entity? No

Part III **Identification of Related Organizations Taxable as a Partnership.** Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related organizations treated as a partnership during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Predominant income (related, unrelated, excluded from tax under sections 512-514)	(f) Share of total income	(g) Share of end-of-year assets	(h) Disproportionate allocations? Yes	(h) No	(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner? Yes	(j) No	(k) Percentage ownership

Part IV **Identification of Related Organizations Taxable as a Corporation or Trust.** Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related organizations treated as a corporation or trust during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(h) Percentage ownership	(i) Section 512(b)(13) controlled entity? Yes	(i) No

Part V **Transactions With Related Organizations.** Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35b, or 36.

			Yes	No
Note: Complete line 1 if any entity is listed in Parts II, III, or IV of this schedule.				
1 During the tax year, did the organization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?				
a Receipt of **(i)** interest, **(ii)** annuities, **(iii)** royalties, or **(iv)** rent from a controlled entity	**1a**			
b Gift, grant, or capital contribution to related organization(s)	**1b**			
c Gift, grant, or capital contribution from related organization(s)	**1c**			
d Loans or loan guarantees to or for related organization(s)	**1d**			
e Loans or loan guarantees by related organization(s)	**1e**			
f Dividends from related organization(s)	**1f**			
g Sale of assets to related organization(s)	**1g**			
h Purchase of assets from related organization(s)	**1h**			
i Exchange of assets with related organization(s)	**1i**			
j Lease of facilities, equipment, or other assets to related organization(s)	**1j**			
k Lease of facilities, equipment, or other assets from related organization(s)	**1k**			
l Performance of services or membership or fundraising solicitations for related organization(s)	**1l**			
m Performance of services or membership or fundraising solicitations by related organization(s)	**1m**			
n Sharing of facilities, equipment, mailing lists, or other assets with related organization(s)	**1n**			
o Sharing of paid employees with related organization(s)	**1o**			
p Reimbursement paid to related organization(s) for expenses	**1p**			
q Reimbursement paid by related organization(s) for expenses	**1q**			
r Other transfer of cash or property to related organization(s)	**1r**			
s Other transfer of cash or property from related organization(s)	**1s**			

2 If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.

	(a) Name of related organization	**(b)** Transaction type (a-s)	**(c)** Amount involved	**(d)** Method of determining amount involved
(1)				
(2)				
(3)				
(4)				
(5)				
(6)				

Part VI **Unrelated Organizations Taxable as a Partnership.** Complete if the organization answered "Yes" on Form 990, Part IV, line 37.

Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.

(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Predominant income (related, unrelated, excluded from tax under sections 512-514)	(e) Are all partners sec. 501(c)(3) orgs.? Yes	(e) No	(f) Share of total income	(g) Share of end-of-year assets	(h) Disproportionate allocations? Yes	(h) No	(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner? Yes	(j) NO	(k) Percentage ownership

Part VII Supplemental Information

Provide additional information for responses to questions on Schedule R. See instructions.